Compositions and methods for treating cancer with anti-CD19 / CD22 immunotherapy
Patent Information
- Application Number
- JP2023527028
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-05
- Filing Date
- 2021-11-05
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-11-05
AI Technical Summary
Current treatments for B-cell leukemia and lymphoma, such as chemotherapy and radiation, are associated with high toxicity and risk of complications, and existing CAR-T therapies do not effectively target CD19 and CD22 antigens, leaving a significant number of patients without adequate treatment options.
Development of tandem CD19/CD22 chimeric antigen receptors (CARs) that combine antigen-binding domains for high surface expression and cytolysis, promoting prolonged T-cell proliferation and persistence, enhancing therapeutic efficacy against CD19 and CD22-expressing cells.
The tandem CARs demonstrate improved cytotoxicity and persistence of transduced T cells, offering enhanced treatment outcomes for B-cell malignancies by targeting both CD19 and CD22 antigens, reducing the need for additional procedures like hematopoietic stem cell transplantation.
Abstract
Description
Technical field
[0001] Cross-reference of related applications This application is filed September 26, 2019, claiming priority benefit under 35 U.S.C. 119(e) to U.S. Provisional Patent Application No. 62 / 736,955, filed September 26, 2018. Continuation of U.S. Patent Application No. 16 / 584,308 (now U.S. Patent No. 10,822,412) and U.S. Provisional Patent Application No. 62 / 736,955 filed September 26, 2018 under 35 U.S.C. 119(e) U.S. Patent Application No. 17 / 072,842, filed October 16, 2020, which is a continuation-in-part of PCT Patent Application No. PCT / US19 / 53240, filed September 26, 2019, claiming priority benefit to No. claims priority benefit to U.S. Utility Patent Application No. 17 / 090,797, filed November 5, 2020, a continuation-in-part application of , each of which is incorporated herein by reference in its entirety.
[0002] Sequence list This application contains a Sequence Listing, filed electronically in ASCII format and incorporated herein by reference in its entirety. The ASCII copy, created on November 3, 2021, is named Sequence_Listing.txt and is 220 kilobytes in size.
[0003] Field of this disclosure This application is directed to the field of cancer, in particular CARs targeting (see TR12, fwigure1a) to CD19 and CD22 B cell antigens, simultaneously through CD19 / CD22, and such CD19 / CD22 antigen targeting domains. and methods of using the same. [Background technology]
[0004] background Cancer is one of the most deadly threats to human health. In the United States alone, cancer affects nearly 1.3 million new cases each year and is the second leading cause of death after cardiovascular disease, accounting for approximately one-quarter of deaths. Solid tumors are responsible for most of these deaths. Although there have been significant advances in the medical treatment of certain cancers, five-year overall survival rates for all cancers have improved by only about 10% over the past 20 years. Cancer or malignant tumors metastasize and grow rapidly and uncontrolled, making treatment very difficult.
[0005] CD19 is an 85-95kDa transmembrane cell surface glycoprotein receptor. CD19 is a member of the immunoglobulin (Ig) superfamily of proteins and contains two extracellular Ig-like domains, a transmembrane, and an intracellular signaling domain (Tedder TF, Isaacs, CM, 1989, J Immunol 143:712-171). CD19 alters B cell receptor signaling, lowering the triggering threshold of B cell receptors to antigen (Carter, RH and Fearon, DT, 1992, Science, 256:105-107), and CD81 and coordinates with CD21 to regulate this essential B cell signaling complex (Bradbury, LE, Kansas GS, Levy S, Evans RL, Tedder TF, 1992, J Immunol, 149:2841-50) . During B-cell ontogeny, CD19 can signal independently of antigen receptors and associates with protein tyrosine kinases of the Src family at the pro-B, pre-pre-B, pre-B, and early B-cell stages. undergoes tyrosine phosphorylation and induces both intracellular calcium mobilization and inositol phospholipid signaling (Uckun FM, Burkhardt AL, Jarvis L, Jun X, Stealy B, Dibirdik I, Myers DE, Tuel-Ahlgren L, Bolen JB, 1983, J Biol Chem 268:21172-84). An important point of relevance for the treatment of B-cell malignancies is that CD19 is present on normal B cells in a tightly regulated manner restricted to early progenitor B cells, mature B cells undergoing IgH gene rearrangement. (Anderson, KC, Bates, MP, Slaughenhout BL, Pinkus GS, Schlossman SF, Nadler LM, 1984, Blood 63:1424~ 1433 pages).
[0006] CD22, also known as SIGLEC-2 (sialic acid-binding immunoglobulin-like lectin 2), is a 95 kDa transmembrane surface glycoprotein that contains six Ig-like type C2 domains and one Ig-like type V domain. (uniprot.org / uniprot / P20273#structure, accessed 07 / 12 / 2017). During B cell ontogeny, CD22 is expressed on the B cell surface from the pre-B cell stage, remains on mature B cells, and is lost on plasma cells (Nitschke L, 2009, Immunological Reviews, vol. 230: (pp. 128-143). CD22 contains an intracellular ITIM (immunoreceptor tyrosine-based inhibition motifs) domain that serves to downregulate cell activation after B cell receptor engagement with antigen. . Antibody binding of CD22 induces colocalization with SHP-1 and intracellular phosphatases that also act to downregulate phosphorylation-based signaling (Lumb S, Fleishcer SJ, Wiedemann A, Daridon C , Maloney A, Shock A, Dorner T, 2016, Journal of Cell Communication and Signaling, vol. 10: 143-151). An important point of relevance for the treatment of B-cell malignancies is that CD22 is expressed in a tightly regulated manner on normal B cells, but not on hematopoietic stem cells or mature plasma cells; , making it a suitable target antigen for B-cell leukemia. Because CD22 is expressed on both adult and pediatric (pre-B-ALL) B-cell malignancies, this target has been exploited for both antibody and chimeric antigen receptor (CAR) T-cell therapy ( Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerlad DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ, 2013, Blood, vol. 121:1165 ~1174 pages) (Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, Stetler-Stevenson M, FitzGerald DJ, Pastan I, 2010, Clinical Cancer Research, 16:1894-1903).
[0007] Several new approaches have been developed for B-cell leukemia and lymphoma treatment, including anti-CD22 antibodies linked to bacterial toxins or chemotherapeutic agents (Wayne AS, FitzGerald DJ, Kreitman RJ, Pastan I, 2014) , Immunotoxins for leukemia, Blood, vol. 123: p. 2470-2477). Inotuzumab ozogamicin (CMC-544, a humanized version of murine monoclonal antibody G5 / 44) is an antibody-drug conjugate currently in clinical trials as a single agent or in combination with chemotherapy. It has been evaluated (NCT01664910, Sponsor: M.D. Anderson Cancer Center) (DiJoseph JF et al., 2004, Blood, vol. 103: 1807-1814). As a single agent, the results were greater than those seen with standard therapy, although significant liver toxicity was noted (Kantarjian H et al., 2016, Inotuzumb ozogamicin versus standard therapy for acute lymphoblastic leukemia, New England Journal of Medicine, vol. 375: pp. 740-753). Epratuzumab, an unmodified CD22 therapeutic antibody, is also being tested in combination with chemotherapy (NCT01219816, Sponsor: Nantes University Hospital). Epratuzumab is a chimeric protein composed of murine CDRs grafted onto a human antibody framework. Moxetumomab pasudotox, although effective in some leukemias, has problems with the immunogenicity of the bacterial toxin to which the antibody is fused, and a modest or comparable level of activity with other drugs. (See NCT01829711, Sponsor: MedImmune, LLC). To date, many of the CD22 binding motifs used in CAR constructs utilize domains derived from these murine antibodies, which do not effectively activate T cells that target this CD22 domain (e.g., moxetumomab HA22 anti-CD22 binder used as base for passotox, James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW, 2008, Journal of Immunology vol. 180: (See pages 7028-7038). One anti-CD22 binder that is effective as an anti-CD22 CAR is currently in clinical trials at the National Institutes of Health (NIH), although the results have not been published (ClinicalTrials.gov Identifier: NCT02315612, Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies, Sponsor: NCI). This binder is based on the m971 fully human antibody developed in the laboratory of Dr. Dimiter Dimitrov, one of the inventors of this application (Xiao X, Ho M, Zhu Z, Pastan I, Dimitrov D, 2009) , Identification and characterization of fully human anti-CD22 monoclonal antibodies, MABS, vol. 1: pp. 297-303). The m971 domain was proven to be effective as a CAR in a study supervised by Dr. Rimas Orentas, one of the other inventors in this application (Haso W et al., 2013, Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia, Blood, vol. 121: p. 1165-1174).
[0008] Traditional treatment approaches for B-lineage leukemia and lymphoma may include chemotherapy, radiation therapy, and stem cell transplantation (see the world wide web at mayclinic.org). The high toxicity associated with these procedures and the risk of complications such as recurrence, secondary malignancy, and GVHD motivate the search for better treatment options. Because CD19 is expressed on both adult and pediatric (pre-B-ALL) B-cell malignancies, this target has been exploited for both antibody and chimeric antigen receptor (CAR) T-cell therapy ( Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA, 2010, Blood 116:4099-102; Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL, 2015, Lancet 385:517-28). Furthermore, the CD22 antigen is also present in lymphomas (DLBCL, FL) and leukemias (CLL), making it an attractive additional target for efficiently eliminating tumors and preventing tumor antigen escape.
[0009] The current standard of care for B-lineage leukemia may consist of induction treatment followed by high-dose or dose chemotherapy or radiation, with the inclusion of stem cell transplantation and additional courses of chemotherapy if necessary. Yes (see the World Wide Web at cancer.gov). The high toxicity associated with these procedures and the risk of complications such as recurrence, secondary malignancy, and GVHD motivate the search for better treatment options. Because CD19 is expressed on both adult and pediatric (pre-B-ALL) B-cell malignancies, this target has been exploited for both antibody and chimeric antigen receptor (CAR) T-cell therapy ( Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA, 2010, Blood 116:4099-102; Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL, 2015, Lancet 385:517-28).
[0010] Bispecific antibodies that link an anti-CD19 or anti-CD22 binding motif to a T-cell binding motif (i.e., are needed for the treatment of Philadelphia chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL)). Several new approaches have been developed for the treatment of B-cell leukemia and lymphoma, including the indicated blinatumomab, Blincyto®). To date, many of the binding moieties for CD19 or CD22 used in CAR constructs utilize domains derived from murine antibodies. Several such products are currently under consideration for approval, including those developed by Novartis and Kite Pharmaceuticals. In April 2017, Novartis announced that it would be a medical drug for adults with refractory or recurrent (r / r) DLBCL (diffuse large B-cell lymphoma) who have had two or more previous unsuccessful treatments. Announced CTL019 (tisagenlecleucel), which received FDA breakthrough designation for the treatment of patients, extending this designation to r / rB cell acute lymphoblastic leukemia (ALL). In addition to These indications are based on the Phase II JULIET study (NCT02445248) and ELIANA study (NCT02435849), respectively. The JULIET trial showed an overall response rate (ORR) of 45% at 3 months, with 37% complete response (CR) and 8% partial response (PR). In the ELIANA study, 82% of patients who received product infusions achieved CR, or CR, including incomplete count recovery, and recurrence-free survival at 6 months was 60%. Kite Pharmaceuticals' CAR-T product (KTE-C19, axicabtagene ciloleucel) is used to treat diffuse large B-cell lymphoma (DLBLC), transformed follicular lymphoma (TFL), and primary mediastinal B-cell Breakthrough therapy designation has been granted for lymphoma (PMBCL). The Kite ZUMA-3 Phase II trial of KTE-C19 in r / rALL reported a 73% CR (at 2 months or longer). Regardless of whether CAR-T therapeutic antibodies are utilized, there are still a significant number of patients who are not helped by these therapies, and there is considerable room for improvement in treatment approaches.
[0011] Chimeric antigen receptors (CARs) are hybrid molecules that contain three essential units: (1) an extracellular antigen-binding motif, (2) a linking / transmembrane motif, and (3) an intracellular T-cell signal. Transfer motif (Long AH, Haso WM, Orentas RJ.Lessons learned from a highly-active CD2-specific chimeric antigen receptor.Oncoimmunology.2013;Volume 2(4):e23621). The antigen-binding motifs of CARs are generally based on single-chain fragment variables (scFvs), which are the smallest binding domains of immunoglobulin (Ig) molecules. Alternative antigen-binding motifs include, for example, receptor ligands (i.e., IL-13 has been engineered to bind to tumor-expressed IL-13 receptors), intact immunoreceptors, library-derived Peptides and innate immune system effector molecules (eg, NKG2D) have also been engineered. Alternative cellular targets (e.g. NK or gamma-delta T cells) for CAR expression are also under development (Brown CE et al. Clin Cancer Res. 2012; 18(8):2199-209; Lehner M et al. PLoS One. 2012; Volume 7 (Issue 2): Page e31210). Considerable work remains to be done in defining the most active T cell populations for transducing CAR vectors, determining optimal culture and expansion techniques, and defining the molecular details of the CAR protein structure itself. There is something left to do.
[0012] The CAR linking motif can be designed to be a relatively stable structural domain, such as the constant domain of IgG, or an extended flexible linker. Structural motifs such as those derived from the constant domain of IgG can be used to extend the scFv binding domain away from the T cell plasma membrane surface. This may be important for some tumor targets whose binding domains are particularly close to the tumor cell surface membrane (eg, for the disialoganglioside GD2; Orentas et al., unpublished observations). To date, the signaling motifs used in CARs always include the CD3-ζ chain, since this core motif is an important signal for T cell activation. The first reported second-generation CAR featured a CD28 signaling domain and a CD28 transmembrane sequence. This motif was similarly used in the third generation CAR containing the CD137(4-1BB) signaling motif (Zhao Y et al. J Immunol. 2009; 183(9):5563-74). With the advancement of new technologies, activation of T cells by beads linked to anti-CD3 and anti-CD28 antibodies, as well as the presence of a canonical "signal 2" derived from CD28, no longer needs to be encoded by the CAR itself. . Using bead activation, 3rd generation vectors were found to be no better than 2nd generation vectors in in vitro assays and to be superior to 2nd generation vectors in mouse models of leukemia. No clear benefit was obtained (Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ. Anti-CD22-chimeric antigen receptors targeting B cell precursor acute lymphoblastic leukemia,Blood.2013;121(7):1165~74;Kochenderfer JN et al.Blood.2012;119(12):2709~20 page). This is the second generation CD28 / CD3-ζ (Lee DW et al. American Society of Hematology Annual Meeting. New Orleans, LA; December 7-10, 2013) and CD137 / CD3-ζ signaling format (Porter DL et al. This is supported by the clinical success of CD19-specific CARs (N Engl J Med. 2011;365(8):725-33). In addition to CD137, other tumor necrosis factor receptor superfamily members such as OX40 can also provide important sustained signals in CAR-transduced T cells (Yvon E et al. Clin Cancer Res. 2009; Volume 15 (Issue 18): pp. 5852-60). Equally important is the culture conditions in which the CAR T cell population was cultured, including the inclusion of the cytokines IL-2, IL-7, and / or IL-15 (Kaiser AD et al. Cancer Gene Ther. 2015 22(2):72-78).
[0013] Current challenges in broader and effective adaptation of CAR therapy to cancer relate to the lack of convincing targets. Although creating binding factors to cell surface antigens is now easily achievable, discovering cell surface antigens specific for tumors while overlooking normal tissues remains a formidable challenge. One potential way to confer higher target cell specificity to CAR-expressing T cells is to use a combinatorial CAR approach. In one system, the CD3-ζ and CD28 signaling units are split between two different CAR constructs that are expressed in the same cell; in another system, the two CARs are expressed in the same T cell, but one has lower affinity and therefore requires an alternative CAR to be bound first for full activity of the second CAR (Lanitis E et al. Cancer Immunol Res. 2013; Vol. 1 ( (No. 1): pp. 43-53; Kloss CC et al. Nat Biotechnol. 2013; Vol. 31 (No. 1): pp. 71-5). A second challenge for the generation of single scFv-based CARs as immunotherapeutic agents is the heterogeneity of tumor cells. At least one group has proposed a method for glioblastoma in which effector cell populations target multiple antigens (HER2, IL-13Ra, EphA2) simultaneously in the hope of avoiding the growth of a target antigen-negative population. We are developing a CAR strategy (Hegde M et al. Mol Ther. 2013; Vol. 21 (Issue 11): pp. 2087-101).
[0014] T cell-based immunotherapy has become an emerging field in synthetic biology; multiple promoters and gene products are envisioned to guide these highly potent cells into the tumor microenvironment, where T Cells can escape negative regulatory signals and mediate effective tumor killing. Elimination of unwanted T cells via drug-induced dimerization of inducible caspase-9 constructs with chemical dimerization agents such as AP1903 is pharmacologically triggered by a powerful switch that can control T cell populations. (Di Stasi A et al., N Engl J Med. 2011; 365(18): 1673-83). The creation of effector T cell populations that are immune to the negative regulatory effects of transforming growth factor-β by expression of decoy receptors further increases the extent to which effector T cells can be engineered for optimal antitumor activity. (Foster AE et al. J Immunother. 2008; Vol. 31 (No. 5): pp. 500-5). Thus, it appears that CAR can induce T cell activation in a manner similar to the endogenous T cell receptor, but the major obstacle to clinical application of this technology to date is the limited availability of CAR+ T cells. in vivo proliferation, rapid disappearance of cells after injection, and disappointing clinical activity. This may be partially due to the murine origin of some of the CAR sequences used.
[0015] The use of blinatumomab, a bispecific anti-CD19 and anti-CD3 antibody, has shown impressive results in sicker patients who received this therapy. Still, long-term remission rates are less than 40%, and at most only 50% of responders can be elevated to hematopoietic stem cell transplantation (HSCT) (Benjamin, JE, Stein AS, 2016, Therapeutic Advances in See Gore et al., 2014, NCT01471782, and Von Stackelberg et al., 2014, NCT01471782, summarized in Hematology 7:142-156). The requirement for patients receiving either bispecific antibody or CAR-T therapy to subsequently undergo HSCT to maintain long-term responses remains an area of active debate. Although high responses have been reported for CD19 CAR-T trials, even exceeding 90%, if the trial is recalculated as an "intent to treat" trial, the figure could approach 70%. (Davis KL, Mackall CL, 2016, Blood Advances vol. 1: 265-268). The best reported results at 12 months after CAR19 treatment show 55% RFS and 79% OS in patients who were able to receive T-cell products at the University of Pennsylvania (Maude SL, Teachey DT, Rheingold SR, Shaw PA, Aplenc R, Barrett DM, Barker CS, Callahan C, Frey NV, Farzana N, Lacey SF, Zheng A, Levine B, Melenhorst JJ, Motley L, Prter DL, June CH, Grupp SA , 2016, J Clin Oncol Volume 34, Special Issue 15 (May 2016) pp. 3011-3011). [Summary of the invention] [Problem to be solved by the invention]
[0016] Therefore, novel compositions and methods for the treatment of B-ALL and other CD19- and / or CD22-expressing B-cell malignancies using techniques that can exhibit specific and effective antitumor effects without the above-mentioned drawbacks. There is an urgent and long-standing need in the art to find a method. [Means to solve the problem]
[0017] The present invention addresses these needs by providing CAR compositions and therapeutic methods that can be used to treat cancer and other diseases and / or conditions. In particular, the invention disclosed and described herein provides CARs that can be used to treat diseases, disorders, or conditions associated with dysregulated expression of CD19 and / or CD22, where the CAR Contains tandem CD19 / CD22 antigen-binding domains that exhibit high surface expression on transduced T cells and exhibit a high degree of cytolysis of CD19-expressing cells and in vivo proliferation and persistence of transduced T cells.
[0018] overview Novel tandem CD19 and CD22 targeting antibodies or antigen binding domains thereof, in which the CD19 targeting moiety is placed either before or after the CD22 targeting moiety in the amino acid sequence (hereinafter referred to as "CD19 / CD22") , and chimeric antigen receptors (tandem CARs) comprising such CD19 and / or CD22 antigen binding domains, and host cells (e.g., T cells) expressing the receptors, and nucleic acid molecules encoding the receptors. provided herein. CAR exhibits high surface expression on transduced T cells, a high degree of cytolysis, and proliferation and persistence of transduced T cells in vivo. Also provided are methods of using the disclosed CARs, host cells, and nucleic acid molecules, eg, to treat cancer in a subject.
[0019] In one aspect, a tandem CD19 / CD22 chimeric antigen receptor (CAR ), wherein the tandem CD19 / CD22 CAR is SEQ ID NO: 1, 3, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, and 86.
[0020] In one aspect, a tandem CD19 / CD22 chimeric antigen receptor (CAR ) is provided, from SEQ ID NOs: 1, 3, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, and 86. The tandem CD19 / CD22CAR encoded by a nucleic acid sequence selected from the group consisting of and 87.
[0021] In one embodiment, an isolated nucleic acid molecule encoding a CAR is provided, wherein the encoded extracellular CD19 / CD22 antigen binding domain comprises at least one single chain variable fragment of an antibody that binds CD19 / CD22. Ru.
[0022] In another embodiment, an isolated nucleic acid molecule encoding a CAR is provided, wherein the encoded extracellular CD19 / CD22 antigen binding domain comprises at least one heavy chain variable region of an antibody that binds CD19 / CD22. be done.
[0023] In yet another embodiment, the encoded CAR extracellular CD19 / CD22 antigen binding domain further comprises at least one lipocalin-based antigen binding antigen (anticalin) that binds CD19 / CD22. Isolated nucleic acid molecules are provided.
[0024] In one embodiment, an isolated nucleic acid molecule is provided in which an encoded extracellular CD19 / CD22 antigen binding domain is connected to a transmembrane domain by a linker domain.
[0025] In another embodiment, an isolated nucleic acid molecule encoding a CAR is provided, wherein the encoded CD19 / CD22 extracellular antigen binding domain is preceded by a sequence encoding a leader or signal peptide.
[0026] In yet another embodiment, the CD19 / CD22 nucleotide sequence comprised within SEQ ID NOs: 1, 3, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, and 86. An isolated nucleic acid molecule is provided encoding a CAR comprising at least one CD19 / CD22 antigen binding domain, each encoded by a nucleotide sequence comprising: CD22, ROR1, mesothelin, CD33, CD38, CD123. (IL3RA), CD138, BCMA(CD269), GPC2, GPC3, FGFR4, c-Met, PSMA, glycolipid F77, EGFRvIII, GD-2, TSLPR, NY-ESO-1 TCR, MAGE A3 TCR, or any of these It further encodes an extracellular antigen binding domain that targets antigens including, but not limited to, combinations of.
[0027] In one embodiment, the CAR construct is composed of two CAR chains co-expressed via a 2A ribosome skipping element in the same cell, one CAR chain containing a targeting domain directed to the CD19 antigen; The other CAR chain contains a CAR targeting domain directed to the CD22 antigen. Each chain includes a hinge / linker / spacer domain, a transmembrane domain, and a CD3z activation domain fused in frame to a targeting domain. Each CAR chain may include one or more costimulatory domains in-frame.
[0028] In one embodiment, the CAR chain comprises two co-stimulatory domains linked in succession (3rd generation CAR).
[0029] In certain embodiments, the extracellular antigen binding domain further encoded is an anti-CD22 scFV antigen binding domain, an anti-ROR1 scFV antigen binding domain, an anti-mesothelin scFV antigen binding domain, an anti-CD33 scFV antigen binding domain. , anti-CD38 scFV antigen-binding domain, anti-CD123 (IL3RA) scFV antigen-binding domain, anti-CD138 scFV antigen-binding domain, anti-BCMA (CD269) scFV antigen-binding domain, anti-GPC2 scFV antigen-binding domain, anti-GPC3 scFV Antigen-binding domain, anti-FGFR4 scFV antigen-binding domain, anti-TSLPR ScFv antigen-binding domain, anti-c-Met scFV antigen-binding domain, anti-PMSA scFV antigen-binding domain, anti-glycolipid F77 scFV antigen-binding domain, anti- EGFRvIII scFV antigen-binding domain, anti-GD-2 scFV antigen-binding domain, anti-NY-ESO-1 TCR scFV antigen-binding domain, anti-MAGE A3 TCR scFV antigen-binding domain, or 85%, 90%, 95%, Isolated nucleic acid molecules encoding CARs are provided that include amino acid sequences thereof having 96%, 97%, 98% or 99% identity, or any combination thereof.
[0030] In one aspect, the CAR provided herein further comprises a linker or spacer domain.
[0031] In one embodiment, an isolated nucleic acid molecule encoding a CAR, wherein the extracellular CD19 / CD22 antigen binding domain, the intracellular signaling domain, or both, is connected to the transmembrane domain by a linker or spacer domain. provided.
[0032] In one embodiment, an isolated nucleic acid molecule encoding a CAR is provided, wherein the encoded linker domain is derived from the extracellular domain of CD8 or CD28 and is linked to a transmembrane domain.
[0033] In another embodiment, the encoded CAR is a T cell receptor alpha, beta or zeta chain, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80. , CD83, CD86, CD134, CD137, and CD154, or a combination thereof. Ru.
[0034] In yet another embodiment, an isolated nucleic acid molecule encoding a CAR is provided, wherein the encoded intracellular signaling domain further comprises a CD3 zeta intracellular domain.
[0035] In one embodiment, an isolated nucleic acid molecule encoding a CAR is provided, wherein the encoded intracellular signaling domain is positioned C-terminal to the CD3 zeta intracellular domain.
[0036] In another embodiment, an isolated nucleic acid molecule encoding a CAR is provided, wherein the at least one encoded intracellular signaling domain comprises a costimulatory domain, a primary signaling domain, or a combination thereof.
[0037] In a further embodiment, the at least one costimulatory domain encoded is OX40, CD70, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), DAP10, DAP12 and 4- Isolated nucleic acid molecules encoding CARs are provided that include functional signaling domains of 1BB (CD137), or combinations thereof.
[0038] In one embodiment, an isolated nucleic acid molecule encoding a CAR is provided, further comprising a leader sequence or signal peptide, wherein the nucleotide sequence of the leader or signal peptide comprises the nucleotide sequence of SEQ ID NO: 11.
[0039] In yet another embodiment, an isolated nucleic acid molecule encoding a CAR is provided, wherein the encoded leader sequence comprises the amino acid sequence of SEQ ID NO: 12.
[0040] In one embodiment, the chimeric antigen receptor (CAR) comprises, from N-terminus to C-terminus, at least one extracellular CD19 / CD22 antigen binding domain, at least one transmembrane domain, and at least one intracellular signaling domain. Provided herein.
[0041] In one embodiment, the extracellular CD19 / CD22 antigen binding domain comprises at least one single chain variable fragment of an antibody that binds an antigen, or at least one heavy chain variable region of an antibody that binds an antigen, or a combination thereof. Including, CAR is provided.
[0042] In another embodiment, the at least one transmembrane domain is the alpha, beta or zeta chain of a T cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64. , CD80, CD86, CD134, CD137, CD154, TNFRSF19, or a combination thereof.
[0043] In some embodiments, the CAR is CD22, ROR1, mesothelin, CD33, CD38, CD123 (IL3RA), CD138, BCMA (CD269), GPC2, GPC3, FGFR4, TSLPR, c-Met, PSMA, glycolipid F77, EGFRvIII, GD-2, TSLPR, NY-ESO-1 TCR, MAGE A3 TCR, or an amino acid sequence thereof having 85%, 90%, 95%, 96%, 97%, 98% or 99% identity, or CARs are provided that further encode extracellular antigen binding domains comprising any combination thereof.
[0044] In one embodiment, the extracellular antigen binding domain is an anti-CD22 scFV antigen binding domain, an anti-ROR1 scFV antigen binding domain, an anti-mesothelin scFV antigen binding domain, an anti-CD33 scFV antigen binding domain, an anti-CD38 scFV antigen binding domain. anti-CD123 (IL3RA) scFV antigen-binding domain, anti-CD138 scFV antigen-binding domain, anti-BCMA (CD269) scFV antigen-binding domain, anti-GPC2 scFV antigen-binding domain, anti-GPC3 scFV antigen-binding domain, FGFR4 scFV antigen-binding domain, anti-TSLPR ScFv antigen-binding domain, anti-c-Met scFV antigen-binding domain, anti-PMSA scFV antigen-binding domain, anti-glycolipid F77 scFV antigen-binding domain, anti-EGFRvIII scFV antigen-binding domain , anti-GD-2 scFV antigen-binding domain, anti-NY-ESO-1 TCR scFV antigen-binding domain, anti-MAGE A3 TCR scFV antigen-binding domain, or 85%, 90%, 95%, 96%, 97%, CARs are provided that include amino acid sequences thereof with 98% or 99% identity, or any combination thereof.
[0045] In another embodiment, a CAR is provided, wherein the at least one intracellular signaling domain comprises a costimulatory domain and a primary signaling domain.
[0046] In yet another embodiment, the at least one intracellular signaling domain comprises OX40, CD70, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), DAP10, DAP12, and A CAR is provided that includes a costimulatory domain that includes a functional signaling domain of a protein selected from the group consisting of 4-1BB (CD137), or a combination thereof.
[0047] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO:1. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO:2.
[0048] In another embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO:3.
[0049] In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO:4. In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO: 60.
[0050] In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO:61.
[0051] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO: 62. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO: 63.
[0052] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO: 64. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO: 65.
[0053] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO: 66. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO:67.
[0054] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO: 68. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO: 69.
[0055] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO:70. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO:71.
[0056] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO: 72. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO:73.
[0057] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO:74. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO:75.
[0058] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO: 76. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO:77.
[0059] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO: 78. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO:79.
[0060] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO:80. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO:81.
[0061] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO:82. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO:83.
[0062] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO:84. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO:85.
[0063] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO:86. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO:87.
[0064] In one aspect, the CARs disclosed herein are used for use in diagnosis, monitoring and / or predicting treatment outcomes such as progression-free survival of cancer patients, or for monitoring the progress of such treatment. Modified to express or contain a detectable marker.
[0065] In one embodiment, a nucleic acid molecule encoding a disclosed CAR can be contained in a vector, such as a viral vector. The vector is a DNA vector, an RNA vector, a plasmid vector, a cosmid vector, a herpesvirus vector, a measles virus vector, a lentiviral vector, an adenoviral vector, or a retroviral vector, or a combination thereof.
[0066] In certain embodiments, the vector further comprises a promoter that is an inducible promoter, a tissue-specific promoter, a constitutive promoter, a suicide promoter, or any combination thereof.
[0067] In yet another embodiment, the CAR-expressing vector includes one or more operable elements to control expression of CAR T cells or eliminate CAR-T cells by a suicide switch. may be further modified. A suicide switch can include, for example, an apoptotic signaling cascade or a drug that induces cell death. In preferred embodiments, vectors expressing CARs can be further modified to express enzymes such as thymidine kinase (TK) or cytosine deaminase (CD).
[0068] In another embodiment, a host cell comprising a nucleic acid molecule encoding a CAR is also provided. In some embodiments, the host cell is a T cell, eg, a primary T cell obtained from the subject. In one embodiment, the host cell is CD8 + They are T cells.
[0069] In yet another embodiment, a pharmaceutical composition comprising an antitumor effective amount of a population of human T cells, wherein the T cells are SEQ ID NO: 2, 4, 61, 63, 65, 67, 69, 71, 73, 75, at least one extracellular antigen comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR) comprising an amino acid sequence of 77, 79, 81, 83, 85, and 87, the CAR comprising a CD19 / CD22 antigen binding domain; A pharmaceutical composition is provided comprising a binding domain, at least one linker domain, at least one transmembrane domain, and at least one intracellular signaling domain, wherein the T cell is a T cell of a human having cancer. . Cancer is inter alia a hematological cancer, such as leukemia (e.g. chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL) or chronic myeloid leukemia (CML)), lymphoma (e.g. mantle cell lymphoma, non-Hodgkin's lymphoma or Hodgkin's lymphoma) or multiple myeloma, or a combination thereof.
[0070] In one embodiment, at least one transmembrane domain of the CAR is a T cell receptor alpha, beta or zeta chain, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, mesothelin, CD33, A pharmaceutical composition is provided comprising a transmembrane domain of a protein selected from the group consisting of CD37, CD64, CD80, CD83, CD86, CD134, CD137, CD154, TNFRSF19, or a combination thereof.
[0071] In another embodiment, the human cancer is oral and pharyngeal cancer (tongue, mouth, pharynx, head and neck), gastrointestinal cancer (esophageal, stomach, small intestine, colon, rectum, anus, liver, intrahepatic cancers of the respiratory system (larynx, lungs and bronchi); cancers of the bone and joints; soft tissue cancers; skin cancers (melanoma, basal cell carcinoma and squamous cell carcinoma); childhood tumors ( neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma), tumors of the central nervous system (brain tumor, astrocytoma, glioblastoma, glioma), and breast, reproductive system (cervix, uterine body, ovaries, vulva, vagina, prostate, testes, penis, endometrium), urinary system (bladder, kidneys and renal pelvis, ureter), eyes and orbits, endocrine system (thyroid), and brain and other nervous systems or any combination thereof.
[0072] In yet another embodiment, a pharmaceutical composition comprising an antitumor effective amount of a population of human T cells in a human having cancer, wherein the cancer is unresponsive to one or more chemotherapeutic agents. A pharmaceutical composition is provided for refractory cancer. Cancer includes hematopoietic cancer, myelodysplastic syndrome, pancreatic cancer, head and neck cancer, skin tumor, acute lymphoblastic leukemia (ALL), minimal residual disease (MRD) in acute myeloid leukemia (AML), Adult B-cell malignancies, including CLL (chronic lymphocytic leukemia), CML (chronic myeloid leukemia), non-Hodgkin's lymphoma (NHL), pediatric B-cell malignancies (including B-cell lineage ALL (acute lymphocytic leukemia)), including multiple myeloma, lung cancer, breast cancer, ovarian cancer, prostate cancer, colon cancer, melanoma or other hematological cancers and solid tumors, or any combination thereof.
[0073] In another aspect, a method of producing CAR-containing T cells (hereinafter "CAR T cells") is provided. The method involves transducing a T cell with a vector or nucleic acid molecule encoding a disclosed CAR that specifically binds CD19 and / or CD22, thereby generating a CAR T cell.
[0074] In yet another embodiment, a method of generating a population of RNA-engineered cells, comprising introducing in vitro transcribed RNA or synthetic RNA of a disclosed CAR-encoding nucleic acid molecule into a subject's cells; A method is provided that includes producing a cell.
[0075] In one embodiment, the disease, disorder or condition associated with CD19 expression is hematopoietic cancer, myelodysplastic syndrome, pancreatic cancer, head and neck cancer, skin tumor, acute lymphoblastic leukemia (ALL), acute bone marrow Adult B-cell malignancies, including minimal residual disease (MRD) in sexual leukemia (AML), CLL (chronic lymphocytic leukemia), CML (chronic myelogenous leukemia), and non-Hodgkin's lymphoma (NHL), and pediatric B-cell malignancies (B cell lineage ALL (acute lymphoblastic leukemia)), multiple myeloma, lung cancer, breast cancer, ovarian cancer, prostate cancer, colon cancer, melanoma or other hematological cancers and solid tumors; or any combination thereof.
[0076] In another embodiment, a method of altering the tumor microenvironment to block T cell inhibition mediated by cells expressing CD19 and / or CD22 and inhibit tumor growth in a mammal, the method comprising: administering to the mammal an effective amount of the composition, wherein the CAR is SEQ ID NO. , and 87. In one embodiment, the cells are selected from the group consisting of tumor cells expressing CD19 and / or CD22, tumor-associated macrophages, and any combination thereof.
[0077] In another embodiment, a method of inhibiting, suppressing or preventing immunosuppression of an anti-tumor or anti-cancer immune response in a mammal, the method comprising: administering to the mammal an effective amount of a composition comprising a CAR. , CAR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, and 87. A method is provided that includes steps. In one embodiment, the CAR inhibits the interaction between the first cell and the T cell, and the first cell is a tumor cell expressing CD19 and / or CD22, a tumor-associated macrophage, and any of their selected from the group consisting of combinations.
[0078] In another embodiment, a method of inducing anti-tumor immunity in a mammal, the method comprising administering to the mammal a therapeutically effective amount of T cells transduced with a vector or nucleic acid molecule encoding a disclosed CAR. , a method is provided.
[0079] In another embodiment, a method of treating or preventing cancer in a mammal, comprising administering one or more disclosed CARs to the mammal in an amount effective to treat or prevent cancer in the mammal. A method is provided comprising the step of administering to a patient. The method comprises: under conditions sufficient to form an immune complex in a subject with an antigen binding domain of a CAR and an extracellular domain of CD19 and / or CD22 and / or one or more of the above-mentioned antigens; administering to the subject a therapeutically effective amount of host cells expressing a disclosed CAR that specifically binds CD19 and / or CD22 and / or one or more of the above-mentioned antigens.
[0080] In yet another embodiment, a method of treating a mammal having a disease, disorder or condition associated with elevated expression of a tumor antigen, comprising administering to the subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells. the T cell comprises a nucleic acid sequence encoding a chimeric antigen receptor (CAR), the CAR comprising at least one extracellular CD19 and / or CD22 antigen binding domain, or any combination thereof, at least one a linker or spacer domain, at least one transmembrane domain, at least one intracellular signaling domain, and the T cell is a T cell of a subject having cancer.
[0081] In yet another embodiment, a method of treating cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising an antitumor effective amount of a population of T cells, wherein the T cells are chimeric. 2, 4, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, and 87. or any combination thereof, wherein the T cell is a T cell of a subject having cancer. In some embodiments of the methods described above, the at least one transmembrane domain is a transmembrane alpha, beta or zeta chain of a T cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, including CD19, CD22, mesothelin, CD33, CD37, CD64, CD80, CD83, CD86, CD134, CD137, CD154, TNFRSF16, TNFRSF19, or combinations thereof.
[0082] In yet another embodiment, a method is provided for generating a persistent population of genetically engineered T cells in a human diagnosed with cancer. In one embodiment, the method comprises administering to a human a T cell genetically engineered to express a CAR, the CAR comprising: 73, 75, 77, 79, 81, 83, 85, and 87 amino acid sequences, or any combination thereof, at least one transmembrane domain, and at least one intracellular signaling domain, and are genetically engineered A persistent population of T cells, or a population of T cell progeny, is present at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months after administration. including steps that persist in humans for months, 9 months, 10 months, 11 months, 12 months, 2 years or 3 years.
[0083] In one embodiment, the progeny T cells in the human include memory T cells. In another embodiment, the T cells are autologous T cells.
[0084] In all of the method aspects and embodiments described herein, any of the cancers, diseases, disorders or conditions described above that are associated with elevated expression of tumor antigens are One or more of them can be used to treat or prevent or ameliorate.
[0085] In yet another embodiment, a kit for producing a chimeric antigen receptor T cell as described above, or in a subject as described above, prevents, treats or treats any cancer, disease, disorder or condition associated with elevated expression of a tumor antigen. A kit for achieving remission, comprising a container containing any one or any combination of the nucleic acid molecules, vectors, host cells or compositions disclosed above, and instructions for using the kit. Kit provided.
[0086] It is understood that the CARs, host cells, nucleic acids and methods have utility beyond the specific aspects and embodiments described in detail herein. The foregoing features and advantages of the present disclosure will become more apparent from the following detailed description, which proceeds with reference to the accompanying drawings. [Brief explanation of the drawing]
[0087] [Figure 1A] FIG. 3 shows a tandem CAR construct targeting CD22 and CD19. Figure 1A: Anti-CD22 and anti-CD19 dual-targeting CAR construct (CAR22-19) combines a single-chain fragment variable sequence membrane distal domain that targets the CD22 antigen with a membrane distal domain that targets the CD19 antigen through a flexible glycine-serine linker. was created by linking the targeting single chain fragment to a variable sequence (membrane proximal). The resulting CD22-CD19 dual targeting domain was then connected in frame to the CD8 hinge and transmembrane domain, the 4-1BB (CD137) signaling domain, and the CD3 zeta signaling domain. [Figure 1B] FIG. 3 shows a tandem CAR construct targeting CD22 and CD19. Figure 1B: Tandem targeting construct CAR19-22 connects the single chain fragment variable region of CD19 (distal to the cell membrane) via a glycine serine flexible linker to the single chain variable region of the CD22 targeting sequence (proximal to the membrane). It was produced in the same manner, except that after linking to the CD8, 4-1BB, and CD3 zeta domains. Each CAR T construct can be activated by binding to either CD19 or CD22 tumor antigens or both.
Figure 2
[0088] detailed description definition As used herein, the singular forms "a," "an," and "the" refer to singular and plural references unless the context clearly dictates otherwise. refers to both. For example, the term "an antigen" includes single or multiple antigens and can be considered equivalent to the phrase "at least one antigen." As used herein, the term "comprises" means "includes." Thus, "comprising one antigen" means "including one antigen," without excluding other elements. The phrase "and / or" means "and" or "or." It is further understood that any and all base or amino acid sizes and all molecular weight or molecular mass values given for nucleic acids or polypeptides are approximate and provided for convenience, unless otherwise specified. It is. Although many methods and materials similar or equivalent to those described herein can be used, particularly suitable methods and materials are described below. In case of conflict, the present specification, including explanations of terms, will control. Furthermore, the materials, methods, and examples are illustrative only and not intended to be limiting. To facilitate review of the various embodiments, the following explanation of terminology is provided.
[0089] The term "about" when referring to a measurable value, e.g., amount, duration of time, etc., means ±20%, or in some instances ±10%, or in some instances from the specified value. is meant to encompass variations of ±5%, or in some instances ±1%, or in some instances ±0.1%, where such variations are appropriate for practicing the disclosed methods. .
[0090] Unless otherwise specified, technical terms herein are used according to conventional usage. Definitions of common terms in molecular biology, Benjamin Lewin, Genes VII, published by Oxford University Press, 1999; Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994; and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, 1995, published by VCH Publishers, Inc.; and other similar references.
[0091] The present disclosure provides CD19 / CD22 antibodies or fragments thereof, and chimeric antigen receptors (CARs) having such CD19 / CD22 antigen binding domains. Enhanced functional activity of CAR is directly related to enhanced functional activity of T cells expressing CAR. As a result of one or more of these modifications, CAR induces a high level of cytokine-induced cytolysis and transduced T cells, along with increased levels of T cell proliferation and persistence of transduced CAR-expressing T cells in vivo. Both cell surface expression and cell surface expression are shown. The CARs of the present disclosure can utilize one CART lentiviral product to treat multiple patient populations (i.e., CD19+, CD22+, or dual CD19+CD22+ cancer patients), thereby saving resources. It is advantageous in that it is flexible in limited situations.
[0092] The unique ability to combine functional moieties derived from different protein domains is an important and innovative feature of chimeric antigen receptors (CARs). The selection of each of these protein domains, as well as their specific combination, is an important design feature. Each design domain is an essential building block that can be used to manipulate lymphocyte function in various CAR platforms. For example, selection of the extracellular binding domain can enable an otherwise ineffective CAR.
[0093] The nonvariable framework components of immunoglobulin-derived protein sequences used to create the extracellular antigen-binding domain of the CAR are either completely neutral or self-associate to drive T cells into a state of metabolic exhaustion. This can make therapeutic T cells expressing this CAR extremely ineffective. This occurs independently of the antigen binding function of this CAR domain. Additionally, the choice of intracellular signaling domain(s) can also determine the activity and durability of the therapeutic lymphocyte population used for immunotherapy. These extracellular and intracellular domains provide a source of extracellular antigen-binding fragments, while the ability to bind target antigens and convey activation signals to T cells are important aspects of CAR design, respectively. It has also become clear that the choice of CAR can have a significant effect on the efficacy of the CAR and therefore have a decisive role in the function and clinical utility of the CAR.
[0094] The CARs disclosed herein are expressed at high levels in cells. Cells expressing CAR have a high proliferation rate in vivo, produce large amounts of cytokines, and have high cytotoxic activity against cells that have the CD19 / CD22 antigen on their surface to which CAR binds. Use of extracellular CD19 / CD22 antigen-binding domains results in the generation of CARs that function better in vivo while avoiding induction of anti-CAR immunity and killing of CAR T cell populations in the host immune response be done. CARs expressing the extracellular CD19 / CD22ScFv antigen-binding domain should i) prevent CAR T persistence and functional deficiencies seen with mouse-derived binding sequences; ii) localize the CAR to be effective (i.e., pleural and iii) the ability to generate CAR T cell designs based on binders with both high and low affinity for CD19 / CD22. This last property allows binders with lower affinity to have greater specificity for tumors than for normal tissues, as tumors express more CD19 / CD22 than normal tissues. , which may prevent non-on-target tumor toxicity and bystander cell death, allowing researchers to better tune the toxicity efficacy and / or tissue specificity of CAR T products. .
[0095] Additional description of CARs, antibodies and antigen-binding fragments thereof, conjugates, nucleotides, expression, vectors and host cells, methods of treatment, compositions and kits using the disclosed CARs, as well as their extracellular CD19 / CD22 antigens. A detailed description of the CAR of the invention, including a description of the binding domain, transmembrane domain and intracellular domain, follows.
[0096] A. Chimeric antigen receptor (CAR) The CARs disclosed herein include at least one CD19 / CD22 antigen binding domain, at least one transmembrane domain, and at least one intracellular domain capable of binding CD19 / CD22.
[0097] Chimeric antigen receptors (CARs) are artificially constructed proteins that contain the antigen-binding domain of an antibody (e.g., a single chain variable fragment (scFv)) linked to a T cell signaling domain via a transmembrane domain. hybrid protein or polypeptide. Characteristics of CARs include their ability to exploit the antigen-binding properties of monoclonal antibodies to redirect T cell specificity and reactivity toward selected targets in a non-MHC-restricted manner. Non-MHC-restricted antigen recognition gives CAR-expressing T cells the ability to recognize antigens independent of antigen processing, thus bypassing key mechanisms of tumor escape. Furthermore, when expressed in T cells, CAR advantageously does not dimerize with the alpha and beta chains of the endogenous T cell receptor (TCR).
[0098] As disclosed herein, the intracellular T cell signaling domain of a CAR can include, for example, a T cell receptor signaling domain, a T cell costimulatory signaling domain, or both. T cell receptor signaling domain refers to a portion of a CAR, including the intracellular domain of the T cell receptor, such as, but not limited to, the intracellular portion of the CD3 zeta protein. Co-stimulatory signaling domain is the portion of a CAR that contains the intracellular domain of costimulatory molecules, which are cell surface molecules other than antigen receptors or their ligands that are required for the efficient response of lymphocytes to antigens. refers to
[0099] 1. Extracellular domain In one embodiment, the CAR includes a target-specific binding element, otherwise referred to as an antigen-binding domain or moiety. The choice of domain depends on the type and number of ligands that define the surface of the target cell. For example, an antigen binding domain can be selected to recognize a ligand that acts as a cell surface marker on target cells associated with a particular disease state. Thus, examples of cell surface markers that can act as ligands for antigen binding domains in CARs include those associated with viral, bacterial and parasitic infections, autoimmune diseases and cancer cells.
[0100] In one embodiment, a CAR can be engineered to target a tumor antigen of interest by engineering the desired antigen binding domain to specifically bind to the antigen on tumor cells. Tumor antigens are proteins produced by tumor cells that elicit an immune response, particularly a T cell-mediated immune response. The choice of antigen binding domain depends on the particular type of cancer being treated. Tumor antigens include, for example, glioma-associated antigen, carcinoembryonic antigen (CEA), beta-human chorionic gonadotropin, alpha-fetoprotein (AFP), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CA IX, human Telomerase reverse transcriptase, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostase, prostate-specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostein, PSMA, Her2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), MAGE, ELF2M, neutrophil elastase, ephrinB2, CD22, insulin-like growth factor (insulin growth factor) (IGF)-I, IGF-II, IGF-I receptor, and CD19 / CD22. The tumor antigens disclosed herein are included by way of example only. This list is not intended to be exclusive, and additional examples will be readily apparent to those skilled in the art.
[0101] In one embodiment, the tumor antigen comprises one or more antigenic cancer epitopes associated with malignancy. Malignant tumors express several proteins that can serve as target antigens for immune attack. These molecules include tissue-specific antigens, such as MART-1, tyrosinase and GP 100 in melanoma, and prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) in prostate cancer. Not limited. Other target molecules belong to the group of transformation-related molecules such as the oncogene HER-2 / Neu / ErbB-2. Yet another group of target antigens are carcinoembryonic antigens, such as carcinoembryonic antigen (CEA). In B-cell lymphomas, tumor-specific idiotypic immunoglobulins constitute truly tumor-specific immunoglobulin antigens that are unique to each individual tumor. B cell differentiation antigens such as CD19, CD22, CD22, BCMA, ROR1, and CD37 are other candidates for target antigens in B cell lymphomas. Some of these antigens (CEA, HER-2, CD19, CD22, idiotype) have been used as targets for passive immunotherapy with monoclonal antibodies with limited success.
[0102] In a preferred embodiment, the tumor antigen is CD19 / CD22 and the tumor associated with CD19 / CD22 expression is lung mesothelioma, ovarian and pancreatic cancer, or those that express high levels of the extracellular protein CD19 / CD22. including any combination of
[0103] The type of tumor antigen can also be a tumor-specific antigen (TSA) or a tumor-associated antigen (TAA). TSA is unique to tumor cells and is not present on other cells in the body. TAAs are not unique to tumor cells; instead, they are also expressed on normal cells under conditions that fail to induce a state of immunological tolerance to the antigen. Expression of antigens on tumors can occur under conditions that allow the immune system to respond to the antigen. TAAs can be antigens that are expressed on normal cells during fetal development, when the immune system is immature and unable to respond, or they are usually present at very low levels on normal cells, but at much higher levels on tumor cells. can be an antigen expressed in
[0104] Non-limiting examples of TSAs or TAAs include: differentiation antigens, such as MART-1 / MelanA (MART-I), gp100 (Pmel 17), tyrosinase, TRP-1, TRP-2 and tumors. specific multilineage antigens, e.g. MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, p15; overexpressed embryonic antigens, e.g. CEA; overexpressed oncogenes and mutated tumor suppressors genes, e.g. p53, Ras, HER-2 / neu; unique tumor antigens resulting from chromosomal translocations; e.g. BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR; and viral antigens, For example, Epstein-Barr virus antigen EBVA and human papillomavirus (HPV) antigens E6 and E7. Other large protein-based antigens include TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY-ESO, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG- 72, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, beta-catenin, CDK4, Mum-1, p 15, p 16, 43-9F, 5T4, 791Tgp72, alpha-fetoprotein, beta -HCG, BCA225, BTAA, CA 125, CA 15-3 / CA 27.29 / BCAA, CA 195, CA 242, CA-50, CAM43, CD68 / P1, CO-029, FGF-5, G250, Ga733 / EpCAM, HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB / 70K, NY-CO-1, RCAS1, SDCCAG16, TA-90 / Mac-2 binding protein / cyclophilin C-related protein, TAAL6, TAG72, TLP and TPS included.
[0105] In one embodiment, the antigen binding domain portion of the CAR includes CD19, CD20, CD22, ROR1, CD33, CD38, CD123, CD138, BCMA, c-Met, PSMA, Glycolipid F77, EGFRvIII, GD-2, FGFR4, Targeting antigens including but not limited to TSLPR, NY-ESO-1 TCR, MAGE A3 TCR, etc.
[0106] In a preferred embodiment, the antigen binding domain portion of the CAR targets extracellular CD19 / CD22 antigen.
[0107] In various embodiments of the CD19 / CD22-specific CARs disclosed herein, the general scheme is specified in Figures 1A and 1B, from N-terminus to C-terminus, signal or leader peptide, anti-CD19 / CD22 ScFv (CD19 The binder is distal to the T cell membrane and the CD22 binder is proximal to the T cell membrane, or the CD22 binder is distal to the T cell membrane and the CD19 binder is proximal to the T cell membrane. ), contains the CD8 extracellular linker, the CD8 transmembrane domain, the 4-1BB costimulatory domain, and the CD3 zeta activation domain.
[0108] In one embodiment, the nucleic acid sequence encoding the CAR is SEQ ID NO. Construct 2219)) containing the nucleic acid sequence of SEQ ID NO: 2 Leader-CD22VH-(GGGGS)-3 CD22VL(GGGGS)-5 CD19VH(GGGGS)-3 CD19VL CD8 Hinge+TM-4-1BB-CD3z (Construct 2219) encodes a CAR containing the amino acid sequence shown.
[0109] In one embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO: 1, or a sequence thereof having 85%, 90%, 95%, 96%, 97%, 98% or 99% identity. , the amino acid sequence shown in SEQ ID NO: 2, or its sequence leader with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity -CD22VH-(GGGGS)-3 CD22VL(GGGGS) -5 CD19VH(GGGGS)-3 CD19VL Encodes a CAR containing CD8 hinge+TM-4-1BB-CD3z (construct 2219).
[0110] In another embodiment, the nucleic acid sequence encoding the CAR is SEQ ID NO: 3 (Leader-CD19VH(GGGGS)3-CD19VL-(GGGGS)5-CD22VL-(GGGGS)3-CD22VH CD3z (construct 1922) (Figure 2)) contains the nucleic acid sequence of SEQ ID NO: 4 [Leader-CD19VH(GGGGS)3-CD19VL-(GGGGS)5-CD22VL-(GGGGS)3-CD22VH CD8 hinge+TM-4- 1BB-CD3z (construct 1922)].
[0111] In another embodiment, the CAR-encoding nucleic acid sequence has 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the nucleic acid sequence of SEQ ID NO. (Leader-CD19VH (GGGGS )3-CD19VL-(GGGGS)5-CD22VL-(GGGGS)3-CD22VHCD8hinge+TM-4-1BB-CD3z (construct 1922)).
[0112] Surface expression of anti-CD19 / CD22 CARs incorporating single chain fragment variable (ScFv) sequences reactive with CD19 / CD22 antigens is demonstrated in Example 2 below. Expression levels for each CAR containing ScFv were determined by flow cytometric analysis of LV-transduced T cells from healthy donors using two detection methods: i) CD22 his followed by anti-his-FL; ii) CD19 Fc recombinant protein followed by anti-Fc-FL was determined. ScFv-based anti-CD19 / CD22 CAR constructs CAR22-19 and CAR19-22 were highly expressed in human primary T cells compared to non-transduced T cell controls.
[0113] As shown in Example 2 and FIG. 3, high cytolytic activity of CD19 / CD22CAR was demonstrated. Figure 3: Human primary T cells were transduced with LVs encoding CAR constructs (CAR22-19(LTG2681, D0023), CAR19-22(D0024), CAR19(LTG1538), or CAR22(LTG2200); see Methods ) and then incubated for 18 hours with firefly luciferase stably transduced Raji, REH, K562, or 293T cell lines for fluorescence-based in vitro killing assays. Raji and Reh leukemia lines express CD19 and CD22 on their surface, whereas the negative control, 293T, does not. Raji and REH cells were effectively lysed by tandem CAR22-19 (LTG2681), tandem CAR19-22 (LTG2719), and single targeting CAR19 (LTG1538) and CAR22 (LTG2200). These results demonstrate limited killing of the target antigen by the single CAR control and the tandem CD19-targeted CD22-targeted CAR.
[0114] As additional specificity controls, we generated 293T-luc and A431-luc strains expressing CD19, CD20, or CD22 (Figures 4A and 4B). 293T-19+ was lysed by CAR19 (LTG1538) and tandem CAR22-19 (LTG2681), but not by CAR22 LTG2200 or untransduced T cell controls (Figure 3). 293T-CD22+ was lysed by tandem CAR22-19 (LTG2681) and single CAR20 LTG2200, but not by single CAR19 (LTG1538) or non-transduced control, demonstrating the antigen specificity of tandem CAR . Finally, 293T luc CD20 cells were not lysed by the CAR construct as this antigen was not targeted (Figure 4A). Similarly, strain A431-luc 19 was lysed by tandem CAR LTG2681 or single CAR19 LTG1538, but not by CAR22 LTG2200 or UTD control. Vice versa, A431 luc CD22 cells were lysed by tandem CAR lTG2681 or single CAR22 LTG2200, but not by CD19 CAR LTG1538 or UTD control. Notably, the A431-luc CD20 strain, which expresses an unrelated antigen, was not lysed by the CAR construct because the CD20 antigen was not targeted (Figure 4B). This result highlights the independent functionality and specificity of each targeting domain of tandem CAR22-19 (Figure 4). Furthermore, this experiment demonstrated that tandem CAR22-19 is effective against tumor cells even though one of the two antigens (CD19CD22) is down-regulated and no longer expressed. Therefore, tandem CARs may alleviate tumor antigen escape in contrast to single CARs.
[0115] The cytokine secretion ability of anti-CD19 / CD22 CAR T cells was then evaluated (Figure 5). CD19+CD22+Raji tumor cells were combined with tandem 22-19 CAR T cells (LTG2681), positive control CAR19 (LTG1538), positive control CAR22 (LTG2200), or negative control untransduced T cells (UTD) at 10:1. Effector-to-target ratios were co-incubated overnight and culture supernatants were analyzed for IFN gamma, TNF alpha, and IL-2 by ELISA. Tandem CAR22-19 (LTG2681) strongly induced cytokines in response to tumor cells, whereas the negative control (untransduced, UTD) did not result in appreciable cytokine induction. Notably, tandem CAR T-expressing cells, LTG2681, showed similar levels of IFN gamma, TNF alpha, IL-2 as the CAR22 control (LTG2200), and slightly higher cytokine responses than the single CAR19 (LTG1538) control; The high efficacy of the drug was demonstrated. Importantly, CAR22-19 did not result in cytokine secretion in the absence of tumor cells (CART alone group), further confirming CAR specificity and suggesting that tonic signaling by tandem CARs (tonic It was suggested that there was no signaling.
[0116] In another embodiment, the CAR-encoding nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 60 [CD22-19 CD8 BBz (construct LTG2737) (FIGS. 6, 7, 8, and 9, respectively)]; It encodes a CAR containing the amino acid sequence shown in [CD22-19 CD8 BBz (construct LTG2737)].
[0117] In another embodiment, the CAR-encoding nucleic acid sequence has 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the nucleic acid sequence of SEQ ID NO: 60, or to that sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity. (CD22-19 CD8 BBz (Construct LTG2737)).
[0118] In another embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO: 64 [CD22-19 CD8 ICOSz DNA (Construct D0136) (FIGS. 6, 7, 8, and 9, respectively)]; 65 [CD22-19 CD8 ICOSz DNA (Construct D0136)].
[0119] In another embodiment, the CAR-encoding nucleic acid sequence has 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the nucleic acid sequence of SEQ ID NO. (CD22-19 CD8 ICOSz DNA (construct D0136)).
[0120] In another embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO: 70 [CD22-19 CD28 CD28z (Construct D0139) (FIGS. 6, 7, 8, and 9, respectively)]; It encodes a CAR containing the amino acid sequence shown in [CD22-19 CD28 CD28z (construct D0139)].
[0121] In another embodiment, the CAR-encoding nucleic acid sequence has 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the nucleic acid sequence of SEQ ID NO: 70, or to that sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity. (CD22-19 CD28 CD28z (Construct D0139)).
[0122] In another embodiment, the nucleic acid sequence encoding the CAR comprises the nucleic acid sequence of SEQ ID NO: 76 [CD19 CD8H&TM ICOS z_CD22 CD8H&TM 3z (Construct D0146) (Figures 6, 7, 8, and 9, respectively)], 77 [CD19 CD8H&TM ICOS z_CD22 CD8H&TM 3z (Construct D0146)].
[0123] In another embodiment, the CAR-encoding nucleic acid sequence has 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the nucleic acid sequence of SEQ ID NO: 76, or to that sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity. (CD19 CD8H&TM ICOS z_CD22 CD8H&TM 3z (construct D0146)).
[0124] In another embodiment, the nucleic acid sequence encoding the CAR is the nucleic acid sequence of SEQ ID NO: 62, 66, 68, 72, 74, 78, 80, 82, 84, and 86, or 85%, 90%, 95%, the amino acid sequences shown in SEQ ID NOs: 63, 67, 69, 73, 75, 79, 81, 83, 85, and 87, comprising sequences thereof having 96%, 97%, 98% or 99% identity, or 85 %, 90%, 95%, 96%, 97%, 98% or 99% identity.
[0125] Surface expression of anti-CD22 / CD19 CARs incorporating single chain fragment variable (ScFv) sequences reactive with CD22 / CD19 antigens is demonstrated in Example 3 below.
[0126] In one embodiment, a dual targeting CAR construct composed of different costimulatory domains was designed. CAR constructs are listed in Table 1 of Example 3 below. A schematic diagram of the CAR design layout is shown in Figures 6A-C. In some embodiments, tandem CAR antigen-binding domains composed of anti-CD22 scFv and anti-CD19 scFv sequences are linked in tandem in the following order: anti-CD22 scFv-anti-CD19-scFv-hinge-transmembrane domain-internal domain. (Figures 6A, 6B). This targeting tandem domain arrangement is in all cases based on CAR22-19 (LTG2681). Anti-CD22-19 CAR construct LTG2737 was identical to anti-CD22-19 CAR construct LTG2681, but contained a CAR sequence that did not use the woodchuck hepatitis virus (WHP) post-transcriptional regulatory element (WPRE) during its construction. .
[0127] In another embodiment, some CAR T constructs were made by linking the CAR antigen-binding domain in-frame to the CD8a hinge and transmembrane domain, as described below in Example 3 ( constructs LTG2737, D0135, D0136, D0137, D0145, D0146, D0147, D0148, and D0149). Other constructs utilized transmembrane domain sequences matching costimulatory domains, namely CD28 for D139, D140 and OX40 for D0137, D0147, D0148. The transmembrane domain is 4-1BB (LTG2737), CD28 (D0135, D0139, D0140), ICOS (D0136, D0146, D0148, D0149), OX40 (D0137, D0145, D0147, D0148), or CD27 (D0138, D0149) was linked in frame to the derived co-stimulatory domain. All CAR molecules contained a CD3 zeta signaling domain (CD247, aa52-163, Ref Sequence ID: NP_000725.1).
[0128] In yet another embodiment, the internal domain of the CAR was composed of two co-stimulatory domains connected in tandem: CD28 and 4-1BB (D0140, Figure 6B). In some embodiments, two separate CAR molecules were coexpressed in the same T cell using the 2A ribosome skipping element for bicistronic expression (D146, D147, D148, D149, Figures 6C, 6D ). In this arrangement, each CAR chain contains only one scFv targeting either the CD19 or CD22 antigen, and each transduction by transduction with a single lentiviral vector encoding a bicistronic sequence Both chains were co-expressed in T cells.
[0129] Still other embodiments do not use a co-stimulatory domain for at least one CAR chain, such that the CD3ζ The activation domains were joined in frame (D0146, D0147, Figure 6C). CAR construct sequences were cloned into a third generation lentiviral plasmid backbone (Lentigen Technology Inc., Gaithersburg, MD) under the control of the human EF-1α promoter.
[0130] Surface expression of anti-CD22-19 CARs incorporating various costimulatory domains is shown in Figure 7. Expression levels for each ScFv-containing CAR were determined by flow cytometric analysis of LV-transduced T cells from healthy donors by co-staining for two scFv CAR targeting domains, i) CD22-his followed by anti- his-PE, ii) determined using CD19 Fc recombinant protein followed by anti-Fc-A647. All anti-CD22-19 CARs were highly expressed in human primary T cells compared to non-transduced T cell controls. CAR expression levels ranged from 71% to 90% (Figure 7).
[0131] As shown in Figures 9A-9D, high cytolytic activity of anti-CD22-19CAR was demonstrated. Human primary T cells were transduced with LVs encoding the CAR constructs LTG2737, D0135, D0136, D0137, D0138, D0139, D0140, D0145, D0146) and then transduced with firefly luciferase for fluorescence-based in vitro killing assays. Incubated with stably transduced Raji, 293T, 293TCD19, or 293TCD22 cell lines for 18 hours. Effector-to-target (ET) ratios of 2.5:1, 5:1, or 10:1 were used as indicated in the legend to the right of each plot. Raji cells express CD19 and CD22 on their surface, but not the negative control, 293T. 293TCD19 and 293TCD22 target strains were generated to stably express either the CD19 or CD22 target antigen, respectively, and were used to determine whether each single target antigen, CD19 or CD22, was independent of the other antigen. We evaluated the ability of dual-targeted CAR constructs with different co-stimulatory domains to achieve targeted lysis when induced by.
[0132] Raji cells were effectively lysed by all dual-targeted CARs, but not by the negative control, non-transduced T cell UTD (Figure 9A). As a comparison, all dual-targeted CAR constructs lysed the single-antigen strains 293TCD19 and 293TCD22, and these CAR constructs showed that their anti-antigenicity increased when activated by either CD19 antigen alone or CD22 antigen alone. The ability to induce oncolytic function was demonstrated (Figures 9B and 9D, respectively). On the other hand, neither dual-targeted anti-CD22-19 CAR lysed the antigen-negative cell line 293T (Figure 9C). Therefore, all anti-CD22-19CARs function in the tumor Raji line, which co-expresses CD19 and CD22 antigens, and in the 293T CD19 and 293T CD22 lines, which express either CD19 or CD22 single antigens, and D19-CD22- No spontaneous killing activity was shown against cell line 293T, highlighting the target specificity of these constructs.
[0133] The cytokine secretion ability of anti-CD22-19 CARs with various costimulatory domains was then evaluated (Figure 8). CD19+CD22+Raji tumor cells were transfected with tandem anti-CD22-19CAR T cells expressing LTG2737, D0135, D0136, D0137, D0138, D0139, D0140, D0145, D0146 constructs, or a negative control, untransduced T cells (UTD ) at a 10:1 effector-to-target ratio overnight and culture supernatants were analyzed for IFN gamma, TNF alpha, and IL-2 by ELISA (Figure 8). All dual-targeted CARs strongly induced IL-2 and TNFα in response to tumor cells, whereas the negative control (non-transduced, UTD) did not result in appreciable cytokine induction ( Figure 8). In particular, exquisite levels of IFN gamma were strongly induced in all CAR22-19s, but were particularly high for CAR constructs D0146, D0139, and D0136, indicating that the strength of the cytokine response of anti-CD22-19 CARs was It was suggested that it may be regulated by the composition of the costimulatory domain utilized. Overall, the induced IFN gamma, TNF alpha, and IL-2 secretion profiles demonstrated high potency of all CAR22-19 constructs. Importantly, anti-CD22-19 CAR produced little or no cytokine secretion in the absence of tumor cells (CAR T alone group), further confirming CAR specificity and Our results suggest that there is no sustained signal transduction by tandem anti-CD22-19 CARs with co-stimulatory domains.
[0134] While not intending to be limited to any particular mechanism of action, possible reasons for the enhanced therapeutic function associated with the exemplary tandem CD22 and CD19-targeted CARs of the present invention include, but are not limited to, a ) improved lateral movement within the plasma membrane allowing for more efficient signal transduction, b) superior location within plasma membrane microdomains such as lipid rafts, and association with T cell activation. c) superior location within the plasma membrane due to preferential movement away from inhibitory or downregulatory interactions, e.g. less interaction with phosphatases such as CD45; d) superior assembly into the T-cell receptor signaling complex (i.e., immune synapse); or e) two distinct targets present on each CAR molecule. superior association with tumor antigens by the binding domain, or any combination thereof.
[0135] Although the present disclosure is illustrated with an exemplary single extracellular CD19 / CD22 variable heavy chain and ScFv antigen binding domain, a single CD19 / CD22 variable heavy chain and within a ScFv antigen binding domain Other nucleotide and / or amino acid variants may be used to obtain the CD19 / CD22 antigen binding domains used in the CARs described herein.
[0136] Depending on the desired antigen to be targeted, the CAR can be further engineered to contain appropriate antigen binding domains specific for the desired antigen target. For example, if CD19 / CD22 is the desired antigen targeted, antibodies against CD19 / CD22 can be used to incorporate the antigen binding domain into the CAR.
[0137] In one exemplary embodiment, the antigen binding domain portion of the CAR further targets CD33. Preferably, the antigen binding domain in the CAR is an anti-CD33 scFV, wherein the nucleic acid sequence of the anti-CD33 scFV comprises the sequence shown in SEQ ID NO:46. In one embodiment, the anti-CD33 scFV comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:46. In another embodiment, the anti-CD19 / CD22 scFV portion of the CAR comprises the amino acid sequence set forth in SEQ ID NO:47.
[0138] In one exemplary embodiment, the antigen binding domain portion of the CAR also targets mesothelin. Preferably, the antigen binding domain in the CAR is an anti-mesothelin ScFv, and the nucleic acid sequence of the anti-mesothelin ScFv comprises the sequence specified in SEQ ID NO:48. In one embodiment, the anti-mesothelin ScFv comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:48. In another embodiment, the anti-mesothelin ScFv portion of the CAR comprises the amino acid sequence set forth in SEQ ID NO:49.
[0139] In one aspect of the invention, for example, and without limitation, Retroviridae (e.g., human immunodeficiency viruses, e.g., HIV-1 and HIV-LP), Picornaviridae (e.g., poliovirus, hepatitis A virus), , enteroviruses, dromedoxackieviruses, rhinoviruses and echoviruses), rubella virus, coronavirus, vesicular stomatitis virus, rabies virus, Ebola virus, parainfluenza virus, mumps virus, measles virus, respiratory polyhedrovirus, influenza virus, B Hepatitis viruses, parvoviruses, adenoviridae, herpesviridae [e.g., herpes simplex virus types 1 and 2 (HSV), varicella-zoster virus, cytomegalovirus (CMV) and herpesviruses], poxviridae (e.g. , smallpox virus, vaccinia virus and poxvirus) or hepatitis C virus, or any combination thereof.
[0140] In another aspect of the invention, CARs are provided that are capable of binding antigens from bacterial strains of Staphylococci, Streptococcus, Escherichia coli, Pseudomonas or Salmonella. In particular, infectious bacteria, such as Helicobacter pyloris, Legionella pneumophilia, Mycobacteria sps. Provided are CARs capable of binding antigens derived from Neisseria meningitides, Listeria monocytogenes, Streptococcus pyogenes, group A Streptococcus, group B Streptococcus (Streptococcus agalactiae), Streptococcus pneumoniae or Clostridium tetani, or combinations thereof.
[0141] 2. Transmembrane domain Regarding transmembrane domains, CARs include one or more transmembrane domains fused to the extracellular CD19 / CD22 antigen binding domain of the CAR.
[0142] Transmembrane domains can be derived from either natural or synthetic sources. If the source is natural, the domain may be derived from any membrane-bound or transmembrane protein.
[0143] Transmembrane regions specifically used in the CARs described herein include T cell receptor alpha, beta or zeta chains, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, mesothelin , CD33, CD37, CD64, CD80, CD83, CD86, CD134, CD137, CD154, TNFRSF16, or TNFRSF19. Alternatively, the transmembrane domain may be synthetic, in which case it contains predominantly hydrophobic residues such as leucine and valine. Preferably, a phenylalanine, tryptophan and valine triplet is found at each end of the synthetic transmembrane domain. Optionally, a short oligopeptide or polypeptide linker, preferably between 2 and 10 amino acids in length, may form the link between the transmembrane domain and the cytoplasmic signaling domain of the CAR. Glycine-serine doublets provide particularly suitable linkers.
[0144] In one embodiment, a transmembrane domain that is naturally associated with one of the domains in the CAR is used in addition to the transmembrane domains described above.
[0145] In some cases, transmembrane domains avoid binding of such domains to transmembrane domains of the same or different surface membrane proteins in order to minimize interactions with other members of the receptor complex. may be selected or obtained by amino acid substitution.
[0146] In one embodiment, the transmembrane domain in a CAR of the invention is a CD8 transmembrane domain. In one embodiment, the CD8 transmembrane domain comprises the nucleic acid sequence of SEQ ID NO: 35. In one embodiment, the CD8 transmembrane domain comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:36. In another embodiment, the CD8 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 36.
[0147] In one embodiment, the encoded transmembrane domain has at least 1, 2, or 3 modifications (e.g., substitutions), but no more than 20, 10, or 5 modifications (e.g., substitutions) of the amino acid sequence of SEQ ID NO: 36. ) or a sequence having 95 to 99% identity to the amino acid sequence of SEQ ID NO: 36.
[0148] In some cases, the transmembrane domain of the CAR includes the CD8 alpha hinge domain. In one embodiment, the CD8 hinge domain comprises the nucleic acid sequence of SEQ ID NO: 37. In one embodiment, the CD8 hinge domain comprises a nucleic acid sequence encoding the amino acid sequence SEQ ID NO: 38. In another embodiment, the CD8 hinge domain comprises the amino acid sequence of SEQ ID NO: 38, or a sequence thereof with 95-99% identity.
[0149] In one embodiment, an isolated nucleic acid molecule is provided, wherein the encoded linker domain is derived from the extracellular domain of CD8 and is linked to a transmembrane CD8 domain, a transmembrane CD28 domain, or a combination thereof. .
[0150] 3. Spacer domain In a CAR, a spacer domain can be placed between the extracellular domain and the transmembrane domain, or between the intracellular domain and the transmembrane domain. Spacer domain refers to any oligopeptide or polypeptide that functions to link a transmembrane domain with an extracellular domain and / or to link a transmembrane domain with an intracellular domain. The spacer domain contains at most 300 amino acids, preferably 10-100 amino acids, most preferably 25-50 amino acids.
[0151] In some embodiments, the linker, if present, increases the size of the linker such that the distance between the effector molecule or detectable marker and the antibody or antigen-binding fragment is increased. May include spacer elements. Exemplary spacers are known to those skilled in the art and include U.S. Pat. No. 7,964,566; U.S. Pat. No. 7,498,298; U.S. Pat. 6,034,065, U.S. Patent No. 5,780,588, U.S. Patent No. 5,665,860, U.S. Patent No. 5,663,149, U.S. Patent No. 5,635,483, U.S. Patent No. 5,599,902, U.S. Patent No. 5,554,725, U.S. Patent No. 5,530,097, U.S. Patent No. 5,521,284 , U.S. Patent No. 5,504,191, U.S. Patent No. 5,410,024, U.S. Patent No. 5,138,036, U.S. Patent No. 5,076,973, U.S. Patent No. 4,986,988, U.S. Patent No. 4,978,744, U.S. Patent No. 4,879,278, U.S. Patent No. 4,816,444, and U.S. Pat. No. 4,486,414, as well as those listed in U.S. Patent Application Publication No. 20110212088 and U.S. Patent Application Publication No. 20110070248, each of which is incorporated herein by reference in its entirety.
[0152] The spacer domain preferably has sequences that promote binding of the CAR to the antigen and enhance signal transduction into the cell. Examples of amino acids predicted to promote binding include cysteine, charged amino acids, and serine and threonine in potential glycosylation sites, which can be used as the amino acids that make up the spacer domain.
[0153] As spacer domains, amino acids 137 to 206 (SEQ ID NO: 39), which is the hinge region of CD8 alpha (NCBI RefSeq: NP_001759.3), amino acids 135 to 195 of CD8 beta (GenBank: AAA35664.1), and amino acids 135 to 195 of CD4 (NCBI RefSeq :NP_000607.1), or amino acid numbers 137 to 152 of CD28 (NCBI RefSeq:NP_006130.1), in whole or in part, can be used. Furthermore, a part of the constant region of an antibody H chain or L chain can be used as a spacer domain. Furthermore, the spacer domain can be an artificially synthesized sequence.
[0154] Additionally, in a CAR, a signal peptide sequence can be linked to the N-terminus. Signal peptide sequences are present at the N-terminus of many secreted and membrane proteins and have a length of 15-30 amino acids. Since many of the protein molecules referred to above as intracellular domains have signal peptide sequences, these signal peptides can be used as signal peptides for CARs. In one embodiment, the signal peptide comprises the amino acid sequence set forth in SEQ ID NO:12.
[0155] 4. Intracellular domain The cytoplasmic or otherwise intracellular signaling domain of the CAR is responsible for activation of at least one of the normal effector functions of the immune cell in which the CAR is placed. The term "effector function" refers to a specialized function of a cell. For example, the effector function of a T cell can be cytolytic activity or helper activity, including secretion of cytokines. Accordingly, the term "intracellular signaling domain" refers to the portion of a protein that transmits effector function signals and directs the cell to perform specialized functions. Although usually the entire intracellular signaling domain may be used, in many cases it is not necessary to use the entire chain. To the extent that truncated portions of intracellular signaling domains are used, such truncated portions may be used in place of the intact chain, so long as it transduces effector function signals. Accordingly, the term intracellular signaling domain is meant to include any truncated portion of an intracellular signaling domain sufficient to transduce an effector function signal.
[0156] Preferred examples of intracellular signaling domains for use in CARs include T cell receptor (TCR) and co-receptor cytoplasmic sequences that act in concert to initiate signal transduction following antigen receptor engagement. , and any derivatives or variants of these sequences, and any synthetic sequences with the same functional capabilities.
[0157] It is known that signals generated through the TCR alone are insufficient for complete activation of T cells, and that secondary or costimulatory signals are also required. T cell activation can therefore be said to be mediated by two distinct classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation via the TCR (primary cytoplasmic signaling sequences); Those that act in an antigen-dependent manner to provide secondary or costimulatory signals (secondary cytoplasmic signaling sequences).
[0158] Primary cytoplasmic signaling sequences regulate the primary activation of the TCR complex, either in a stimulatory or inhibitory manner. Primary cytoplasmic signaling sequences that act in a stimulatory manner may contain a signaling motif known as an immunoreceptor activation tyrosine motif or ITAM.
[0159] Examples of ITAMs containing primary cytoplasmic signaling sequences specifically used in the CARs disclosed herein include TCR zeta (CD3 zeta), FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5 , CD22, CD79a, CD79b and CD66d. Specific non-limiting examples of ITAM include amino acid numbers 51-164 of CD3 zeta (NCBI RefSeq:NP_932170.1), amino acid numbers 45-86 of Fc epsilon RI gamma (NCBI RefSeq:NP_004097.1), Fc Amino acid numbers 201-244 of Epsilon RI beta (NCBI RefSeq:NP_000130.1), amino acid numbers 139-182 of CD3 gamma (NCBI RefSeq:NP_000064.1), amino acid numbers 128-128 of CD3 delta (NCBI RefSeq:NP_000723.1) 171, amino acid number 153-207 of CD3 epsilon (NCBI RefSeq:NP_000724.1), amino acid number 402-495 of CD5 (NCBI RefSeq:NP_055022.2), amino acid number 707-847 of 0022 (NCBI RefSeq:NP_001762.2) , amino acid numbers 166 to 226 of CD79a (NCBI RefSeq:NP_001774.1), amino acid numbers 182 to 229 of CD79b (NCBI RefSeq:NP_000617.1), and amino acid numbers 177 to 252 of CD66d (NCBI RefSeq:NP_001806.2). Peptides having the sequence as well as variants thereof that have the same function as these peptides are included. Amino acid numbers based on NCBI RefSeq ID or GenBank amino acid sequence information described herein are numbered based on the total length of each protein precursor (including signal peptide sequence, etc.). In one embodiment, the cytoplasmic signaling molecule in the CAR comprises a cytoplasmic signaling sequence derived from CD3 zeta.
[0160] In a preferred embodiment, the intracellular domain of the CAR is designed to include a CD3-zeta signaling domain, either by itself or in combination with any other desired cytoplasmic domain(s) useful in the context of a CAR. can be done. For example, the intracellular domain of a CAR can include a CD3 zeta chain portion and a costimulatory signaling region. Co-stimulatory signaling region refers to the portion of the CAR that contains the intracellular domain of costimulatory molecules. Co-stimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are required for the efficient response of lymphocytes to antigens. Examples of such costimulatory molecules include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT , NKG2C, B7-H3, and ligands that specifically bind to CD83. Specific non-limiting examples of such costimulatory molecules include amino acid numbers 236-351 of CD2 (NCBI RefSeq: NP_001758.2), amino acids 421-458 of CD4 (NCBI RefSeq: NP_000607.1), CD5 ( NCBI RefSeq:NP_055022.2) amino acid number 402-495, CD8 alpha (NCBI RefSeq:NP_001759.3) amino acid number 207-235, CD83 (GenBank:AAA35664.1) amino acid number 196-210, CD28 (NCBI RefSeq) :NP_006130.1) amino acid numbers 181-220, CD137 (4-1BB, NCBI RefSeq:NP_001552.2) amino acid numbers 214-255, CD134 (OX40, NCBI RefSeq:NP_003318.1) amino acid numbers 241-277, and Included are peptides having the sequence of amino acid numbers 166 to 199 of ICOS (NCBI RefSeq: NP_036224.1), as well as variants thereof that have the same functions as these peptides. Therefore, although this disclosure primarily exemplifies 4-1BB as a costimulatory signaling element, other costimulatory elements are within the scope of this disclosure.
[0161] The cytoplasmic signaling sequences within the cytoplasmic signaling portion of the CAR can be linked to each other randomly or in a specified order. Optionally, short oligopeptide or polypeptide linkers, preferably between 2 and 10 amino acids in length, may form the linkage. Glycine-serine doublets provide particularly suitable linkers.
[0162] In one embodiment, the intracellular domain is designed to include a CD3-zeta signaling domain and a CD28 signaling domain. In another embodiment, the intracellular domain is designed to include a CD3-zeta signaling domain and a 4-1BB signaling domain. In yet another embodiment, the intracellular domain is designed to include a CD3-zeta signaling domain and a CD28 and 4-1BB signaling domain.
[0163] In one embodiment, the intracellular domain in the CAR is designed to include a 4-1BB signaling domain and a CD3-zeta signaling domain, wherein the 4-1BB signaling domain is SEQ ID NO: 40. The signaling domain of CD3-zeta comprises the nucleic acid sequence shown in SEQ ID NO: 42.
[0164] In one embodiment, the intracellular domain in the CAR is designed to include a 4-1BB signaling domain and a CD3-zeta signaling domain, wherein the 4-1BB signaling domain is SEQ ID NO: 41 The signaling domain of CD3-zeta comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 43.
[0165] In one embodiment, the intracellular domain in the CAR is designed to include a 4-1BB signaling domain and a CD3-zeta signaling domain, wherein the 4-1BB signaling domain is SEQ ID NO: 41 The signaling domain of CD3-zeta comprises the amino acid sequence shown in SEQ ID NO: 43.
[0166] 5. Further description of CAR Functional portions of the CARs disclosed herein are also expressly included within the scope of the present invention. The term "functional portion" when used with respect to a CAR refers to any part or fragment of one or more of the CARs disclosed herein, which part or fragment is a part of Retains the biological activity of a CAR (parent CAR). A functional portion includes, for example, a portion of a CRA that retains the ability to recognize target cells, or to detect, treat or prevent disease, to a similar degree, to the same degree, or to a higher degree than the parent CAR. do. With respect to a parent CAR, the functional portion may, for example, constitute about 10%, 25%, 30%, 50%, 68%, 80%, 90%, 95% or more of the parent CAR.
[0167] A functional moiety may contain additional amino acids at the amino or carboxy terminus of the moiety, or at both termini, which are not found in the amino acid sequence of the parent CAR. Desirably, the additional amino acids do not interfere with the biological function of the functional moiety, such as recognizing target cells, detecting cancer, treating or preventing cancer. More desirably, the additional amino acid enhances its biological activity as compared to that of the parent CAR.
[0168] Functional variants of the CARs disclosed herein are included within the scope of this disclosure. The term "functional variant" as used herein refers to a CAR, polypeptide or protein that has substantial or significant sequence identity or similarity to a parent CAR; It retains the biological activity of its variant CAR. Functional variants include, for example, variants of the CARs described herein (parental CARs) that retain the ability to recognize target cells to a similar, the same, or a higher degree as the parent CAR. . With respect to a parent CAR, a functional variant can, for example, be at least about 30%, 50%, 75%, 80%, 90%, 98% or more amino acid sequence identical to the parent CAR.
[0169] A functional variant can, for example, include the amino acid sequence of a parent CAR with at least one conservative amino acid substitution. Alternatively, or in addition, a functional variant may include the amino acid sequence of a parent CAR with at least one non-conservative amino acid substitution. In this case, it is preferred that the non-conservative amino acid substitutions do not interfere with or inhibit the biological activity of the functional variant. Non-conservative amino acid substitutions can enhance the biological activity of a functional variant, such that the biological activity of the functional variant is increased compared to the parent CAR.
[0170] Amino acid substitutions in the CAR are preferably conservative amino acid substitutions. Conservative amino acid substitutions are known in the art and involve replacing one amino acid with certain physical and / or chemical properties with another amino acid with the same or similar chemical or physical properties. Includes amino acid substitutions that are exchanged. For example, conservative amino acid substitutions include replacing an acidic / negatively charged polar amino acid with another polar amino acid (e.g., Asp or Glu), replacing another amino acid with a nonpolar side chain (e.g., Ala , Gly, Val, He, Leu, Met, Phe, Pro, Trp, Cys, Val, etc.) with a basic / positively charged polar amino acid (e.g. Lys, His , Arg, etc.), a basic / positively charged polar amino acid to replace another uncharged amino acid with a polar side chain (e.g., Asn, Gin, Ser, Thr, Tyr, etc.); A charged amino acid, an amino acid with a beta-branched side chain replacing another amino acid with a beta-branched side chain (e.g. He, Thr and Val), another amino acid with an aromatic side chain (e.g. His, Phe, Trp and Tyr) may be an amino acid with an aromatic side chain replacing the amino acid.
[0171] A CAR can consist essentially of the identified amino acid sequence(s) described herein, such that other components, e.g., other amino acids, enhance the biological activity of the functional variant. does not change significantly.
[0172] CARs (including functional parts and functional variants) can be of any length, i.e., contain any number of amino acids, provided that the CAR (or functional parts or functional variants thereof) Retains biological activity, such as the ability to specifically bind an antigen, detect diseased cells in a mammal, or treat or prevent disease in a mammal. For example, a CAR may be about 50 to about 5000 amino acids in length, e.g., 50, 70, 75, 100, 125, 150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more amino acids. It can be long.
[0173] CARs (including functional portions and functional variants of the invention) may include synthetic amino acids in place of one or more naturally occurring amino acids. Such synthetic amino acids are known in the art and include, for example, aminocyclohexanecarboxylic acid, norleucine, -amino n-decanoic acid, homoserine, S-acetylaminomethyl-cysteine, trans-3-hydroxyproline and trans- -4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, β-phenylserine, β-hydroxyphenylalanine, phenylglycine, a-naphthylalanine, cyclohexylalanine, cyclohexylglycine, Indoline-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aminomalonic acid, aminomalonic acid monoamide, N'-benzyl-N'-methyl-lysine, Ν',Ν'- Dibenzyl-lysine, 6-hydroxylysine, ornithine, -aminocyclopentanecarboxylic acid, a-aminocyclohexanecarboxylic acid, a-aminocycloheptanecarboxylic acid, a-(2-amino-2-norbornane)-carboxylic acid, γ- Includes diaminobutyric acid, β-diaminopropionic acid, homophenylalanine and a-tert-butylglycine.
[0174] CARs (including functional moieties and functional variants) can be glycosylated, amidated, carboxylated, phosphorylated, esterified, N-acylated, cyclized, e.g. via disulfide bridges, or converted into acid addition salts and / or may optionally be dimerized or polymerized or conjugated.
[0175] CARs (including functional parts and functional variants thereof) can be obtained by methods known in the art. CARs can be made by any suitable method of making polypeptides or proteins. Suitable methods for de novo synthesis of polypeptides and proteins are described in Chan et al., Fmoc Solid Phase Peptide Synthesis, Oxford University Press, Oxford, United Kingdom, 2000; Peptide and Protein Drug Analysis, Reid, R., ed., Marcel Dekker, Inc. ., 2000; Epitope Mapping, Westwood et al., eds., Oxford University Press, Oxford, United Kingdom, 2001; and U.S. Patent No. 5,449,752. Polypeptides and proteins can also be produced recombinantly using the nucleic acids described herein using standard recombinant methods. For example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Press, Cold Spring Harbor, NY 2001; and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, NY, 1994. checking ... Additionally, some CARs (including functional moieties and functional variants thereof) can be isolated and / or purified from sources such as plants, bacteria, insects, mammals, eg, rats, humans, etc. Isolation and purification methods are well known in the art. Alternatively, the CARs described herein (including functional moieties and functional variants thereof) can be commercially synthesized by companies. In this regard, the CAR may be synthetic, recombinant, isolated, and / or purified.
[0176] B. Antibodies and antigen-binding fragments One embodiment further provides a CAR, a T cell expressing the CAR, an antibody or antigen binding domain or portion thereof that specifically binds to one or more of the antigens disclosed herein. As used herein, "CAR-expressing T cell" or "CAR T cell" refers to a T cell that expresses a CAR, e.g. It has specificity.
[0177] As used herein, "antigen-binding domain" can include antibodies and antigen-binding fragments thereof. The term "antibody" is used herein in its broadest sense and includes monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and the like, so long as they exhibit the desired antigen binding activity. It encompasses a variety of antibody structures including, but not limited to, antigen-binding fragments of. Non-limiting examples of antibodies include, for example, intact immunoglobulins known in the art, as well as variants and fragments thereof that retain binding affinity for the antigen.
[0178] A "monoclonal antibody" is an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies that make up the population are identical except for possible naturally occurring variations that may be present in trace amounts. be. Monoclonal antibodies are highly specific, being directed against a single antigenic epitope. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. In some cases, a monoclonal antibody is an antibody produced by a single clone of B lymphocytes, or a nucleic acid encoding the antibody light and heavy chain variable regions of a single antibody (or an antigen-binding fragment thereof). is an antibody produced by a transfected cell or its progeny. In some instances, monoclonal antibodies are isolated from the subject. Monoclonal antibodies may have conservative amino acid substitutions that have substantially no effect on antigen binding or other immunoglobulin functions. Exemplary methods of producing monoclonal antibodies are known, see, eg, Harlow & Lane, Antibodies, A Laboratory Manual, 2nd edition Cold Spring Harbor Publications, New York (2013).
[0179] Typically, immunoglobulins have heavy (H) and light (L) chains interconnected by disulfide bonds. Immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable domain genes. There are two types of light chains, lambda (λ) and kappa (κ). There are five major heavy chain classes (or isotypes) that determine the functional activity of antibody molecules: IgM, IgD, IgG, IgA and IgE.
[0180] Each heavy and light chain contains a constant region (or constant domain) and a variable region (or variable domain; see, for example, Kindt et al., Kuby Immunology, 6th edition, W.H. Freeman and Co., p. 91 (2007) checking). In some embodiments, the heavy and light chain variable regions combine to specifically bind an antigen. In further embodiments, only the heavy chain variable region is required. For example, naturally occurring camelid antibodies, consisting only of heavy chains, are functional and stable in the absence of light chains (e.g., Hamers-Casterman et al., Nature, 363:446-448). , 1993; see Sheriff et al., Nat. Struct. Biol., 3:733-736, 1996). Reference to "VH" or "VH" refers to the variable region of an antibody heavy chain, including those of antigen-binding fragments such as Fv, scFv, dsFv or Fab. References to "VL" or "VL" refer to the variable domains of antibody light chains, including those of Fv, scFv, dsFv or Fab.
[0181] The variable regions of light and heavy chains contain a "framework" region interrupted by three hypervariable regions, also called "complementarity determining regions" or "CDRs" (e.g., Kabat et al., Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services, 1991). The sequences of the framework regions of different light or heavy chains are relatively conserved within species. The framework regions of antibodies, which are the combined framework regions of the component light and heavy chains, function to position and align the CDRs in three-dimensional space.
[0182] CDRs are primarily responsible for binding to epitopes of antigens. The amino acid sequence boundaries for a given CDR are determined by Kabat et al. -Lazikani et al. (JMB Vol. 273, pp. 927-948, 1997; "Chothia" numbering scheme) and Lefranc et al. ("IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains", Dev.Comp.Immunol., vol. 27:55-77, 2003; obtain. The CDRs of each chain are typically referred to as CDR1, CDR2 and CDR3 (from N-terminus to C-terminus) and are also typically identified by the strand in which the particular CDR is located. Thus, VH CDR3 is a CDR3 derived from the variable domain of the heavy chain of the antibody in which it is found, whereas VL CDR1 is a CDR1 derived from the variable domain of the light chain of the antibody in which it is found. Light chain CDRs are also sometimes referred to as LCDR1, LCDR2 and LCDR3. Heavy chain CDRs are sometimes referred to as LCDR1, LCDR2 and LCDR3.
[0183] "Antigen-binding fragments" are portions of a full-length antibody that retain the ability to specifically recognize a cognate antigen, as well as various combinations of such portions. Non-limiting examples of antigen-binding fragments include Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments. Antibody fragments include antigen-binding fragments produced by whole antibody modification or synthesized de novo using recombinant DNA methodologies (e.g., Kontermann and Dubel (eds.), (See Antibody Engineering, Volumes 1-2, 2nd Edition, Springer Press, 2010).
[0184] A single chain antibody (scFv) is a genetically engineered molecule that contains the VH and VL domains of one or more antibody(s) as a genetically fused single chain molecule linked by a suitable polypeptide linker. (e.g., Bird et al., Science, 242:423-426, 1988; Huston et al., Proc. Natl. Acad. Sci., 85:5879-5883, 1988; Ahmad et al., Clin.Dev. Immunol., 2012, doi:10.1155 / 2012 / 980250; see Marbry, IDrugs, 13:543-549, 2010). The intramolecular orientation of the VH and VL domains in scFvs is typically not critical to the scFv. Therefore, scFvs with both possible configurations (VH domain-linker domain-VL domain; VL domain-linker domain-VH domain) can be used.
[0185] In dsFv, the heavy and light variable chains are mutated to introduce disulfide bonds to stabilize chain association. Although the VH and VL domains are expressed on a single polypeptide chain, linkers that are too short to allow pairing between the two domains on the same chain are used, thereby separating the domains. Also included are diabodies, which are bivalent, bispecific antibodies that pair with complementary domains of the chains of a protein, creating two antigen-binding sites (e.g., Holliger et al., Proc. Natl. Acad. Sci. , 90:6444-6448, 1993; see Poljak et al., Structure, 2:1121-1123, 1994).
[0186] Antibodies also include genetically engineered forms, such as chimeric antibodies (eg, humanized murine antibodies) and heteroconjugate antibodies (eg, bispecific antibodies). See also Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, IL); Kuby, J., Immunology, 3rd edition, W.H. Freeman & Co., New York, 1997.
[0187] Non-naturally occurring antibodies can be constructed using solid-phase peptide synthesis, produced recombinantly, or described, for example, in Huse et al., Science 246:1275-1281 (1989), which is incorporated herein by reference. can be obtained by screening a combinatorial library consisting of variable heavy chains and variable light chains, as described in 2010). For example, these and other methods of making chimeric, humanized, CDR-grafted, single-chain and bifunctional antibodies are well known to those skilled in the art (Winter and Harris, Immunol. Today 14:243-246 (1993). Ward et al., Nature 341:544-546 (1989); Harlow and Lane, supra, 1988; Hilyard et al., Protein Engineering: A practical approach (IRL Press 1992); Borrabeck, Antibody Engineering, Vol. 2nd edition (Oxford University Press 1995); each of which is incorporated herein by reference).
[0188] An antibody that binds to the same epitope as a reference antibody refers to an antibody that blocks binding of the reference antibody to its antigen by 50% or more in a competitive assay; block antibody binding by 50% or more. Antibody competition assays are known, and exemplary competition assays are provided herein.
[0189] A "humanized" antibody or antigen-binding fragment comprises human framework regions and one or more CDRs from a non-human (eg, murine, rat or synthetic) antibody or antigen-binding fragment. The non-human antibody or antigen-binding fragment that provides the CDRs is called the "donor" and the human antibody or antigen-binding fragment that provides the framework is called the "acceptor." In one embodiment, all CDRs are derived from the donor immunoglobulin in the humanized immunoglobulin. Constant regions need not be present, but if present can be substantially identical, eg, at least about 85-90%, eg, about 95% or more, identical to a human immunoglobulin constant region. Thus, all parts of a humanized antibody or antigen-binding fragment are substantially identical to the corresponding parts of natural human antibody sequences, with the possible exception of the CDRs.
[0190] A "chimeric antibody" is an antibody that contains sequences derived from two different antibodies, typically from different species. In some instances, a chimeric antibody comprises one or more CDRs and / or framework regions from one human antibody and CDRs and / or framework regions from another human antibody.
[0191] A "fully human antibody" or "human antibody" is an antibody that contains sequences derived from (or derived from) the human genome, but does not contain sequences from another species. In some embodiments, the human antibody comprises CDRs from (or derived from) the human genome, framework regions, and (if present) an Fc region. Human antibodies can be identified and isolated, for example, by phage display, using technologies for creating sequences based on sequences derived from the human genome, or using transgenic animals (e.g., Barbas et al. Phage display: A Laboratory Manuel. 1st edition New York: Cold Spring Harbor Laboratory Press, 2004 Print.; Lonenberg, Nat. Biotech., vol. 23: 1117-1125, 2005; Lonenberg, Curr. Opin. Immunol. , 20:450-459, 2008).
[0192] An antibody can have one or more binding sites. If more than one binding site is present, these binding sites may be the same or different from each other. For example, naturally occurring immunoglobulins have two identical binding sites, single chain antibodies or Fab fragments have one binding site, whereas bispecific or bifunctional antibodies have two different Has a binding site.
[0193] Methods for testing antibodies for the ability to bind any functional portion of a CAR are known in the art and include any antibody-antigen binding assay, e.g., radioimmunoassay (RIA), ELISA, Western blot. , immunoprecipitation and competitive inhibition assays (see, eg, Janeway et al., infra, US Patent Application Publication No. 2002 / 0197266 Al, and US Patent No. 7,338,929).
[0194] The CAR, T cell expressing the CAR, antibody or antigen-binding portion thereof may also be labeled with a detectable label, such as a radioisotope, a fluorophore (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE)), an enzyme, etc. (eg, alkaline phosphatase, horseradish peroxidase), elemental particles (eg, gold particles), and the like.
[0195] C. Conjugate Monoclonal antibodies or antigen-binding fragments thereof specific for a CAR, a T cell expressing the CAR, or one or more of the antigens disclosed herein can be produced using any number of means known to those skilled in the art. may be conjugated to an agent such as an effector molecule or a detectable marker. Both covalent and non-covalent means of binding may be used. Conjugates include molecules in which there is covalent linkage of an effector molecule or detectable marker to an antibody or antigen-binding fragment that specifically binds to one or more of the antigens disclosed herein. but is not limited to these. Those skilled in the art will appreciate that chemotherapeutic agents, anti-angiogenic agents, toxins, radioactive agents, e.g. 125 I, 32 P, 14 C, 3 H and 35 It is understood that a variety of effector molecules and detectable markers may be used, including but not limited to S, and other labels, targeting moieties and ligands.
[0196] The selection of a particular effector molecule or detectable marker depends on the particular target molecule or cell and the desired biological effect. Thus, for example, an effector molecule can be a cytotoxin used to bring about the death of specific target cells (eg, tumor cells).
[0197] Procedures for attaching effector molecules or detectable markers to antibodies or antigen-binding fragments vary according to the chemical structure of the effector. Polypeptides typically contain a variety of functional groups; for example, carboxylic acid (COOH), free amines (-NH 2) or sulfhydryl (-SH) groups, which are available for reaction with appropriate functional groups on the antibody to result in conjugation of effector molecules or detectable markers. Alternatively, the antibody or antigen-binding fragment is derivatized to expose or attach additional reactive functional groups. Derivatization can include attachment of any of several known linker molecules, such as those available from Pierce Chemical Company, Rockford, IL. A linker can be any molecule used to join an antibody or antigen-binding fragment to an effector molecule or detectable marker. The linker can form a covalent bond to both the antibody or antigen-binding fragment and the effector molecule or detectable marker. Suitable linkers are well known to those skilled in the art and include, but are not limited to, straight or branched carbon linkers, heterocyclic carbon linkers or peptide linkers. When the antibody or antigen-binding fragment and effector molecule or detectable marker are polypeptides, the linker can be attached to the component amino acids through their side groups (e.g., via a disulfide linkage to cysteine) or to the terminal It can be attached to the amino and carboxyl groups of the alpha carbon of an amino acid.
[0198] In some embodiments, the linker, if present, increases the size of the linker such that the distance between the effector molecule or detectable marker and the antibody or antigen-binding fragment is increased. May include spacer elements. Exemplary spacers are known to those skilled in the art and include U.S. Pat. No. 7,964,566; U.S. Pat. No. 7,498,298; U.S. Pat. 6,034,065, U.S. Patent No. 5,780,588, U.S. Patent No. 5,665,860, U.S. Patent No. 5,663,149, U.S. Patent No. 5,635,483, U.S. Patent No. 5,599,902, U.S. Patent No. 5,554,725, U.S. Patent No. 5,530,097, U.S. Patent No. 5,521,284 , U.S. Patent No. 5,504,191, U.S. Patent No. 5,410,024, U.S. Patent No. 5,138,036, U.S. Patent No. 5,076,973, U.S. Patent No. 4,986,988, U.S. Patent No. 4,978,744, U.S. Patent No. 4,879,278, U.S. Patent No. 4,816,444, and U.S. Pat. No. 4,486,414, as well as those listed in U.S. Patent Application Publication No. 20110212088 and U.S. Patent Application Publication No. 20110070248, each of which is incorporated herein by reference in its entirety.
[0199] In some embodiments, the linker is cleavable under intracellular conditions such that cleavage of the linker releases an effector molecule or detectable marker from the antibody or antigen-binding fragment in the intracellular environment. let In yet other embodiments, the linker is non-cleavable and the effector molecule or detectable marker is released, eg, by antibody lysis. In some embodiments, the linker is cleavable by a cleavage agent that is present in the intracellular environment (eg, within a lysosome or endosome or caveolea). The linker can be, for example, a peptide linker that is cleaved by intracellular peptidase or protease enzymes, including but not limited to lysosomal or endosomal proteases. In some embodiments, the peptide linker is at least 2 amino acids long or at least 3 amino acids long. However, the linker may be 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids long, e.g. 1-2, 1-3, 2-5, 3-10, 3 Can be ~15, 1-5, 1-10, 1-15 amino acids long. Proteases may include cathepsins B and D and plasmin, all of which are known to hydrolyze dipeptide drug derivatives resulting in release of active drug inside target cells (e.g., Dubowchik and Walker, 1999, Pharm.Therapeutics 83:67-123). For example, a peptide linker cleavable by the thiol-dependent protease cathepsin B can be used (eg, a phenylalanine-leucine or glycine-phenylalanine-leucine-glycine linker). Other examples of such linkers are described, for example, in US Pat. No. 6,214,345, which is incorporated herein by reference. In specific embodiments, the peptide linker cleavable by an intracellular protease is a valine-Citruline linker or a phenylalanine-lysine linker (e.g., U.S. patents describing the synthesis of doxorubicin using valine-citrulline linkers) No. 6,214,345).
[0200] In other embodiments, the cleavable linker is pH sensitive, ie, susceptible to hydrolysis at certain pH values. Typically, pH-sensitive linkers are hydrolyzable under acidic conditions. For example, acid-labile linkers that are hydrolyzable in the lysosome (e.g., hydrazones, semicarbazones, thiosemicarbazones, cis-aconitic amide, orthoesters, acetals, ketals, etc.) may be used (e.g., U.S. Patent No. 5,122,368; U.S. Patent No. 5,824,805; U.S. Patent No. 5,622,929; Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123; Neville et al., 1989, Biol. Chem. 264:14653 (See pages ~14661). Such linkers are relatively stable under neutral pH conditions, such as in blood, but are unstable at pHs below 5.5 or 5.0, the approximate pH of lysosomes. In certain embodiments, the hydrolyzable linker is a thioether linker, such as a thioether attached to a therapeutic agent via an acylhydrazone linkage (see, eg, US Pat. No. 5,622,929).
[0201] In other embodiments, the linker is cleavable under reducing conditions (eg, a disulfide linker). A variety of disulfide linkers are known in the art, including, for example, SATA (N-succinimidyl-S-acetylthioacetate), SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate), SPDB ( N-succinimidyl-3-(2-pyridyldithio)butyrate) and SMPT (N-succinimidyl-oxycarbonyl-alpha-methyl-alpha-(2-pyridyl-dithio)toluene)-, formed using SPDB and SMPT (e.g. Thorpe et al., 1987, Cancer Res. 47:5924-5931; Wawrzynczak et al., Immunoconjugates: Antibody Conjugates in Radioimagery and Therapy of Cancer (ed. C.W. Vogel, Oxford U.Press, 1987) ); see Phillips et al., Cancer Res. 68:9280-9290, 2008). See also US Pat. No. 4,880,935.
[0202] In still other specific embodiments, the linker is a malonate linker (Johnson et al., 1995, Anticancer Res. 15:1387-93), a maleimidobenzoyl linker (Lau et al., 1995, Bioorg-Med-Chem 3(10): 1299-1304) or 3'-N-amide analogs (Lau et al., 1995, Bioorg-Med-Chem. 3(10): 1305-12).
[0203] In yet other embodiments, the linker is non-cleavable and the effector molecule or detectable marker is released upon antibody lysis (U.S. Patent Application Publication No. 2005 / 0238649, the entire contents of which are incorporated herein by reference. (see issue).
[0204] In some embodiments, the linker is resistant to cleavage in the extracellular environment. For example, when the conjugate is present in the extracellular environment (e.g., in plasma), no more than about 20%, no more than about 15%, no more than about 10%, no more than about 5%, no more than about 3 % or less, or about 1% or less is cut off. Whether a linker is resistant to cleavage in the extracellular environment can be determined, for example, by injecting a conjugate containing the linker of interest for a defined period of time (e.g., 2, 4, 8, 16, or 24 hours). can be determined by incubating with plasma for a period of time and then quantifying the amount of free effector molecules or detectable markers present in the plasma. Various exemplary linkers that can be used in conjugates are described in WO2004 / 010957, US Patent Application Publication No. 2006 / 0074008, US Patent Application Publication No. 2005 / 0238649, and US Patent Application Publication No. 2006 / 0024317. , each of which is incorporated herein by reference in its entirety.
[0205] In some embodiments, a conjugate of a CAR, a T cell expressing the CAR, an antibody, or an antigen-binding portion thereof, and one or more small molecule toxins, e.g., calicheamycin, maytansinoid, Dolastatin, auristatin, trichothecin and CC1065 and derivatives of these toxins having toxin activity are provided.
[0206] Maytansine compounds suitable for use as maytansinoid toxin moieties are well known in the art and can be isolated from natural sources according to known methods and genetic engineering techniques (Yu et al. (2002) PNAS 99 Vol. 7968-7973) or maytansinol and maytansinol analogs prepared synthetically according to known methods. Maytansinoids are mitototic inhibitors that act by inhibiting tubulin polymerization. Maytansine was first isolated from the East African shrub Maytenus serrata (US Pat. No. 3,896,111). Subsequently, it was discovered that certain microorganisms also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (US Pat. No. 4,151,042). Synthetic maytansinol and its derivatives and analogs are disclosed, for example, in U.S. Pat. No. 4,137,230; U.S. Pat. No. 4,248,870; U.S. Pat. Patent No. 4,307,016; U.S. Patent No. 4,308,268; U.S. Patent No. 4,308,269; U.S. Patent No. 4,309,428; U.S. Patent No. 4,313,946; U.S. Patent No. 4,315,929; No. 4,331,598; US Pat. No. 4,361,650; US Pat. No. 4,364,866; US Pat. No. 4,424,219; US Pat. No. 4,450,254; US Pat. incorporated herein by. Conjugates containing maytansinoids, methods of making them, and their therapeutic uses are described, for example, in US Pat. No. 5,208,020; US Pat. No. 5,416,064; US Pat. have been disclosed, the disclosures of which are expressly incorporated herein by reference.
[0207] Additional toxins can be used with the CAR, T cells expressing the CAR, antibodies, or antigen-binding portions thereof. Exemplary toxins include Pseudomonas exotoxin (PE), castor toxin, abrin, diphtheria toxin and its subunits, ribotoxin, ribonuclease, saporin and calicheamycin, and botulinum toxins A-F. These toxins are well known in the art, and many are readily available from commercial sources (eg, Sigma Chemical Company, St. Louis, MO). Contemplated toxins also include variants of these toxins (see, eg, US Pat. No. 5,079,163 and US Pat. No. 4,689,401).
[0208] Saporin is a toxin derived from Saponaria officinalis that disrupts protein synthesis by inactivating the 60S portion of the ribosomal complex (Stirpe et al., Bio / Technology, 10:405-412, 1992). However, this toxin does not have a mechanism for specific entry into cells and is therefore efficiently taken up by cells by antibodies or antigen-binding fragments that recognize internalized cell surface proteins. Requires conjugation to.
[0209] Diphtheria toxin is isolated from Corynebacterium diphtheriae. Typically, diphtheria toxin for use in immunotoxins is mutated to reduce or eliminate nonspecific toxicity. A variant known as CRM107, which has full enzymatic activity but significantly reduced nonspecific toxicity, has been known since the 1970s (Laird and Groman, J. Virol. 19:220, 1976). , has been used in human clinical trials. See US Patent No. 5,792,458 and US Patent No. 5,208,021.
[0210] Castor bean toxin is the lectin RCA60 derived from Ricinus communis (castor bean). For examples of castor bean toxin, see US Pat. No. 5,079,163 and US Pat. No. 4,689,401. Ricinus communis agglutinin (RCA), according to its molecular weight of approximately 65kD and 120kD, respectively. 60 and R.C.A. 120 (Nicholson and Blaustein, J. Biochim. Biophys. Acta 266:543, 1972). The A chain is responsible for inactivating protein synthesis and killing cells. The B chain binds castor toxin to cell surface galactose residues and facilitates transport of the A chain into the cytosol (Olsnes et al., Nature 249:627-631, 1974 and US Pat. No. 3,060,165). .
[0211] Ribonucleases have also been conjugated to targeting molecules for use as immunotoxins (see Suzuki et al., Nat. Biotech. 17:265-70, 1999). Exemplary ribotoxins, such as α-sarcin and restrictocin, are described in, for example, Rathore et al., Gene 190:31-5, 1997; and Goyal and Batra, Biochem. 345. Discussed in Part 2: pp. 247-54, 2000. Calicheamycin was originally isolated from Micromonospora echinospora and is a member of the enediyne antitumor antibiotic family (e.g., Lee et al., J. Antibiot. 42:1070-87, 1989). This drug is the toxic portion of an immunotoxin in clinical trials (see, eg, Gillespie et al., Ann. Oncol. 11:735-41, 2000).
[0212] Abrin contains toxic lectins from Abrus precatorius. The toxins abrin a, b, c and d have molecular weights of approximately 63 kD and 67 kD and are composed of two disulfide-linked polypeptide chains A and B. The A chain inhibits protein synthesis; the B chain (abrin-b) binds to D-galactose residues (Funatsu et al., Agr. Biol. Chem. 52:1095, 1988; and Olsnes, Methods Enzymol 50:330-335, 1978).
[0213] CAR, T cells expressing the CAR, monoclonal antibodies specific for one or more of the antigens disclosed herein, antigen-binding fragments thereof, can also be used with detectable markers; e.g., ELISA, spectrophotometric method, flow cytometry, microscopy or diagnostic imaging techniques (e.g. computed tomography (CT), computed axial tomography (CAT) scans, magnetic resonance imaging (MRI), nuclear magnetic resonance imaging) (NMRI), magnetic resonance tomography (MTR), ultrasound, fiber optic testing and laparoscopic testing). Specific non-limiting examples of detectable markers include fluorophores, chemiluminescent agents, enzymatic linkages, radioactive isotopes, and heavy metals or compounds (e.g., superparamagnetic iron oxide nanocrystals for detection by MRI). ) is included. For example, useful detectable markers include fluorescent compounds including fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-1-napthalenesulfonyl chloride, phycoerythrin, lanthanide phosphors, and the like. Bioluminescent markers such as luciferase, green fluorescent protein (GFP), yellow fluorescent protein (YFP) are also used. The CAR, T cell expressing the CAR, antibody or antigen-binding portion thereof may also be conjugated to useful enzymes for detection, such as horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase, glucose oxidase, etc. . When a CAR, a T cell expressing a CAR, an antibody or an antigen-binding portion thereof is conjugated to a detectable enzyme, it is necessary to add additional reagents that the enzyme uses to produce a discernible reaction product. can be detected by For example, when the drug horseradish peroxidase is present, addition of hydrogen peroxide and diaminobenzidine results in a visually detectable colored reaction product. CARs, T cells expressing CARs, antibodies or antigen-binding portions thereof can also be conjugated with biotin and detected through indirect measurement of avidin or streptavidin binding. It should be noted that avidin itself can be conjugated with enzymes or fluorescent labels.
[0214] The CAR, T cell expressing the CAR, antibody or antigen-binding portion thereof can be conjugated with a paramagnetic agent such as gadolinium. Paramagnetic agents such as superparamagnetic iron oxide are also used as labels. Antibodies can also be conjugated to lanthanides (eg, europium and dysprosium) and manganese. The antibody or antigen-binding fragment can also be labeled with a predetermined polypeptide epitope that is recognized by a second reporter (eg, a leucine zipper pair sequence, a binding site for a second antibody, a metal binding domain, an epitope tag).
[0215] The CAR, T cell expressing the CAR, antibody or antigen-binding portion thereof can also be conjugated with a radiolabeled amino acid. Radiolabels can be used for both diagnostic and therapeutic purposes. For example, radiolabels can be used to detect one or more of the antigens and antigen-expressing cells disclosed herein by x-ray, emission spectroscopy, or other diagnostic techniques. Additionally, radiolabels can be used therapeutically as toxins for the treatment of tumors in a subject, such as for the treatment of neuroblastoma. Examples of labels for polypeptides include, but are not limited to, the following radioisotopes or radionucleotides: 3 H, 14 C, 15 N, 35 S, 90 Y, 99 Tc, 111 In, 125 I, and 131 I.
[0216] Means for detecting such detectable markers are well known to those skilled in the art. Thus, for example, radiolabels may be detected using photographic film or a scintillation counter, and fluorescent markers may be detected using a photodetector to detect the emitted illumination. Enzyme labels are typically detected by providing a substrate for the enzyme and detecting the reaction product produced by the enzyme's action on the substrate, and chromogenic labels are detected by simply visualizing the colored label. Ru.
[0217] D. Nucleotides, expression, vectors and host cells Further provided by one embodiment of the invention is a nucleic acid comprising a nucleotide sequence encoding any of the CARs, antibodies or antigen-binding portions thereof (including functional portions and functional variants thereof) described herein. be done. Nucleic acids of the invention can include nucleotide sequences encoding any of the leader sequences, antigen binding domains, transmembrane domains and / or intracellular T cell signaling domains described herein.
[0218] In some embodiments, the nucleotide sequence may be codon modified. Without being bound to any particular theory, it is believed that codon optimization of a nucleotide sequence increases the efficiency of translation of an mRNA transcript. Codon optimization of a nucleotide sequence involves replacing a native codon with another codon that encodes the same amino acid but can be translated by tRNAs that are more readily available in the cell, thus increasing translation efficiency. may be included. Nucleotide sequence optimization may also reduce secondary mRNA structures that interfere with translation, thus increasing translation efficiency.
[0219] In embodiments of the invention, the nucleic acid may include a codon-modified nucleotide sequence encoding the antigen binding domain of a CAR of the invention. In another embodiment of the invention, the nucleic acid may include a codon-modified nucleotide sequence encoding any of the CARs described herein (including functional portions and functional variants thereof).
[0220] "Nucleic acid" as used herein includes "polynucleotides," "oligonucleotides," and "nucleic acid molecules," and is generally single-stranded or double-stranded and obtained from synthetic or natural sources. (e.g., isolated and / or purified) and may contain natural, non-natural or modified nucleotides, in place of the phosphodiester found between the nucleotides of the unmodified oligonucleotide. , refers to a polymer of DNA or RNA that may contain non-natural or modified internucleotide linkages, such as phosphoroamidate or phosphorothioate linkages. In some embodiments, the nucleic acid does not contain any insertions, deletions, inversions and / or substitutions. However, in some cases, as discussed herein, it may be appropriate for the nucleic acid to contain one or more insertions, deletions, inversions and / or substitutions.
[0221] A recombinant nucleic acid can have a sequence that is not naturally occurring or one that is created by the artificial combination of two otherwise separated segments of a sequence. This artificial combination is achieved by the artificial manipulation of isolated segments of nucleic acids by chemical synthesis or, more commonly, by genetic engineering techniques such as those described in Sambrook et al., supra. There are many cases where Nucleic acids may be constructed based on chemical synthesis and / or enzymatic ligation reactions using procedures known in the art. See, eg, Sambrook et al., supra and Ausubel et al., supra. For example, a nucleic acid is a naturally occurring nucleotide, or one designed to increase the biological stability of a molecule or to increase the physical stability of a duplex formed upon hybridization. It can be chemically synthesized using variously modified nucleotides, such as phosphorothioate derivatives and acridine substituted nucleotides. Examples of modified nucleotides that can be used to generate nucleic acids include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxylic Hydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyl adenine, 1-methylguanine , 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-substituted adenine, 7-methylguanine, 5-methylaminomethyl Uracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyl adenine, uracil-5- Oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid These include, but are not limited to, methyl ester, 3-(3-amino-3-N-2-carboxypropyl)uracil and 2,6-diaminopurine. Alternatively, one or more of the nucleic acids of the invention can be purchased from companies such as Integrated DNA Technologies (Coralville, IA, USA).
[0222] The nucleic acid may include any isolated or purified nucleotide sequence encoding a CAR or any functional portion or variant thereof. Alternatively, the nucleotide sequence may include a nucleotide sequence that is degenerate with any of the sequences, or a combination of degenerate sequences.
[0223] One embodiment includes a nucleotide sequence that is complementary to the nucleotide sequence of any of the nucleic acids described herein, or that hybridizes under stringent conditions to the nucleotide sequence of any of the nucleic acids described herein. Also provided are isolated or purified nucleic acids containing the nucleotide sequences.
[0224] Nucleotide sequences that hybridize under stringent conditions are capable of hybridizing under conditions of high stringency. "Conditions of high stringency" means that a nucleotide sequence is specifically hybridized to a target sequence (the nucleotide sequence of any of the nucleic acids described herein) in an amount that is detectably stronger than non-specific hybridization. means to hybridize. High stringency conditions range from random sequences that happen to have several small regions (e.g., 3-10 bases) matched to the nucleotide sequence, to polynucleotides that have exactly complementary sequences, or a few scattered Conditions are included that identify polynucleotides that contain only mismatches. Such small regions of complementarity are more easily fused than the 14-17 or more base full-length complements, and high stringency hybridization makes them easily distinguishable. Conditions of relatively high stringency include low salt and / or high temperature conditions, such as those provided by, for example, about 0.02-0.1 M NaCl or equivalent at a temperature of about 50-70°C. Such high stringency conditions tolerate little, if any, mismatch between the nucleotide sequence and the template or target strand and are particularly suitable for detecting expression of any of the CARs of the invention. . It is generally understood that conditions can be made more stringent by the addition of increasing amounts of formamide.
[0225] For any of the nucleic acids described herein, at least about 70% or more, such as about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about Nucleic acids comprising nucleotide sequences that are 95%, about 96%, about 97%, about 98% or about 99% identical are also provided.
[0226] In one embodiment, the nucleic acid can be incorporated into a recombinant expression vector. In this regard, one embodiment provides a recombinant expression vector comprising any of the nucleic acids. For purposes herein, the term "recombinant expression vector" means when the construct comprises a nucleotide sequence encoding an mRNA, protein, polypeptide or peptide; A genetically modified oligonucleotide or polynucleotide that enables expression of an mRNA, protein, polypeptide or peptide by a host cell when contacted with the cell under conditions sufficient for the peptide to be expressed within the cell. means construct. Vectors do not occur in nature in their entirety.
[0227] However, some of the vectors may be naturally occurring. Recombinant expression vectors include DNA and RNA, which may be single-stranded or double-stranded, synthetic or derived in part from natural sources, and may contain natural, non-natural or modified nucleotides. may include any type of nucleotide, including but not limited to. Recombinant expression vectors may contain naturally occurring or non-naturally occurring internucleotide linkages, or both types of linkages. Preferably, the non-naturally occurring or altered nucleotides or internucleotide linkages do not interfere with either transcription or replication of the vector.
[0228] In one embodiment, the recombinant expression vector can be any suitable recombinant expression vector and can be used to transform or transfect any suitable host cell. Suitable vectors include those designed for propagation and propagation or for expression, or both, such as plasmids and viruses. Vectors include the pUC series (Fermentas Life Sciences, Glen Burnie, MD), pBluescript series (Stratagene, LaJolla, CA), pET series (Novagen, Madison, WI), pGEX series (Pharmacia Biotech, Uppsala, Sweden) and pEX series ( Clontech, Palo Alto, CA).
[0229] Bacteriophage vectors such as λυΤΙΟ, λυΤΙ 1, λZapII (Stratagene), EMBL4 and λΝΜΙ 149 can also be used. Examples of plant expression vectors include pBIOl, pBI101.2, pBHOl.3, pBI121 and pBIN19 (Clontech). Examples of animal expression vectors include pEUK-Cl, pMAM and pMAMneo (Clontech). A recombinant expression vector can be a viral vector, such as a retroviral vector or a lentiviral vector. Lentiviral vectors include, in particular, self-inactivating lentiviral vectors such as those provided in Milone et al., Mol. Ther. 17(8):1453-1464 (2009). It is a vector derived from a portion. Other examples of lentiviral vectors that may be used in the clinic include, but are not limited to, Oxford BioMedica plc's LENTIVECTOR® gene delivery technology, Lentigen's LENTIMAX® vector system, and the like. Non-clinical lentiviral vectors are also available and known to those skilled in the art.
[0230] Several transfection techniques are generally known in the art (e.g., Graham et al., Virology, 52:456-467 (1973); Sambrook et al., supra; Davis et al., Basic Methods in Molecular Biology, Elsevier). (1986); and Chu et al., Gene 13:97 (1981)).
[0231] Transfection methods include calcium phosphate coprecipitation (e.g., see Graham et al., supra), direct microinjection into cultured cells (e.g., Capecchi, Cell, 22:479-488 (1980)). ), electroporation (see, e.g., Shigekawa et al., BioTechniques, 6:742-751 (1988)), liposome-mediated gene transfer (e.g., Mannino et al., BioTechniques, 6:682). ~690 (1988)), lipid-mediated transduction (see, e.g., Feigner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987)) and nucleic acid delivery using high velocity microprojectiles (see, eg, Klein et al., Nature 327:70-73 (1987)).
[0232] In one embodiment, recombinant expression vectors can be prepared using standard recombinant DNA techniques, eg, as described in Sambrook et al., supra and Ausubel et al., supra. Expression vector constructs, circular or linear, can be prepared to contain a functional replication system in a prokaryotic or eukaryotic host cell. Replication systems can be derived from, for example, ColEl, 2μ plasmid, λ, SV40, bovine papillomavirus, etc.
[0233] Recombinant expression vectors can be used as appropriate for the type of host cell into which the vector is introduced (e.g., bacteria, fungi, plants or animals), taking into account whether the vector is DNA-based or RNA-based. It may contain specific regulatory sequences, such as transcription and translation initiation and termination codons. Recombinant expression vectors may contain restriction sites to facilitate cloning.
[0234] Recombinant expression vectors may contain one or more marker genes that allow selection of transformed or transfected host cells. Marker genes include biocide resistance, eg, resistance to antibiotics, heavy metals, etc., complementation in an auxotrophic host to provide prototrophy, and the like. Marker genes suitable for the expression vectors of the invention include, for example, neomycin / G418 resistance genes, hygromycin resistance genes, histidinol resistance genes, tetracycline resistance genes, and ampicillin resistance genes.
[0235] The recombinant expression vector contains a nucleotide sequence encoding a CAR (including functional portions and functional variants thereof) or a nucleotide sequence that is complementary to or hybridizes to a nucleotide sequence encoding a CAR. It may contain an operably linked native or non-native promoter. The selection of promoters, eg, strong, weak, inducible, tissue-specific and development-specific, is within the skill of those skilled in the art. Similarly, it is also within the skill of those skilled in the art to combine nucleotide sequences with promoters. The promoter can be a non-viral promoter or a viral promoter, such as the cytomegalovirus (CMV) promoter, the SV40 promoter, the RSV promoter, or the promoter found in the terminal repeat sequences of murine stem cell viruses.
[0236] Recombinant expression vectors can be designed for transient expression, stable expression, or both. Also, recombinant expression vectors can be created for constitutive or inducible expression.
[0237] Additionally, recombinant expression vectors can be made to contain suicide genes. As used herein, the term "suicide gene" refers to a gene that causes cells expressing the suicide gene to die. A suicide gene can be a gene that confers sensitivity to an agent, such as a drug, in the cell in which it is expressed, or a gene that causes the cell to die if it comes into contact with or is exposed to the agent. Suicide genes are known in the art (e.g., Suicide Gene Therapy: Methods and Reviews, Springer, Caroline J. (Cancer Research UK Center for Cancer Therapeutics at the Institute of Cancer Research, Sutton, Surrey, UK), Humana Press , 2004), including, for example, the herpes simplex virus (HSV) thymidine kinase (TK) gene, cytosine deaminase, purine nucleoside phosphorylase and nitroreductase.
[0238] One embodiment further provides a host cell comprising any of the recombinant expression vectors described herein. As used herein, the term "host cell" refers to any type of cell that can contain a recombinant expression vector of the invention. The host cell may be a eukaryotic cell, such as a plant, animal, fungus or algae, or a prokaryotic cell, such as a bacterium or protist. The host cell may be a cultured cell or a primary cell, ie, isolated directly from an organism such as a human. The host cell can be an adherent cell or a suspension cell, ie, a cell that grows in suspension. Suitable host cells are known in the art and include, for example, DH5a E. coli cells, Chinese hamster ovary cells, monkey VERO cells, COS cells, HEK293 cells, and the like. For purposes of amplifying or replicating recombinant expression vectors, the host cell may be a prokaryotic cell, such as a DH5a cell. For the purpose of producing a recombinant CAR, the host cell can be a mammalian cell. The host cell can be a human cell. Although host cells can be of any cell type, originating from any type of tissue, and at any stage of development, host cells include peripheral blood lymphocytes (PBLs) or peripheral blood mononuclear cells. It can be a sphere (PBMC). The host cell can be a T cell.
[0239] For purposes herein, a T cell is any T cell, e.g., a cultured T cell, e.g., a primary T cell, or a cultured T cell line, e.g., a T cell derived from Jurkat, SupTl, etc., or a mammalian T cell. may be T cells obtained from. When obtained from a mammal, T cells can be obtained from a number of sources including, but not limited to, blood, bone marrow, lymph nodes, thymus or other tissues or body fluids. T cells can also be enriched or purified. The T cell can be a human T cell. The T cell can be a T cell isolated from a human. T cells include CD4+ / CD8+ double positive T cells, CD4+ helper T cells, e.g. Th1 and Th2 cells, CD8+ T cells (e.g. cytotoxic T cells), tumor-infiltrating cells, memory T cells, memory stem cells. , ie, can be any type of T cell, including but not limited to Tscm, naive T cells, etc., and can be at any stage of development. T cells can be CD8+ T cells or CD4+ T cells.
[0240] In one embodiment, the CARs described herein can be used in appropriate non-T cells. Such cells include cells with immune effector functions, such as NK cells and T-like cells generated from pluripotent stem cells.
[0241] Also provided by one embodiment is a population of cells comprising at least one host cell described herein. The population of cells does not contain any recombinant expression vector and contains at least one other cell, such as a host cell (e.g., a T cell), or a cell other than a T cell, such as a B cell, a macrophage, a neutrophil, an erythrocyte. , hepatocytes, endothelial cells, epithelial cells, muscle cells, brain cells, etc., as well as host cells containing any of the recombinant expression vectors described. Alternatively, the population of cells can be a substantially homogeneous population, where the population primarily includes (eg, consists essentially of) host cells that contain (eg, consist essentially of) the recombinant expression vector. A population can also be a clonal population of cells, where all cells of the population are clones of a single host cell containing the recombinant expression vector, such that all cells of the population are clones of a single host cell that contains the recombinant expression vector. Contains recombinant expression vectors. In one embodiment of the invention, the population of cells is a clonal population comprising host cells containing the recombinant expression vectors described herein.
[0242] CARs (including functional portions and variants thereof), nucleic acids, recombinant expression vectors, host cells (including populations thereof) and antibodies (including antigen-binding portions thereof) may be isolated and / or purified. For example, a purified (or isolated) host cell preparation is one in which the host cells are purer than the cells in their natural environment within the body. Such host cells can be produced, for example, by standard purification techniques. In some embodiments, the preparation of host cells is purified so that the host cells represent at least about 50%, such as at least about 70%, of the total cell content of the preparation. For example, purity can be at least about 50%, greater than about 60%, about 70% or about 80%, or about 100%.
[0243] E. Method of treatment It is contemplated that the CARs disclosed herein can be used in methods of treating or preventing disease in mammals. In this regard, one embodiment provides the use of a CAR, a nucleic acid, a recombinant expression vector, a host cell, a population of cells, an antibody and / or an antigen-binding portion thereof, and / or a pharmaceutical composition to treat or treat cancer in a mammal. A method of treating or preventing cancer in a mammal is provided, the method comprising administering to the mammal a prophylactically effective amount.
[0244] One embodiment further comprises lymphodepleting the mammal prior to administering the CAR disclosed herein. Examples of lymphodepletion may include, but are not limited to, non-myeloablative lymphodepleting chemotherapy, myeloablative lymphodepletion chemotherapy, total body irradiation, and the like.
[0245] For purposes of the method by which the host cell, or population of cells, is administered, the cell can be allogeneic or autologous to the mammal. Preferably the cells are autologous to the mammal. As used herein, homologous refers to any material that is derived from a different animal of the same species as the individual into which the material is introduced. Two or more individuals are said to be the same species as each other if their genes are not identical at one or more loci. In some embodiments, allogeneic materials from individuals of the same species may be sufficiently genetically different to interact antigenically. As used herein, "autologous" refers to any material derived from the same individual that is later reintroduced to the individual.
[0246] A mammal referred to herein may be any mammal. As used herein, the term "mammal" refers to any mammal, including, but not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits. Refers to mammals. The mammal can be from the order Carnivora, including Felines (cats) and Canines (dogs). Mammals are from the order Artiodactyla, which includes the bovine (cow) and the swine (pig), or from the order Perissodactyla, which includes the equine (horse). It can be of. The mammal can be of the order Primates, the New World Ceboid or Simoid orders (monkeys), or the Anthropoid orders (humans and apes). Preferably the mammal is a human.
[0247] For these methods, the cancer may be acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bladder cancer (e.g., bladder cancer), bone cancer, brain cancer (e.g., medullary bud cancer). meduloblastoma), breast cancer, cancer of the anus, anal canal or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder or pleura, nose, Cancer of the nasal cavity or middle ear, cancer of the oral cavity, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, cervical cancer, fibrosarcoma , gastrointestinal carcinoid tumors, head and neck cancers (e.g. head and neck squamous cell carcinoma), Hodgkin lymphoma, hypopharyngeal cancer, kidney cancer, laryngeal cancer, leukemia, liquid tumors, liver cancer, lung cancer (e.g. Non-small cell lung cancer and lung adenocarcinoma), lymphoma, mesothelioma, mast cell tumor, melanoma, multiple myeloma, nasopharyngeal cancer, non-Hodgkin lymphoma, B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphoma sexual leukemia (ALL) and Burkitt's lymphoma, ovarian cancer, pancreatic cancer, peritoneal, omental and mesenteric cancer, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer, skin cancer, small intestine cancer It can be any cancer, including any of cancer, soft tissue cancer, solid tumors, synovial sarcoma, gastric cancer, testicular cancer, thyroid cancer and ureteral cancer.
[0248] The terms "treat" and "prevent" and words derived therefrom, as used herein, do not necessarily mean 100% or complete treatment or prevention. Rather, there are varying degrees of treatment or prevention that those skilled in the art would recognize as having potential beneficial or therapeutic effects. In this regard, the method may provide any amount or level of treatment or prevention of cancer in a mammal.
[0249] Additionally, treatment or prevention provided by this method can include treatment or prevention of one or more conditions or symptoms of the disease, such as cancer, being treated or prevented. Also, for purposes herein, "prevention" may include delaying the onset of a disease, or a symptom or condition thereof.
[0250] Another embodiment is a method of detecting the presence of cancer in a mammal, the method comprising: (a) treating a sample comprising one or more cells of mammalian origin with a CAR, a nucleic acid, a recombinant expression vector, a host cell; contacting a population of cells, an antibody and / or an antigen-binding portion thereof, or a pharmaceutical composition, thereby forming a complex; and (b) detecting the complex, the step of: detecting the complex. provides a method of indicating the presence of cancer in a mammal.
[0251] The sample may be obtained by any suitable method, eg, biopsy or autopsy. A biopsy is the removal of tissue and / or cells from an individual. Such removal may be the collection of tissues and / or cells from the individual in order to perform experiments on the removed tissues and / or cells. The experimentation may include experimentation to determine whether an individual has and / or is suffering from a particular condition or disease state. The condition or disease can be, for example, cancer.
[0252] For embodiments of methods for detecting the presence of a proliferative disorder, e.g., cancer, in a mammal, the sample comprising mammalian cells may include whole cells, lysates thereof, or fractions of whole cell lysates, e.g., nuclei or cytoplasm. The sample can be a fraction, a whole protein fraction, or a nucleic acid fraction. If the sample contains whole cells, these cells can be of any organ or tissue of a mammal, including blood cells or endothelial cells.
[0253] The contacting step can occur in vitro or in vivo with respect to the mammal. Preferably, the contacting step is in vitro.
[0254] Detection of complexes can also be performed by many methods known in the art. For example, a CAR, a polypeptide, a protein, a nucleic acid, a recombinant expression vector, a host cell, a population of cells, or an antibody or antigen-binding portion thereof disclosed herein is detectable. Labels such as the radioisotopes disclosed above, fluorophores (e.g. fluorescein isothiocyanate (FITC), phycoerythrin (PE)), enzymes (e.g. alkaline phosphatase, horseradish peroxidase) and elemental particles (e.g. gold particles), etc.
[0255] Methods for testing CARs for their ability to recognize target cells and antigen specificity are known in the art. For example, Clay et al., J. Immunol, 163:507-513 (1999), cytokines (e.g., interferon-γ, granulocyte / monocyte colony stimulating factor (GM-CSF) ), teaches methods for measuring the release of tumor necrosis factor a (TNF-a) or interleukin 2 (IL-2)). Additionally, CAR function can be assessed by measuring cytotoxicity, as described in Zhao et al., J. Immunol. 174:4415-4423 (2005).
[0256] Another embodiment describes the use of the CARs, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies or antigen-binding portions thereof, and / or pharmaceutical compositions of the invention to treat the proliferation of cancer, etc. in mammals. Provide treatment or prevention of disorders. The cancer can be any of the cancers described herein.
[0257] Any method of administration can be used for the disclosed therapeutic agents, including local and systemic administration. For example, topical, oral, intravenous, intravenous, intravenous, intramuscular, intraperitoneal, intranasal, intradermal, intrathecal and subcutaneous administration may be used. The particular mode of administration and dosing regimen will be selected by the attending clinician in view of the characteristics of the case (eg, the subject, the disease, the disease state involved, and whether the treatment is prophylactic). If more than one agent or composition is being administered, one or more routes of administration may be used; for example, the chemotherapeutic agent may be administered orally and the antibody or antigen-binding fragment or conjugate or composition may be administered orally. may be administered intravenously. Methods of administration include transporting the CAR, CAR T cell, conjugate, antibody, antigen-binding fragment or composition in a non-toxic pharmaceutically acceptable carrier, such as water, saline, Ringer's solution, dextrose solution, % human serum albumin, injections provided in solid oil, ethyl oleate or liposomes. In some embodiments, local administration of a disclosed compound involves, for example, applying an antibody or antigen-binding fragment to an area of tissue from which a tumor has been removed or an area suspected of being prone to tumor development. can be used by In some embodiments, sustained intratumoral (or proximal) release of a pharmaceutical preparation comprising a therapeutically effective amount of an antibody or antigen-binding fragment may be beneficial. In other examples, the conjugate is applied topically to the cornea as eye drops or intravitreally to the eye.
[0258] The disclosed therapeutic agents can be formulated in unit dosage forms suitable for individual administration of precise dosages. Additionally, the disclosed therapeutic agents can be administered in a single dose or on a multiple dose schedule. A multi-dose schedule is one in which the main course of treatment consists of more than one separate dose, e.g. 1 to 10 doses, followed by subsequent time intervals as necessary to maintain or enhance the action of the composition. The schedule may depend on the other doses given. Treatment may include a daily dose or multiple daily doses of the compound(s) over a period of days to months or even years. Accordingly, the dosage regime is also determined at least in part based on the particular needs of the subject being treated and is dependent on the judgment of the administering practitioner.
[0259] Typical dosages of antibodies or conjugates can range from about 0.01 to about 30 mg / kg, such as from about 0.1 to about 10 mg / kg.
[0260] In certain instances, the subject may administer the conjugate, antibody, composition, etc. on multiple daily dosing schedules, e.g., at least 2 consecutive days, 10 consecutive days, etc., over a period of weeks, months, or years. A therapeutic composition comprising one or more of a drug, a CAR, a CAR T cell, or an additional agent is administered. In one example, the subject receives the conjugate, the antibody, for a period of at least 30 days, such as at least 2 months, at least 4 months, at least 6 months, at least 12 months, at least 24 months or at least 36 months. , composition or additional agent is administered.
[0261] In some embodiments, the disclosed methods involve administering surgery, radiotherapy, and / or chemotherapy drugs in combination with a disclosed antibody, antigen-binding fragment, conjugate, CAR, or T cell expressing a CAR. (e.g., sequentially, substantially simultaneously, or simultaneously) to a subject. Such agents and methods of treatment and therapeutic dosages are known to those skilled in the art and can be determined by the skilled clinician. Preparation and dosing schedules for additional agents may be used according to manufacturer's instructions or as determined empirically by one of ordinary skill in the art. Preparation and dosing schedules for such chemotherapy are also described in Chemotherapy Service, (1992) edited by M. C. Perry, Williams & Wilkins, Baltimore, Md.
[0262] In some embodiments, the combination treatment may include administering to the subject a therapeutically effective amount of an additional cancer inhibitor. Non-limiting examples of additional therapeutic agents that may be used in combination therapy include microtubule binding agents, DNA intercalators or crosslinkers, DNA synthesis inhibitors, DNA and RNA transcription inhibitors, antibodies, enzymes, enzyme inhibitors, Includes gene regulators as well as angiogenesis inhibitors. These agents (administered in therapeutically effective amounts) and treatments may be used alone or in combination. For example, any suitable anti-cancer or anti-angiogenic agent can be administered in combination with a CAR, CAR-T cell, antibody, antigen-binding fragment or conjugate disclosed herein. Methods and therapeutic dosages of such agents are known to those skilled in the art and can be determined by the skilled clinician.
[0263] Additional chemotherapeutic agents include alkylating agents such as nitrogen mustards (e.g. chlorambucil, chlormethine, cyclophosphamide, ifosfamide and melphalan), nitrosoureas (e.g. carmustine, fotemustine, lomustine and streptozocin), platinum compounds (e.g. carboplatin, cisplatin, oxaliplatin and BBR3464), busulfan, dacarbazine, mechlorethamine, procarbazine, temozolomide, thiotepa and uramustine; antimetabolites such as folic acid (e.g. methotrexate, pemetrexed and raltitrexed), purines ( cladribine, clofarabine, fludarabine, mercaptopurine and thioguanine), pyrimidines (e.g. capecitabine), cytarabine, fluorouracil and gemcitabine; plant alkaloids, e.g. podophyllum (e.g. etoposide and teniposide), taxanes (e.g. docetaxel and paclitaxel), Vincas (e.g. vinblastine, vincristine, vindesine and vinorelbine); cytotoxic / antitumor antibiotics, e.g. members of the anthracycline family (e.g. daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone and valrubicin), bleomycin, rifampicin , hydroxyurea and mitomycin; topoisomerase inhibitors, such as topotecan and irinotecan; monoclonal antibodies, such as alemtuzumab, bevacizumab, cetuximab, gemtuzumab, rituximab, panitumumab, pertuzumab and trastuzumab; tumor-tropic photosensitive dyes, such as aminolevulinic acid, aminolevulinic acid methyl, porfimer sodium and verteporfin; and other drugs such as alitretinoin, altretamine, amsacrine, anagrelide, arsenic trioxide, asparaginase, axitinib, bexarotene, bevacizumab, bortezomib, celecoxib, denileukin diftitox, erlotinib, est Includes, but is not limited to, ramustine, gefitinib, hydroxycarbamide, imatinib, lapatinib, pazopanib, pentostatin, masoprocol, mitotane, pegaspargase, tamoxifen, sorafenib, sunitinib, vemurafinib, vandetanib and tretinoin. The selection and therapeutic dosage of such agents are known to those skilled in the art and can be determined by the skilled clinician.
[0264] Combination therapy may provide a synergistic effect and may prove to be synergistic, i.e. the effect achieved when the active ingredients are used together does not result from using the compounds separately. greater than the sum of the effects obtained. A synergistic effect occurs when the active ingredients are (1) co-formulated and administered or delivered simultaneously in combined unit dosage formulations; (2) delivered alternately or in parallel as separate formulations; or (3) Can be achieved with some other regimens. When delivered alternately, a synergistic effect may be achieved when the compounds are administered or delivered sequentially, eg, by different injections in separate syringes. Generally, during alternation, an effective dosage of each active ingredient is administered sequentially, ie, sequentially, whereas in combination therapy, effective dosages of two or more active ingredients are administered together.
[0265] In one embodiment, an effective amount of an antibody or antigen-binding fragment or conjugate thereof that specifically binds one or more of the antigens disclosed herein is administered to a subject having a tumor following anti-cancer treatment. be done. After a sufficient amount of time has elapsed for the administered antibody or antigen-binding fragment or conjugate to form an immune complex with the antigen expressed on the respective cancer cells, the immune complex is detected. Ru. The presence (or absence) of immune complexes indicates the effectiveness of treatment. For example, an increase in immune complexes compared to controls taken before treatment indicates that the treatment is not effective, and a decrease in immune complexes compared to controls taken before treatment indicates that the treatment is not effective. Indicates that it is valid.
[0266] F. Biopharmaceutical composition A disclosed CAR, or a T cell expressing a CAR, an antibody, an antigen-binding fragment, a conjugate, a CAR, or one or more of the herein disclosed in a carrier (e.g., a pharmaceutically acceptable carrier). A biopharmaceutical or biopharmaceutical composition for use in gene therapy, immunotherapy and / or cell therapy, comprising one or more T cells expressing a CAR that specifically binds multiple antigens (as defined herein) Provided herein are compositions (hereinafter referred to as "compositions"). These compositions may be prepared in unit dosage form for administration to a subject. The amount and timing of administration to achieve the desired outcome is at the discretion of the treating clinician. These compositions may be formulated for systemic (eg, intravenous) or local (eg, intratumoral) administration. In one example, the disclosed CARs, or T cells, antibodies, antigen-binding fragments, conjugates expressing the CARs, are formulated for parenteral administration, such as intravenous administration. Compositions comprising the CARs disclosed herein, or T cells, conjugates, antibodies or antigen-binding fragments expressing CARs, can be used for the treatment of tumors, such as, but not limited to, neuroblastoma. and used for detection, etc. In some instances, these compositions are useful in treating or detecting cancer. Compositions comprising the CARs disclosed herein, or T cells, conjugates, antibodies or antigen-binding fragments expressing CARs, are also used, for example, in the detection of pathological angiogenesis.
[0267] Compositions for administration can include a solution of the CAR, or T cells, conjugates, antibodies or antigen-binding fragments expressing the CAR, dissolved in a pharmaceutically acceptable carrier such as an aqueous carrier. . Various aqueous carriers may be used, such as buffered saline. These solutions are sterile and generally free of undesirable substances. The composition may be sterilized by conventional, well-known sterilization techniques. The composition contains pharmaceutically acceptable auxiliary substances necessary to approximate physiological conditions, such as pH adjusting agents and buffers, toxicity modifiers, adjuvant drugs, etc., such as sodium acetate, sodium chloride, potassium chloride, etc. , calcium chloride, sodium lactate, and the like. The concentration of CAR, or T cells, antibodies or antigen-binding fragments or conjugates expressing the CAR, in these formulations can vary widely, depending on the volume, viscosity, and subject requirements of the particular mode of administration chosen. , selected primarily based on weight, etc. Actual methods of preparing such dosage forms for use in gene therapy, immunotherapy and / or cell therapy are known or will be apparent to those skilled in the art.
[0268] A typical composition for intravenous administration includes about 0.01 to about 30 mg / kg of antibody or antigen-binding fragment or conjugate (or corresponding dose of CAR, or T cells expressing CAR) per subject per day. , conjugates containing antibodies or antigen-binding fragments). Actual methods for preparing administrable compositions are known or apparent to those skilled in the art and are described in more detail in publications such as Remington's Pharmaceutical Science, 19th Edition, Mack Publishing Company, Easton, PA (1995). It is described in.
[0269] The CAR, or T cells, antibodies, antigen-binding fragments, or conjugates expressing the CAR, may be provided in lyophilized form and rehydrated with sterile water prior to administration; Also provided in sterile solution. A solution of the CAR, or T cells expressing the CAR, antibody or antigen-binding fragment or conjugate, is then added to an infusion bag containing 0.9% sodium chloride, USP, in some cases between 0.5 and 15 mg. Administered at a dosage of / kg body weight. Considerable experience is available in the field with the administration of antibodies or antigen-binding fragments and conjugate drugs; for example, antibody drugs have been commercially available in the United States since the approval of RITUXAN® in 1997. . The CAR, or T cells expressing the CAR, antibodies, antigen-binding fragments and conjugates thereof, can be administered by slow infusion rather than by intravenous injection or intravenous bolus. In one example, a higher loading dose is administered with a subsequent maintenance dose administered at a lower level. For example, an initial loading dose of 4 mg / kg of antibody or antigen-binding fragment (or a corresponding dose of a conjugate comprising an antibody or antigen-binding fragment) can be infused over a period of approximately 90 minutes, followed by A weekly maintenance dose of 2 mg / kg for 4 to 8 weeks infused over a period of 30 minutes can be infused if the dose is well tolerated.
[0270] Controlled-release parenteral formulations can be made as implants, oily injections, or as particulate systems. For a broad overview of protein delivery systems, see Banga, A.J., Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, Technomic Publishing Company, Inc., Lancaster, PA (1995). Particulate systems include microspheres, microparticles, microcapsules, nanocapsules, nanospheres and nanoparticles. Microcapsules contain therapeutic proteins, such as cytotoxins or drugs, as a central core. In microspheres, the therapeutic agent is dispersed throughout the particles. Particles, microspheres and microcapsules smaller than about 1 μm are commonly referred to as nanoparticles, nanospheres and nanocapsules, respectively. The capillary has a diameter of approximately 5 μm so that only nanoparticles are administered intravenously. Microparticles are typically approximately 100 μm in diameter and are administered subcutaneously or intramuscularly. See, for example, Kreuter, J., Colloidal Drug Delivery Systems, edited by J. Kreuter, Marcel Dekker, Inc., New York, NY, pp. 219-342 (1994); and Tice and Tabibi, Treatise on Controlled Drug Delivery, A. See Kydonieus (ed.), Marcel Dekker, Inc. New York, NY, pp. 315-339 (1992).
[0271] The polymers can be used for ionically controlled release of the CARs disclosed herein, or T cells, antibodies or antigen-binding fragments or conjugate compositions expressing the CARs. A variety of degradable and non-degradable polymeric matrices used for controlled drug delivery are known in the art (Langer, Accounts Chem. Res. 26:537-542, 1993). For example, the block copolymer polaxamer 407 exists as a viscous but still mobile liquid at low temperatures, but forms a semi-fluid gel at body temperature. It has been shown to be an effective vehicle for the formulation and sustained delivery of recombinant interleukin-2 and urease (Johnston et al., Pharm. Res. 9:425-434, 1992). and Pec et al., J.Parent.Sci.Tech. 44(2):58-65, 1990). Alternatively, hydroxyapatite has been used as a microcarrier for the controlled release of proteins (Ijntema et al., Int. J. Pharm. 112:215-224, 1994). In yet another aspect, liposomes are used for controlled release and drug targeting of lipid-encapsulated drugs (Betageri et al., Liposome Drug Delivery Systems, Technomic Publishing Co., Inc., Lancaster, PA (1993). ). A number of additional systems for controlled delivery of therapeutic proteins are known (US Patent No. 5,055,303; US Patent No. 5,188,837; US Patent No. 4,235,871; US Patent No. 4,501,728; US Patent No. 4,837,028; U.S. Patent No. 4,957,735; U.S. Patent No. 5,019,369; U.S. Patent No. 5,055,303; U.S. Patent No. 5,514,670; U.S. Patent No. 5,413,797; U.S. Patent No. 5,268,164; No. 5,506,206; US Pat. No. 5,271,961; US Pat. No. 5,254,342 and US Pat. No. 5,534,496).
[0272] G.Kit In one aspect, kits using the CARs disclosed herein are also provided. For example, a kit for treating a tumor in a subject or a kit for producing CAR T cells expressing one or more of the CARs disclosed herein. Kits typically include a disclosed antibody, antigen-binding fragment, conjugate, nucleic acid molecule, CAR, or T cell expressing a CAR, as disclosed herein. More than one of the disclosed antibodies, antigen-binding fragments, conjugates, nucleic acid molecules, CARs, or T cells expressing CARs can be included in the kit.
[0273] The kit can include a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, and the like. Containers may be formed from a variety of materials such as glass or plastic. The container typically holds a composition comprising one or more of the disclosed antibodies, antigen-binding fragments, conjugates, nucleic acid molecules, CARs, or T cells expressing the CARs. In some embodiments, the container can have a sterile access port (eg, the container can be an intravenous solution bag or vial with a stopper pierceable by a hypodermic needle). The label or package insert indicates that the composition is used to treat a particular condition.
[0274] The label or package insert typically describes the disclosed antibody, antigen-binding fragment, conjugate, nucleic acid molecule, CAR or CAR in, for example, a method of treating or preventing a tumor, or a method of producing a CAR T cell. Further includes instructions for the use of T cells expressing . Package inserts are typically customary in the commercial packaging of therapeutic products, containing information about indications, usage, dosage, administration, contraindications and / or such warnings regarding the use of the therapeutic product. Including instructions included. The educational materials may be written in electronic form (eg, computer diskettes or compact discs) or visual (eg, video files). Kits may also contain additional components to facilitate the particular application for which the kit is designed. Thus, for example, the kit may further include means for detecting a label (eg, an enzyme substrate for an enzyme label, a filter set for detecting a fluorescent label, a suitable secondary label such as a secondary antibody, etc.). Kits may further include buffers and other reagents conventionally used for performing a particular method. Such kits and appropriate contents are well known to those skilled in the art.
Example
[0275] The invention is further illustrated by the following examples, which should in no way be construed as imposing limitations on the scope of the invention. On the contrary, one should resort to various other embodiments, modifications, and equivalents thereof, which after reading this specification may be determined to be within the spirit of the invention and / or the scope of the appended claims. It will be readily understood that such things may occur to those skilled in the art without departing from this.
[0276] Example 1A Isolation of CD19-specific antibodies from fully human phage and yeast-displayed scFv libraries material and method: a) Production of human scFv and CD19-specific antibodies A naive human ScFv (variable recombinant single chain fragment of immunoglobulin) phage display library constructed from peripheral blood B cells of 50 healthy donors (approximate diversity, 10 10 species unique specificity) (Z.Y. Zhu and D.S. Dimitrov, unpublished data) was used for selection of ScFv for recombinant human CD19 protein (Miltenyi Biotec, unpublished). Phage-displayed scFv10 12The amplified library of species was incubated with 5, 3, and 1 μg of coated CD19 in a volume of 5 × 100 μl and wells of a 96-well plate during the first, second, and third rounds of biopanning, respectively. It was divided into 5 equal portions and left at room temperature for 2 hours. After each round of incubation, wash the wells with phosphate-buffered saline (PBST) containing 0.05% Tween20 5 times in the first round and 10 times in subsequent rounds to remove non-specifically bound phage. Then, the bound phages were mixed with TG1 competent cells for 1 hour at 37°C, and the phages were amplified from the infected cells and used for the next round of biopanning. After the third round of biopanning, 380 clones were randomly picked from the infected TG1 cells and each was placed in a 96-well plate by using an automated BioRobotics BioPick colony picking system (Genomic Solutions, Ann Arbor, MI). The cells were inoculated into 150 μl of 2YT medium containing 100 μg / ml carbenicillin and 0.2% glucose. After the bacterial culture reached an optical density at 600 nm (OD600) of 0.5, helper phage M13K07 at a multiplicity of infection (MOI) of 10 and kanamycin at 50 μg / ml (final concentration) were added to the medium and the plate was placed on a shaker. Further incubation was carried out overnight at 30° C. at 250 rpm. The phage supernatant was mixed with 3% nonfat milk solution in PBS at a 4:1 volume ratio and used for enzyme-linked immunosorbent assay (ELISA) to determine which phages displaying scFv or VH with high CD19 binding affinity. A clone was identified. The supernatant was incubated with 50 ng of coated recombinant human CD19 per well in a 96-well plate for 2 h at room temperature, washed 5 times with PBST (3% in PBS after overnight incubation at 4 °C) Blocked with skim milk solution and washed three times with PBS containing 0.05% Tween20.) Phages bound to CD19 were detected using a goat anti-M13 antibody conjugated with horseradish peroxidase. After incubation with antibody, non-specifically bound antibody was removed by washing the wells, 3,3',5,5'-tetramethylbenzidine (TMB) substrate was added, and the solution absorbance at 450 nm was measured. (A450) was measured. Clones that bound to CD19 with A450 greater than 1.0 were selected for further characterization.
[0277] b) Expression and purification of selected soluble scFv The VH and VL of the selected clones were DNA sequenced, and the scFv encoded by the clone with unique sequences was expressed and purified as described below. Plasmids extracted from these clones were used to transform HB2151 cells. A single colony was picked from a plate containing newly transformed cells and inoculated into 200 ml of 2YT medium containing 100 μg / ml ampicillin and 0.2% glucose and incubated at 37°C with shaking at 250 rpm. When the culture OD at 600 nm reached 0.90, isopropyl-β- d -thiogalactopyranoside was added at a final concentration of 0.5 mM and the culture was further incubated overnight at 30 °C. After centrifugation at 8,000 × g for 20 min, the bacterial pellet was collected and resuspended in PBS buffer containing 0.5 mU of polymixin B (Sigma-Aldrich, St. Louis, MO). After incubation for 30 min at room temperature with rotation at 50 rpm, the resuspended pellet was centrifuged at 25,000 x g for 25 min at 4 °C, and the supernatant was purified using Ni-NTA resin according to the supplier's protocol ( Qiagen) was used for ScFv purification.
[0278] c) ELISA binding assay ELISA Binding Assay 50 μl of recombinant human CD19 diluted to 2 μg / ml in PBS was coated onto a 96-well plate overnight at 4°C. Purified ScFv with His and Flag tags were serially diluted and added to target protein coated wells. After washing, anti-Flag antibody conjugated with HRP diluted 1:3000 was added for 1 h at RT. After washing, 3,3,5,5'-tetramethylbenzidine (TMB) substrate was added and incubated for 10 min at room temperature, followed by 1N H 2 S.O. 4 was added to stop the reaction and the O.D. was read at 450 nm to quantify the relative ability of the ScFv to bind to CD19.
[0279] d) Yeast display of scFv library The same ScFv starting material for phage display was also incorporated into the yeast ScFv display system. To complement the phage-based scFv analysis, a yeast library expressing the human scFv library was also screened. To enrich for yeast expressing scFvs that bind both recombinant CD19-Fc and CD19 expressed on the cell surface of CHOK1 cells, we performed cell panning on CHOK1 cells transfected with CD19. For the first round of panning on the cell surface, CHOK1-CD19 cells were seeded in 6-well plates and grown in F12K medium to 50% confluency 2 days before panning. Then 5×10 7 Yeast cells were washed twice with PBSA buffer, resuspended in 3 mL of F12K medium, and then gently added dropwise to CHOK1-CD19 cells. CHOK1-CD19 cells were incubated on ice with gentle rocking for 2 hours, then washed three times with ice-cold PBSA to remove yeast cells that did not bind to CHOK1-CD19, and then treated with 0.05% trypsin. -EDTA (Gibco) was used to dissociate CHOK1-CD19 cells and bound yeast cells from the plates. The cell mix containing yeast cells and CHOK1 cells was then inoculated into 10 mL of SDCAA medium, amplified overnight at 30°C, and then induced for 16 hours at 30°C in SGCAA medium. For the second round of cell panning, a similar protocol as above was performed, but with more stringent washing conditions. This panning method yielded m19217 binder. Further characterization of this binder, as well as other binders from phage display, indicated that the biological characteristics of the CAR generated from this hit were still suboptimal, indicating the need for affinity maturation.
[0280] To increase the affinity of m19217, a yeast display m19217 mutant scFv library was created by using error-prone PCR to generate random point mutations in the scFv gene sequence. After electroporation, the resulting mutant library was then grown overnight at 30°C in SDCAA medium for 16 hours, then switched to SGCAA medium for another 16 hours at 30°C. The mutant library was then screened by MACS (immunomagentic column, Miltenyi Biotec) using CD19-Fc as the capture antigen to reduce the size of the library and bind to CD19-Fc. We have increased the number of mutants that can do this. The most potent binder was then determined by double staining the pool with anti-c-Myc-Alexa488 and CD19-Fc / anti-Hu-Fc and selecting the binder that showed the highest binding affinity and c-Myc expression level. was selected. This process was then repeated two more times until the average binding affinity of the mutant pool was greater than that of the starting construct by flow cytometry of yeast particles using fluorescently tagged antigen. Binding affinity was estimated by flow cytometry of yeast pools using decreasing amounts of labeled CD19. As a result of this process, the EC50 (effective concentration that binds 50% of labeled CD19 on yeast presenting ScFv) of 0.5 μg / ml for M19217 is lower than that of affinity matured binders (M19217-1, 19217-2). , M19217-7, M19217-23, M19217-29, M19217-38, M19217-40).
[0281] result: Due to the unique antigen loading of the CD19 structure, phage display candidates have not yielded biologically functional CAR constructs, and therefore ScFv identification yielding bioactive binders was achieved by yeast display. . Based on flow cytometry analysis of ScFv by yeast display, eight ScFv clones specific for recombinant human CD19 were identified, each containing human anti-CD19 ScFv binder M19217 (LTG2050, primary clone, EC50 of 0.5 μg / ml). , and the following affinity matured binders (EC50 less than 0.01 μg / ml): M19217-1(LTG2065), M19217-2(LTG2066), M19217-7(LTG2067), M19217-23(LTG2068) , M19217-29 (LTG2069), M19217-38 (LTG2070), and M19217-40 (LTG2071). The generation of tandem CARs incorporating anti-CD19 scFv M19217-1 sequences is outlined in Example 2 below.
[0282] Example 1B Isolation of CD22-specific antibodies from ScFv libraries by fully human phage and yeast display material and method: a) Production of human ScFv and CD22-specific antibodies A naive human ScFv (variable recombinant single chain fragment of immunoglobulin) phage display library constructed from peripheral blood B cells of 50 healthy donors (approximate diversity, 10 10unique specificity of the species) (Z.Y. Zhu and D.S. Dimitrov, unpublished data) was used for selection of ScFvs for recombinant human CD19 protein (Miltenyi Biotec, unpublished). Phage-displayed ScFv10 12 The amplified library of species was incubated with coated CD22, 5, 3, and 1 μg in a volume of 5 × 100 μl, wells of a 96-well plate during the first, second, and third rounds of biopanning, respectively. It was divided into 5 equal portions and left at room temperature for 2 hours. After each round of incubation, wash the wells with phosphate-buffered saline (PBST) containing 0.05% Tween20 5 times in the first round and 10 times in subsequent rounds to remove non-specifically bound phage. Then, the bound phages were mixed with TG1 competent cells at 37°C for 1 hour, and the phages were amplified from the infected cells and used for the next round of biopanning. After the third round of biopanning, 380 clones were randomly picked from the infected TG1 cells and each was placed in a 96-well plate by using an automated BioRobotics BioPick colony picking system (Genomic Solutions, Ann Arbor, MI). The cells were inoculated into 150 μl of 2YT medium containing 100 μg / ml carbenicillin and 0.2% glucose. After the bacterial culture reached an optical density at 600 nm (OD600) of 0.5, helper phage M13K07 at a multiplicity of infection (MOI) of 10 and kanamycin at 50 μg / ml (final concentration) were added to the medium and the plate was placed on a shaker. Further incubation was carried out overnight at 30° C. at 250 rpm. The phage supernatant was mixed with 3% nonfat milk solution in PBS at a volume ratio of 4:1 and used for enzyme-linked immunosorbent assay (ELISA) to identify phage clones displaying scFv with high CD22 binding affinity. Identified. The supernatant was incubated with 50 ng of coated recombinant human CD22 per well in a 96-well plate for 2 h at room temperature, washed 5 times with PBST (3% in PBS after overnight incubation at 4 °C) Blocked with skim milk solution and washed 3 times with PBS containing 0.05% Tween20). Phage bound to CD22 was detected using a goat anti-M13 antibody conjugated to horseradish peroxidase. After incubation with antibody, non-specifically bound antibody was removed by washing the wells, 3,3',5,5'-tetramethylbenzidine (TMB) substrate was added, and the solution absorbance at 450 nm was measured. (A450) was measured. Clones that bound CD22 with A450 greater than 1.0 were selected for further characterization.
[0283] b) Expression and purification of selected soluble ScFv The VH and VL of selected clones were DNA sequenced, and ScFvs encoded by clones with unique sequences were expressed and purified as described below. Plasmids extracted from these clones were used to transform HB2151 cells. A single colony was picked from a plate containing freshly transformed cells and inoculated into 200 ml of 2YT medium containing 100 μg / ml ampicillin and 0.2% glucose and incubated at 37°C with shaking at 250 rpm. When the culture OD at 600 nm reached 0.90, isopropyl-β- d -thiogalactopyranoside was added at a final concentration of 0.5 mM and the culture was further incubated overnight at 30 °C. After centrifugation at 8,000 × g for 20 min, the bacterial pellet was collected and resuspended in PBS buffer containing 0.5 mU polymyxin B (Sigma-Aldrich, St. Louis, MO). After incubation for 30 min at room temperature with rotation at 50 rpm, the resuspended pellet was centrifuged at 25,000 x g for 25 min at 4 °C, and the supernatant was purified using Ni-NTA resin according to the supplier's protocol ( Qiagen) was used for scFv purification.
[0284] c) ELISA binding assay For ELISA analysis, 50 μl of recombinant human CD22 diluted to 2 μg / ml in PBS was coated onto a 96-well plate overnight at 4°C. Purified scFv with His and Flag tags were serially diluted and added to target protein coated wells. After washing, anti-Flag antibody conjugated with HRP diluted 1:3000 was added for 1 hour at room temperature. After washing, 3,3,5,5'-tetramethylbenzidine (TMB) substrate was added and incubated for 10 min at room temperature, followed by 1N H 2 S.O. 4 was added to stop the reaction and the O.D. was read at 450 nm to quantify the relative ability of the scFv to bind CD22.
[0285] d) Yeast display of scFv library The same ScFv starting material for phage display was also incorporated into the yeast ScFv display system. To complement the phage-based scFv analysis, a yeast library expressing a human scFv library was also screened. To enrich for yeast expressing scFvs that bind both recombinant CD22-Fc and CD19 expressed on the cell surface of CHOK1 cells, we performed cell panning on CHOK1 cells transfected with CD22. For the first round of panning on the cell surface, CHOK1-CD22 cells were seeded in 6-well plates and grown in F12K medium to 50% confluence 2 days before panning. Then 5×10 7 Yeast cells were washed twice with PBSA buffer, resuspended in 3 mL of F12K medium, and then gently added dropwise to CHOK1-CD22 cells. CHOK1-CD22 cells were incubated on ice for 2 hours with gentle rocking, then washed three times with ice-cold PBSA to remove yeast cells that did not bind to CHOK1-CD22, and then treated with 0.05% trypsin. -EDTA (Gibco) was used to dissociate CHOK1-CD22 cells and bound yeast cells from the plates. The cell mix containing yeast cells and CHOK1 cells was then inoculated into 10 mL of SDCAA medium, amplified overnight at 30°C, and then induced for 16 hours at 30°C in SGCAA medium. For the second round of cell panning, a similar protocol as above was performed, but with more stringent washing conditions. This panning method yielded 16P, 24P, 25P, 11S, and 12S binders. In a series of in vitro CART functional assays, binder sequences were incorporated into CART constructs as described in Example 2 below. Characterization of these binders from phage display in CART format revealed that only the 16P binder showed specific oncolytic activity in vitro, but the activity was lower compared to the CAR positive control. Ta. Furthermore, when 16P-based CART cells were tested in an in vivo xenograft model, their antitumor function was very weak (Example 2, below). Taken together, these results indicated that the affinity of the anti-CD22 ScFv binder needed to be matured, as the biological characteristics of the CARs created from this binder set were still suboptimal.
[0286] To increase the affinity of 16P, a yeast display mutant scFv library was created to generate random point mutations in the scFv gene sequence by using error-prone PCR. After electroporation, the resulting mutant library was then grown overnight at 30°C in SDCAA medium for 16 hours, then switched to SGCAA medium and placed at 30°C for another 16 hours. The mutant library was then screened by MACS (immunomagnetic columns, Miltenyi Biotec) using CD22-Fc as the capture antigen to reduce the size of the library and to identify mutants capable of binding to CD22-Fc. Increased the population of mutants. The most potent binder was then determined by double staining the pool with anti-c-Myc-Alexa488 and CD19-Fc / anti-Hu-Fc and selecting the binder that showed the highest binding affinity and c-Myc expression level. was selected. This process was then repeated two more times until the average binding affinity of the mutant pool was greater than that of the starting construct by flow cytometry of yeast particles using fluorescently tagged antigen. Binding affinity was estimated by flow cytometry of yeast pools using decreasing amounts of labeled CD22. As a result of this process, the EC50 (effective concentration to bind 50% of labeled CD19 on yeast presenting ScFv) of 0.5 μg / ml for 16P is lower than that of affinity matured binders (16P1, 16P2, 16P3, 16P3v2). , 16P6, 16P8, 16P10, 16P13, 16P15, 16P16, 16P17, 16P20, 16P20v2) to less than 0.01 μg / ml.
[0287] result: Due to the unique antigen loading of the CD22 structure, phage display candidates did not yield fully functional CAR structures with high biological activity and specificity. Therefore, ScFv for bioactive and highly specific binders were obtained by yeast display. Based on flow cytometry analysis of ScFv by yeast display, 13 ScFv clones specific for recombinant human CD22 were identified, each with human anti-CD22 ScFv binder 16P (LTG2202, primary clone, EC50 of 0.5 μg / ml) , and the following affinity matured binders (EC50 less than 0.01 μg / ml), named 16P1, 16P2, 16P3, 16P3v2, 16P6, 16P8, 16P10, 16P13, 16P15, 16P17, 16P20, and 16P20v2. . Generation of tandem CARs incorporating anti-CD22 scFv 16P17 sequences is outlined in Example 2 below.
[0288] Example 2 Fully human anti-CD22 and anti-CD19 scFv binding sequences expressing dual targeting tandem CARs This example discusses the creation of a dual-targeted CAR that simultaneously targets the tumor antigens CD19 and CD22. The need for this approach is to help alleviate tumor antigen escape, which is responsible for a significant proportion of CAR therapy failures using a single CAR approach, i.e., anti-CD19CAR or anti-CD22CAR therapy. (Sotillo, Elena et al., “Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy”, Cancer discovery (2015); Gardner, Rebecca et al., “Acquisition of a CD19 negative myeloid phenotype allows immune escape of MLL -rearranged B-ALL from CD19 CAR-T cell therapy", Blood (2016): blood-2015; Fry, Terry J. et al., "CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to "CD19-targeted CAR immunotherapy", Nature medicine Volume 24.1 (2018): Issue 20).
[0289] Utilization of murine scFv sequences as CAR components has been shown to cause immune rejection or allergic anaphylactic reactions in patients, thus limiting the continuation and utilization of CAR T therapy and increasing the risk of toxicity. . Therefore, the utilization of fully human scFv binder sequences in CAR design should be a high priority for future CAR development.
[0290] CD19 is an 85-95kDa transmembrane cell surface glycoprotein receptor. CD19 is a member of the immunoglobulin (Ig) superfamily of proteins and contains two extracellular Ig-like domains, a transmembrane, and an intracellular signaling domain (Tedder TF, Isaacs, CM, 1989, J Immunol 143:712-171). CD19 alters B cell receptor signaling, lowering the triggering threshold of B cell receptors to antigen (Carter, RH and Fearon, DT, 1992, Science, 256:105-107), and CD81 and coordinates with CD21 to regulate this essential B cell signaling complex (Bradbury, LE, Kansas GS, Levy S, Evans RL, Tedder TF, 1992, J Immunol, 149:2841-50) . During B-cell ontogeny, CD19 can signal independently of antigen receptors and associates with protein tyrosine kinases of the Src family at the pro-B, pre-pre-B, pre-B, and early B-cell stages. undergoes tyrosine phosphorylation and induces both intracellular calcium mobilization and inositol phospholipid signaling (Uckun FM, Burkhardt AL, Jarvis L, Jun X, Stealy B, Dibirdik I, Myers DE, Tuel-Ahlgren L, Bolen JB, 1983, J Biol Chem 268:21172-84). An important point relevant to the treatment of B-cell malignancies is that CD19 is present on normal B cells in a tightly regulated manner restricted to early progenitor B cells undergoing IgH gene rearrangement, and to mature B cells. (Anderson, KC, Bates, MP, Slaughenhout BL, Pinkus GS, Schlossman SF, Nadler LM, 1984, Blood 63:1424~ 1433 pages).
[0291] Homo sapiens CD22 (SIGLEC-2, Leu14) is a well-studied cell surface glycoprotein expressed in B-cell leukemias and lymphomas. At least two anti-CD22 antibody drugs (inotuzumab ozogamicin) or immunotoxin conjugates (moxetumomab passudotox) are the subject of clinical trials (NCT02981628, NCT00659425). These approaches have had some success and are still being investigated, for example in combination with other chemotherapeutic agents (Muller F, Stookey S, Cunningham T, Pastan I, 2017, Paclitaxel synergizes with exposure tume adjusted CD22-targeted immunotoxins against B-cell malignancies, Oncotarget vol. 8: p. 30644-30655). However, given current advances in T-cell therapy with CD19 CARs, cell-based immunotherapy is the best approach to target CD22-expressing malignancies. A therapy featuring an m971-based anti-CD22 CAR is currently in clinical trials at the National Cancer Institute (NCT02315612, P.I.: Terry Fry, M.D.). The tandem CD22 CD19-targeted CAR construct provided here creates and implements novel fully human CD19 and CD22 binding moieties in one construct to achieve complete and durable remission and prevent tumor antigen escape. This is an innovative new method.
[0292] In this example, a single CAR control is used as a comparison to a tandem CAR targeting CD19 and CD22. The CAR construct LTG1538, which utilizes scFv from mouse hybridoma FMC63, serves as an activity control. This mouse-derived sequence is the current binder used in commercial development (see KTE-C19, Kite Pharma, and CTL019, Novartis). The m971 CAR, LTG2200, is equivalent to the CAR being evaluated at NCI and will be used as an anti-CD22 CAR control.
[0293] material and method: (a) Cell line Burkitt's lymphoma cell line, Raji, and chronic myeloid leukemia line, K562, were purchased from American Tissue Culture Collection (ATCC, Manassass, VA). The REH leukemia strain was purchased from DSMZ (Leibniz Institute DSMZ, Braunschwieg, Germany). Cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS, Hyclone, Logan, UT) and 2mM L-Glutamax (Thermo Fisher Scientific, Grand Island, NY). Human fetal kidney line 293T was purchased from ATCC (Gibco / Thermo Fisher Scientific, Grand Island, NY). Luciferase-expressing cell lines were generated by stably transducing wild-type tumor lines with lentiviral vectors encoding firefly luciferase (Lentigen Technology, Inc., Gaithersburg, MD), followed by cloning and selection of luciferase-positive clones. Single cell clones were generated. Raji clones were generated by passage of luciferase-transduced Raji cells in mice and selected for their proliferative ability. Whole blood was collected from healthy volunteers at the Oklahoma Blood Institute (OBI) with written donor consent. The treated buffy coat was purchased from OBI (Oklahoma City, OK). CD4- and CD8-positive human T cells were purified from buffy coats by positive selection using a 1:1 mixture of CD4 and CD8 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's protocol.
[0294] (b) Creation of chimeric antigen receptor (CAR)-expression vector The CAR antigen binding domain, ScFv, sequence was derived from human anti-CD22 ScFv or heavy chain variable fragment. The binder sequence was inserted in frame with the CD8a linking and transmembrane domain (aa123-191, Ref Sequence ID NP_001759.3), followed by the 4-1BB (CD137, aa214-255, UniProt Sequence ID Q07011) signaling domain and the CD3 zeta signal. The CAR T construct was generated by ligating to the transduction domain (CD247, aa52-163, Ref Sequence ID: NP_000725.1). CAR construct sequences were cloned into a third generation lentiviral plasmid backbone (Lentigen Technology Inc., Gaithersburg, MD). A supernatant containing the lentiviral vector (LV) was generated by transient transfection of HEK 293T cells, and the vector was pelleted by centrifugation of the supernatant containing the lentiviral vector and stored at -80°C.
[0295] (c) Primary T cell purification and transduction CD4 according to the manufacturer's protocol (Miltenyi Biotec, Bergisch Gladbach, Germany) + and CD8 +Human primary T cells from healthy volunteers were purified from whole blood or buffy coats (purchased from a commercial provider with written donor consent) using immunomagnetic bead selection of cells. T cells were cultured in TexMACS medium supplemented with 200 IU / ml IL-2 at 0.3–2 × 10 6 cells / ml and activated with CD3 / CD28 MACS® GMP T Cell TransAct reagent (Miltenyi Biotec), and on the second day 10ug / ml of protamine sulfate (Sigma-Aldrich, St. Louis, The lentiviral vector encoding the CAR construct was transduced overnight in the presence of MO), and the medium was changed on day 3. Cultures were propagated in TexMACS medium supplemented with 200 IU / ml IL-2 from days 8 to 13 until harvest.
[0296] (d) Immune effector assay (CTL and cytokines) To determine cell-mediated cytotoxicity (CTL assay), 5,000 target cells stably transduced with firefly luciferase were combined with CAR T cells at various effector-to-target ratios and incubated overnight. SteadyGlo reagent (Promega, Madison WI) was added to each well and the resulting luminescence was quantified as counts per second (sample CPS). Target-only wells (maximum CPS) and target-only wells with 1% Tween-20 (minimal CPS) were used to determine the assay range. The specific percent lysis was calculated as (1-(sample CPS-minimum CPS) / (maximum CPS-minimum CPS)). Supernatants from the 10:1 E:T ratio co-cultures were removed and analyzed for IFNγ, TNFα, and IL-2 concentrations by ELISA (eBioscience, San Diego, CA).
[0297] (e) Flow cytometry analysis For cell staining, 500,000 CAR T-transduced cells were harvested from culture and washed twice in cold AutoMACS buffer supplemented with 0.5% bovine serum albumin (Miltenyi Biotec), followed by CD22-Fc peptide. CAR surface expression was detected by staining with anti-Fc-PE conjugate (Jackson ImmunoResearch, West Grove, PA). Anti-CD4 antibody conjugated to the VioBlue fluorophore (Miltenyi Biotec) was used where indicated, per the supplier's protocol. Non-transduced cells were used as a negative control. In all studies, dead cells were excluded by 7AAD staining (BD Biosciences, San Jose, CA). Cells were washed twice and resuspended in 200ul of staining buffer before quantitative analysis by flow cytometry. Flow cytometry analysis was performed on a MACSQuant® 10 Analyzer (Miltenyi Biotec) and data plots were generated using FlowJo software (Ashland, OR).
[0298] result To overcome tumor antigen escape, we developed a tandem CAR construct for dual targeting of CD22 and CD19 tumor antigens. An overview (shema) of the tandem CAR design is shown in Figures 1A and 1B. Fully human scFv binders targeting CD19 and CD22 were connected in tandem by flexible linkers in either the 22-19 or 19-22 orientation shown as membrane distal to proximal. The resulting CAR-binding segment is then linked in-frame to the CD8 hinge and transmembrane domain, 4-1BB costimulatory domain, and CD3 zeta activation domain to generate CAR22-19 (LTG2681, Figure 1A) or CAR19. -22 (LTG2719, Figure 1B) was produced. The CAR sequence was incorporated into a third generation lentiviral vector and applied to transduce primary human T cells.
[0299] In this example, a single CAR control is used as a comparison to a tandem CAR targeting CD19 and CD22. The CAR construct LTG1538, which utilizes scFv from mouse hybridoma FMC63, serves as an activity control. This mouse-derived sequence is the current binder used in commercial development (see KTE-C19, Kite Pharma, and CTL019, Novartis). The m971 CAR, LTG2200, is equivalent to the CAR being evaluated at NCI and will be used as an anti-CD22 CAR control.
[0300] Surface expression of anti-CD19 / CD22 CARs incorporating single chain fragment variable (ScFv) sequences reactive with CD19 / CD22 antigens is shown in Figure 2. Expression levels for each ScFv-containing CAR were determined by flow cytometric analysis of LV-transduced T cells from healthy donors using two detection methods: i) CD22-his followed by anti-his-PE, ii) ) CD19 Fc recombinant protein followed by anti-Fc-A647. ScFv-based anti-CD19 / CD22 CAR constructs CAR22-19 LTG2681 and CAR19-22 LTG2719 were highly expressed in human primary T cells compared to non-transduced T cell controls.
[0301] As shown in Figure 3, high cytolytic activity of CD19 / CD22CAR was demonstrated. Human primary T cells were transduced with LVs encoding CAR constructs (CAR22-19(LTG2681, D0023), CAR19-22(LTG2791, D0024), CAR19(LTG1538), or CAR22(LTG2200); see Methods. ) and then incubated for 18 hours with Raji, REH, or 293T cell lines stably transduced with firefly luciferase for fluorescence-based in vitro killing assays. Raji and Reh leukemia lines express CD19 and CD22 on their surface, whereas the negative control, 293T, does not. Raji and REH cells were effectively lysed by tandem CAR22-19 (LTG2681), tandem CAR19-22 (LTG27190), and single targeting controls CAR19 (LTG1538) and CAR22 (LTG2200) (Figure 3). Thus, tandem CAR22-19 and CAR19-22 both function in tumor lines that co-express CD19 and CD22 antigens, exhibit no spontaneous killing activity against the CD19-CD22- cell line 293T, and demonstrate that these constructs Target specificity was emphasized.
[0302] We then demonstrated the functionality and specificity of each scFv in tandem CARs by using tumor lines A431 or 293T engineered to express only a single target antigen (CD19 or CD22, or the unrelated antigen CD20). was separated and tested. A 293T-luc strain expressing CD19 (293T luc CD19+) or CD22 (293T luc-20+) was created, and CD20+ (293T luc CD20) was used as an irrelevant target control (Figure 4A). 293T-19+ was lysed by CAR19 (LTG1538) and tandem CAR22-19 (LTG2681), but not by CAR22 LTG2200 or untransduced T cell controls (Figure 3). 293T-CD22+ was lysed by tandem CAR22-19 (LTG2681) and single CAR20 LTG2200, but not by single CAR19 (LTG1538) or non-transduced control, demonstrating the antigen specificity of tandem CAR . Finally, 293T luc CD20 cells were not lysed by the CAR construct as this antigen was not targeted (Figure 4A). Similarly, A431 clones expressing only the CD19 antigen (A431 luc CD19) or only the CD22 antigen (A431 luc-CD22), or expressing a CD20 antigen that is not intended to be recognized by the tandem CAR19-22 and 22-19. Tandem CAR T cells were also tested in an overnight killing assay against A431 luc -CD20, an unrelated target control strain (Figure 4B). Again, the A431 luc CD19 strain was lysed only by CAR19(LTG1538) and tandem CAR22-19(LTG2681), but not by CAR22 LTG2200 or the untransduced T cell control, whereas the A431 luc CD22 strain , tandem CAR22-19 (LTG2681) and single CAR20 were lysed by LTG2200, but not by single CAR19 (LTG1538) or non-transduced controls, demonstrating the antigenic specificity of tandem CAR. Additionally, A431 luc CD20 cells were not lysed by the CAR construct as this antigen was not targeted (Figure 4B). These results demonstrate the independent functionality and specificity of each targeting domain of tandem CAR22-19 (Figures 4A-4B) and the potential of tandem CARs targeting CD19 and CD22 antigens to alleviate tumor antigen escape. It emphasizes.
[0303] The cytokine secretion ability of anti-CD19 / CD22 CAR T cells was then evaluated (Figure 5). CD19+CD22+Raji tumor cells were combined with tandem 22-19 CAR T cells (LTG2681), positive control CAR19 (LTG1538), positive control CAR22 (LTG2200), or negative control untransduced T cells (UTD) at 10:1. Effector-to-target ratios were co-incubated overnight and culture supernatants were analyzed for IFN gamma, TNF alpha, and IL-2 by ELISA. Tandem CAR22-19 (LTG2681) strongly induced cytokines in response to tumor cells, whereas the negative control (untransduced, UTD) did not result in appreciable cytokine induction. Notably, tandem CAR T-expressing cells, LTG2681, showed similar levels of IFN gamma, TNF alpha, IL-2 as the CAR22 control (LTG2200), and slightly higher cytokine responses than the single CAR19 (LTG1538) control; The high efficacy of the drug was demonstrated. Importantly, CAR22-19 did not result in cytokine secretion in the absence of tumor cells (CART alone group), further confirming CAR specificity and no sustained signaling by tandem CAR. It has been suggested.
[0304] Example 3 Dual-targeted CAR22-19 constructs incorporating various costimulatory domains exhibit robust antitumor function This example discusses tandem CD22 and CD19 dual targeting CAR constructs that incorporate various co-stimulatory domains. Co-stimulatory domains utilized in the CAR22-19 design in this example include ICOS, OX40, CD27, CD137 / 4-1BB, and CD28. These costimulatory domain sequences are found on the T cell surface known to be involved in the positive regulation of T cell functions, including T cell activation, proliferation, persistence, phenotypic differentiation, memory formation, and antitumor responses. Molecularly derived (Zhao Z, Condomines M, van der Stegen SJ et al., Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer cell 28:415-428, 2015; Guedan S, Posey AD , Jr., Shaw C et al., Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.JCI Insight Volume 3, 2018; Song D-G, Ye Q, Poussin M et al., CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119:696-706, 2012; Hombach AA, Heiders J, Foppe M, et al. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells.Oncoimmunology1 Volume: 458-466, 2012; Yoshinaga SK, Whoriskey JS, Khare SD et al., T-cell co-stimulation through B7RP-1 and ICOS. Nature 402: 827-832, 1999). In some cases, the CAR linker / hinge region was also derived from the costimulatory domain utilized.
[0305] Simultaneous dual targeting of CD19 and CD22 antigens precludes therapeutic benefit in subpopulations of patients who have received single CAR therapy targeting either CD19 or CD22, tumor Designed to alleviate antigen escape (Sotillo, Elena et al., “Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy,” Cancer discovery (2015); Gardner, Rebecca et al., “Acquisition of a CD19 negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T cell therapy,” Blood (2016): blood-2015; Fry, Terry J. et al., “CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy”, Nature medicine Volume 24.1 (2018): Issue 20).
[0306] In CAR design, it is preferable to avoid sequences of non-human origin that may provoke an anti-"foreign" immune response in the host, as this is believed to contribute to improved persistence of CAR T cells. All CAR components utilized in this example were of human origin. Example 3 A CAR binder arrangement based on an anti-CD22-19 CAR (LTG2737) consisting of a T cell membrane distal human scFv targeting CD22 linked in frame to a T cell membrane proximal human scFv targeting CD19 was used for all CAR constructs.
[0307] material and method: (a) Cell line The Burkitt lymphoma cell line, Raji, was purchased from American Tissue Culture Collection (ATCC, Manassass, VA). Cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS, Hyclone, Logan, UT) and 2 mM L-Glutamax (Thermo Fisher Scientific, Grand Island, NY). Human fetal kidney line 293T was purchased from ATCC (Gibco / Thermo Fisher Scientific, Grand Island, NY). Luciferase-expressing cell lines were generated by stably transducing a wild-type tumor line with a lentiviral vector encoding firefly luciferase (Lentigen Technology, Inc., Gaithersburg, MD), followed by cloning and selecting luciferase-positive clones. Single cell clones were generated. 293T cell line clones expressing CD19 and CD22, referred to as 293TCD19 and 293TCD22, respectively, were created by lentivirally transducing the parental 293T-luciferase-expressing clone with human CD19 protein and human CD22 protein, and then, if necessary, producing a single Generated by cell cloning, selection and expansion of CD19 or CD22 positive target cell clones. Stable luciferase-expressing Raji clones were generated by passage of luciferase-transduced Raji cells in mice and selected for their proliferative ability. Whole blood was collected from healthy volunteers at the Oklahoma Blood Institute (OBI) with written donor consent. The treated buffy coat was purchased from OBI (Oklahoma City, OK). CD4- and CD8-positive human T cells were purified from buffy coats by positive selection using a 1:1 mixture of CD4 and CD8 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's protocol.
[0308] (b) Creation of chimeric antigen receptor (CAR)-expression vector Tandem CAR antigen-binding domains were obtained from human anti-CD22 ScFv and human anti-CD19 scFv sequences and linked in tandem in the following arrangement: anti-CD22 scFv-anti-CD19 scFv-hinge-transmembrane domain-internal domain. Some CAR T constructs combine the CAR antigen-binding domain with the CD8a hinge and transmembrane domain (aa123-191, Ref Sequence ID NP_001759.3) followed by 4-1BB (CD137, aa214-255, UniProt Sequence ID Q07011). ) signaling domain and CD3 zeta signaling domain (CD247, aa52-163, Ref Sequence ID: NP_000725.1) in frame. In other constructs, the 4-1BB costimulatory domain was replaced with the human ICOS, CD27, CD28, OX-40 costimulatory domain using the complete signaling domain sequence of each molecule. In some embodiments, the CD8 transmembrane domain is replaced by a transmembrane sequence from the same protein as the costimulatory domain. In some embodiments, the internal domain of the CAR contained two costimulatory domains connected in tandem. In some embodiments, a costimulatory domain is not used and the CD3ζ activation domain is linked directly in frame to the transmembrane domain. In some embodiments, the two CAR chains are encoded within the same bicistronic expression cassette and separated by a 2A ribosome skipping element, and thus a lentiviral construct encoding a bicistronic CAR is transduced. This enabled simultaneous expression of two CAR chains in each T cell. CAR construct sequences were cloned into a third generation lentiviral plasmid backbone (Lentigen Technology Inc., Gaithersburg, MD) under the control of the human EF-1α promoter. A supernatant containing the lentiviral vector (LV) was generated by transient transfection of HEK293T cells, and the vector was pelleted by centrifugation of the supernatant containing the lentiviral vector and stored at -80°C.
[0309] (c) Primary T cell purification and transduction CD4 according to the manufacturer's protocol (Miltenyi Biotec, Bergisch Gladbach, Germany) + and CD8 + Human primary T cells from healthy volunteers were purified from whole blood or buffy coats (purchased from a commercial provider with written donor consent) using immunomagnetic bead selection of cells. T cells were cultured in TexMACS medium supplemented with 200 IU / ml IL-2 at 0.3–2 × 10 6 cells / ml and activated with CD3 / CD28 MACS® GMP T Cell TransAct reagent (Miltenyi Biotec), and on the second day 10ug / ml of protamine sulfate (Sigma-Aldrich, St. Louis, The lentiviral vector encoding the CAR construct was transduced overnight in the presence of MO), and the medium was changed on day 3. Cultures were propagated in TexMACS medium supplemented with 200 IU / ml IL-2 from day 8 until harvest on day 13.
[0310] (d) Immune effector assay (CTL and cytokines) To determine cell-mediated cytotoxicity (CTL assay), 5,000 target cells stably transduced with firefly luciferase were combined with CAR T cells at various effector-to-target ratios and incubated overnight. SteadyGlo reagent (Promega, Madison WI) was added to each well and the resulting luminescence was quantified as counts per second (sample CPS). Target-only wells (maximum CPS) and target-only wells with 1% Tween-20 (minimal CPS) were used to determine the assay range. Percent specific lysis was calculated as (1-(Sample CPS-Min CPS) / (Max CPS-Min CPS)). Supernatants from the 10:1 E:T ratio co-cultures were removed and analyzed for IFNγ, TNFα, and IL-2 concentrations by ELISA (eBioscience, San Diego, CA).
[0311] (e) Flow cytometry analysis For cell staining, 500,000 CAR T-transduced cells were harvested from culture and washed twice in cold AutoMACS buffer supplemented with 0.5% bovine serum albumin (Miltenyi Biotec), followed by CD22-His peptide. CAR surface expression was detected by staining with anti-His secondary detection reagent and simultaneously with CD19Fc peptide followed by anti-Fc conjugate (secondary detection reagent was purchased from Jackson ImmunoResearch, West Grove, PA). . Anti-CD4 antibody conjugated to the VioBlue fluorophore (Miltenyi Biotec) was used where indicated, per the supplier's protocol. Non-transduced cells were used as a negative control. In all studies, dead cells were excluded by 7AAD staining (BD Biosciences, San Jose, CA). Cells were washed twice and resuspended in 200 μl of staining buffer before quantitative analysis by flow cytometry. Flow cytometry analysis was performed on a MACSQuant® 10 Analyzer (Miltenyi Biotec) and data plots were generated using FlowJo software (Ashland, OR).
[0312] result: We designed a dual-targeting CAR construct composed of different costimulatory domains. CAR constructs are listed in Table 1. A schematic diagram of the CAR design layout is shown in Figures 6A-D. In some embodiments, tandem CAR antigen-binding domains composed of anti-CD22 scFv and anti-CD19 scFv sequences are linked in tandem in the following order: anti-CD22 scFv-anti-CD19-scFv-hinge-transmembrane domain-internal domain. (Figures 6A and 6B). This targeting tandem domain arrangement is in all cases based on CAR22-19 (LTG2681). Anti-CD22-19 CAR construct LTG2737 was identical to anti-CD22-19 CAR construct LTG2681, but contained a CAR sequence that did not use the woodchuck hepatitis virus (WHP) post-transcriptional regulatory element (WPRE) during its construction. .
[0313] Several CAR T constructs were created by linking the CAR antigen-binding domain in-frame to the CD8a hinge and transmembrane domain (constructs LTG2737, D0135, D0136, D0137, D0145, D0146, D0147, D0148, and D0149). Other constructs utilized transmembrane domain sequences matching costimulatory domains, namely CD28 for D139, D140 and OX40 for D0137, D0147, D0148. The transmembrane domain is 4-1BB (LTG2737), CD28 (D0135, D0139, D0140), ICOS (D136, D146, D148, D149), OX40 (D0137, D0145, D0147, D0148), or CD27 (D0138, D0149) was linked in frame to the derived co-stimulatory domain. All CAR molecules contained a CD3 zeta signaling domain (CD247, aa52-163, Ref Sequence ID: NP_000725.1). In one embodiment, the internal domain of the CAR was composed of two costimulatory domains connected in tandem: CD28 and 4-1BB (D0140, Figure 6B). In some embodiments, two separate CAR molecules were coexpressed in the same T cell using the 2A ribosome skipping element for bicistronic expression (D146, D147, D148, D149, Figures 6C, 6D ). In this arrangement, each CAR chain contains only one scFv targeting either the CD19 or CD22 antigen, and each transduction by transduction with a single lentiviral vector encoding a bicistronic sequence Both chains were co-expressed in T cells. In some embodiments, no co-stimulatory domain is used for at least one CAR chain, such that the CD3ζ The activation domains were joined in frame (D0146, D0147, Figure 6C). CAR construct sequences were cloned into a third generation lentiviral plasmid backbone (Lentigen Technology Inc., Gaithersburg, MD) under the control of the human EF-1α promoter.
[0314]
table 1
[0315] Surface expression of anti-CD22-19 CARs incorporating various costimulatory domains is shown in Figure 7. Expression levels for each ScFv-containing CAR were determined by flow cytometric analysis of LV-transduced T cells from healthy donors by co-staining for two scFv CAR targeting domains, i) CD22-his followed by anti- his-PE, ii) determined using CD19 Fc recombinant protein followed by anti-Fc-A647. All anti-CD22-19 CARs were highly expressed in human primary T cells compared to non-transduced T cell controls. CAR expression levels ranged from 71% to 90% (Figure 7).
[0316] As shown in Figures 9A-D, high cytolytic activity of anti-CD22-19CAR was demonstrated. Human primary T cells were transduced with LVs encoding the CAR constructs LTG2737, D0135, D0136, D0137, D0138, D0139, D0140, D0145, D0146) and then transduced with firefly luciferase for fluorescence-based in vitro killing assays. Incubated with stably transduced Raji, 293T, 293TCD19, or 293TCD22 cell lines for 18 hours. Effector-to-target (ET) ratios of 2.5:1, 5:1, or 10:1 were used as indicated in the legend to the right of each plot. Raji cells express CD19 and CD22 on their surface, but not the negative control, 293T. 293TCD19 and 293TCD22 target strains were generated to stably express either the CD19 or CD22 target antigen, respectively, and were used to determine whether each single target antigen, CD19 or CD22, was independent of the other antigen. We evaluated the ability of dual-targeted CAR constructs with different co-stimulatory domains to achieve targeted lysis when induced by.
[0317] Raji cells were effectively lysed by all dual-targeted CARs, but not by the negative control, non-transduced T cell UTD (Figure 9A). As a comparison, all dual-targeted CAR constructs lysed the single-antigen strains 293TCD19 and 293TCD22, and these CAR constructs showed that their anti-antigenicity increased when activated by either CD19 antigen alone or CD22 antigen alone. The ability to induce oncolytic function was demonstrated (Figures 9B and 9D, respectively). On the other hand, neither dual-targeted anti-CD22-19 CAR lysed the antigen-negative cell line 293T (Figure 9C). Therefore, all anti-CD22-19 CARs function in tumor lines co-expressing CD19 and CD22 antigens, and in 293T CD19 and 293T CD22 lines expressing either CD19 or CD22 single antigens, and in D19-CD22- cells. No spontaneous killing activity was shown against strain 293T, highlighting the target specificity of these constructs.
[0318] The cytokine secretion ability of anti-CD22-19 CARs with various costimulatory domains was then evaluated (Figure 8). CD19+CD22+Raji tumor cells were transfected with tandem anti-CD22-19CAR T cells expressing LTG2737, D0135, D0136, D0137, D0138, D0139, D0140, D0145, D0146 constructs, or a negative control, untransduced T cells (UTD ) at a 10:1 effector-to-target ratio overnight and culture supernatants were analyzed for IFN gamma, TNF alpha, and IL-2 by ELISA (Figure 8). All dual-targeted CARs strongly induced IL-2 and TNFα in response to tumor cells, whereas the negative control (non-transduced, UTD) did not result in appreciable cytokine induction ( Figure 8). In particular, exquisite levels of IFN gamma were strongly induced in all CAR22-19s, but were particularly high for CAR constructs D0146, D0139, and D0136, indicating that the strength of the cytokine response of anti-CD22-19 CARs was It was suggested that it may be regulated by the composition of the costimulatory domain utilized. Overall, the induced IFN gamma, TNF alpha, and IL-2 secretion profiles demonstrated high potency of all CAR22-19 constructs. Importantly, anti-CD22-19 CAR produced little or no cytokine secretion in the absence of tumor cells (CAR T alone group), further confirming CAR specificity and Our results suggest that there is no sustained signal transduction by tandem anti-CD22-19 CARs with co-stimulatory domains.
[0319] Example 4 In-vivo testing of dual CD22-CD19 targeting tandem CAR and bicistronic CAR material and method: Cell line: Burkitt's lymphoma cell line Raji was cultured in Corning Glutgro RPMI-1640 (Corning, NY) and 10% heat-inactivated fetal bovine serum (FBS, Hyclone, Logan, UT). Raji cells were transduced with the firefly luciferase gene. The Raji clones used herein were generated by transplanting luciferase-expressing Raji cells into mice and selected for their proliferative ability.
[0320] Induction of Raji CD19 or CD22 knockout lines and different target density lines CD19 knockout (KO), CD22KO and CD19CD22 double KO lines were generated based on luciferase expressing Raji using CRISPR Cas9 gene editing technique. For the Raji19KO strain, a LentiCRISPR v2 plasmid carrying human single guide RNA (sgRNA, AAGCGGGGACTCCCGAGACC, Genscript, Piscataway, NJ) was electroporated into Raji cells using a Lonza 4D-Nuclefector X unit. For the Raji CD22KO strain, an Alt-R CRISPR-Cas9 crRNA RNP complex (guide RNA: CCCGAGTGCTGGACCTTCAC, PAM CGG, IDT, Coralville, Iowa) was generated and introduced into the Raji cell line by electroporation according to the manufacturer's instructions. did. Single cell cloning was achieved by limiting dilution (0.5 cells per 96 well) before CD19 or CD22 microbeads (Miltenyi, Bergisch Gladbach, Germany) depletion. All knockout cell lines were verified using surface protein staining by flow cytometry and DNA sequencing. A CD19CD22 double KO strain was generated based on the CD22KO strain following the same procedure as the CD19 knockout strategy described above.
[0321] To generate Raji cell lines with different CD19 or CD22 densities, CD19CD22 double KO Raji cell lines were stably transduced with lentiviral vectors encoding CD19 or CD22 fused to puromycin by the F2A peptide. Prior to limiting dilution (0.5 cells / well), each available clone was screened for target molecule expression by flow cytometry staining.
[0322] Immune effector assay (cytotoxicity) Cytotoxic overnight killing assays were performed as described by others (13) to assess the functionality of the different CAR constructs. Briefly, CAR T cells were co-cultured with 5,000 target cells harboring firefly luciferase activity for 16-18 hours at various effector-to-target ratios. SteadyGlo reagent (Promega, Madison WI) was added to each well and the resulting luminescence was quantified by a GloMax Luminometer and used to calculate the specific percentage of lysis.
[0323] Flow cytometry analysis Flow cytometry analysis was performed to detect cell surface molecule expression. Cells were washed and stained with cold AutoMACS buffer supplemented with 0.5% bovine serum albumin (Miltenyi Biotec) and resuspended in 200ul of running buffer, followed by a MACSQuant® 10 Analyzer (Miltenyi Biotec). Obtained with. For CAR surface expression, we used CD22-his peptide (Abcam, Cambridge, MA) and CD19Fc peptide (R&D System, Minneapolis, MN), followed by anti-His-PE or anti-Fc-AF647 (Jackson ImmunoResearch, West Grove, PA). )It was used. T cell subtypes were further identified using anti-CD4 antibodies conjugated to the VioBlue fluorophore. In all studies, dead cells were excluded by 7AAD staining (BD Biosciences, San Jose, CA) or Viobility 405 / 520 Fixable Dye. For CD19 or CD22 surface expression on cell lines, anti-human CD19 antibody LT19 conjugated to a PE fluorophore and anti-human CD22 antibody REA340 conjugated to APC or APC-Vio770 fluorophores were used. To quantify CD19 or CD22 surface molecule density, antibody binding capacity (ABC) assays were performed using the PE Fluorescence Quantitation Kit from BD Bioscience (San Jose, CA) and BD's anti-human CD19-PE ( SJ25C1) and anti-human CD22-PE (S-HCL-1). All antibodies and staining reagents listed were from Miltenyi Biotec unless otherwise stated. Flow data was analyzed with FlowJo software (Ashland, OR).
[0324] In vivo NSG xenograft model All animal studies were performed by the MI Bioresearch Animal Care and Use Committee (Ann Arbor, MI). NSG(NOD.Cg-Prkdc scid Il2rg tm1Wjl / SzJ) mouse, 5×10 5mice were injected with mouse-adapted WT Raji-luc cells, or a Raji mixture with equal proportions of Raji, Raji19KO and Raji 22KO for the heterogeneous model. Tumor burden was measured using bioluminescence imaging with a Xenogen IVIS-200 instrument (Perkin Elmer, Shelton, Connecticut). Mice with comparable tumor burdens were randomly distributed into each group for CAR T administration on day 7. Kinetics of tumor development was determined by live animal imaging at the indicated time points. Tissue samples including blood, bone marrow and spleen were collected on request.
[0325] Viral copy number analysis in animal tissues Mouse blood, bone marrow and spleen were collected at the end of the animal study. Tissue samples were extracted using the DNeasy Blood & Tissue Kit (Qiagen, Germantown, MD) as per the instructions in the manual, and genomic DNA was quantified with a Nanodrop (ThermoFisher, Carlsbad, CA). 50 ng of DNA per sample per reaction was used in real-time PCR using a TaqMan Fast Advanced Master (ThermoFisher, Carlsbad, CA) on a BioRad CFX qPCR instrument. Primers and probes were synthesized by IDT Technology. Thermal cycling conditions were a three-step amplification cycle of 50°C for 2 min, followed by 40 repetitions of 95°C for 20 s, 95°C for 5 s, 56°C for 20 s, and 65°C for 20 s. . The viral copy number (VCN) of each sample was calculated based on the standard curve.
[0326] TaqMan primer and probe sets: About tandem CAR, Tan For:5’-GAGCGACATAGGCAACAAGA-3’, Tan Rev:5’-GGCGATCGTAGTCATCATACAC-3’, Tan probe: 5’-ACAGAAACCAGGTCAAGCACCTGT-3’.
[0327] Regarding bicistronic dual targeting CARs, Dual targeting For:5’-CACTTACTACCGGTCCAAAT-3’ Dual targeting Rev:5’-GAGTGAGAACTGGTTCTTCGAG-3’ Dual targeting probe: 5’-ACTACGCCGTGTCCGTGAAGAATC-3’.
[0328] statistical analysis Statistical analysis was performed using GraphPad Prism 8 software. Both biological replicates representing different donors as well as technical replicates representing repeated measurements were included in the statistical analysis. Bioluminescence data as log-normal parametric data were log-transformed before analysis. Differences between groups were determined by two-way or one-way ANOVA followed by Dunnett's or Tukey's post hoc test. A paired t-test was used to compare data between two groups. P values were reported as follows: ns - no significance, p>0.05; * p≦0.05, ** p≦0.01, *** p≦0.001, **** p≦0.0001. An outlier test was used to exclude mice with results inconsistent with the group.
[0329] result We constructed a series of CAR constructs that can simultaneously target CD19 and CD22 B cell antigens. All constructs were fully human and utilized human scFv sequences for CD19 (m19217-1) and human scFv sequences for CD22 (16P17). Second generation CARs, third generation CARs and bicistronic dual targeting CARs against CD19 and CD22 were constructed (Table 2).
[0330] [Table 2]
[0331] The costimulatory domain of CAR modulates the antitumor efficacy of tandem CAR22-19 in Raji NSG xenografts Using wild-type NSG Raji xenografts and CD19- or CD22-antigen-heterogeneous Raji xenograft mouse models, we investigated the in vivo tumor rejection functionality of CARs with costimulatory domains derived from different TNFR superfamily or Ig superfamily. Further investigation was conducted (Figures 10A-I). In wild-type Raji xenografts, the highest tumor regression was achieved with dual-targeted CAR construct D0146, followed by third generation CAR D0140 and second generation D0135, followed by D0136, D0137, D0138, D0139. In the third group, LTG2737 CAR produced only weak antitumor activity (FIGS. 10A, 10B, 10C). Unexpectedly, among the two CARs with OX40 costimulation that differ only in the composition of the hinge and transmembrane domains, CAR D0145 showed higher expression and functionality than D0137 in vitro (Figures 9A-9D ) was the least effective CAR in vivo (Figures 10A and 10B). When comparing CD28 domain 22-19 tandem CARs, CAR D0135 performed better than D0139 in vivo despite similar in vitro function (Figures 10A, 10C, Figures 9A-9D).
[0332] In vivo proliferation and persistence of the 22-19CAR variant was observed in total human T cells (Figures 10D-10F) and CD8. + (FIGS. 10G-10I) T cell populations were measured in peripheral blood on study days 14, 21, and 28 by flow cytometric counting. At day 14, dual-targeted CAR D0146, which had the most rapid tumor clearance, also showed the most significant total T cell proliferation in peripheral blood. Several CAR22-19 costimulatory domain variants also showed evidence of proliferation in the blood, including an increase in total T cells for D0135, D0136, D0137 and D0138 (FIG. 10D). Although not significant, D0140 showed a trend towards T cell proliferation. CD8 + A commensurate increase in T cell numbers was detected for these CAR treatments (Figure 10G). However, total T cell levels and CD8 in 22-19CAR LTG2737, D0139 and D0145 + Both T levels remained low at day 14 (Figures 10D, 10G). At day 21, two CARs containing BB-costimulatory sequences, LTG2737 and D0140, stimulate total T cells and CD8 + Both T cell levels were elevated, while other CAR variants were attenuated in peripheral blood by this point (FIGS. 10E, 10H). By day 28 of the study, 3rd generation CAR D0140 increased total T cell and CD8 + CAR LTG2737 remained elevated in both T cell levels, but CAR LTG2737 remained elevated in total T cell numbers but CD8 + This is not maintained in the T subset; this + This suggests that T cells were responsible for sustaining the LTG2737 CAR at this point (Figures 10F, 10I). Apparently, third generation CAR22-19 with 28-BB co-stimulation stimulates total T cells as well as CD8 + We were able to maintain the longest persistence of the T portion, which is responsible for the overall anti-inflammatory activity of the CAR through differentiation into CTLs (cytotoxic T-cell lymphocytes, an effector subset that can kill tumor cells). It is thought that it greatly contributes to tumor function. Notably, as seen for CAR D0146, D0135, D0136, D0137 and D0138, early CAR proliferation at day 14 was required for effective tumor clearance even in the absence of long-term blood persistence. . By comparison, long-term persistence in the absence of early CAR T proliferation was insufficient for tumor clearance, as was seen for the second generation 22-19BB tandem CARs LTG2737 and CAR D0145.
[0333] To investigate the ability of bispecific CAR22-19 variants to eradicate antigen-negative, antigen-low or antigen-heterogeneous tumors, we developed a CAR construct that mediated strong tumor regression in wild-type Raji xenografts. It was further investigated in an antigen-heterogeneous model. Mice were implanted with an equal ratio mixture of Raji 19KO, Raji22KO, and wild-type Raji tumor cells, all stably expressing firefly luciferase, to facilitate detection of tumor progression. Experiments treated with alternative costimulatory domain variant CARs D0140, D0135, D0136, D0137, dual targeting CARs D0146, D0148 and D0186, comparator CARs LTG2737, and single targeting CAR19 and CAR22. Group, UTD, as well as a tumor alone negative control were included (Figure 11). Tumor progression was monitored by bioluminescence imaging. Mouse number 6 in group D0140 developed a high tumor burden, likely due to dosing error, and was excluded from the data plot by outlier test (FIGS. 11A, 11B). The bispecific CD22- and CD19-targeted CARs D0140, D0135, D0136, D0137, D0146, D0148, D0186 and the comparator CAR LTG2737 all strongly rejected antigen-heterogeneous Raji tumors, but only Monotargeting CAR22 and CAR19 enabled tumor progression (FIGS. 11A, 11B). Thus, the bispecific 22-19 CAR, but not the single CAR control, prevented tumor escape from removal in this xenograft model.
[0334] As seen from the bioluminescence data on day 9 of the study, the most rapid tumor rejection was mediated by CARs D0135, D0137, D0148 and D0186, closely followed by D0136, D0140 and D0146 CARs, while LTG2737 CAR , lagged behind other CAR22-19 variants at day 9 and also at day 14, but the differences between tandem CARs were not statistically significant (Figure 11B).
[0335] CAR persistence of CD19- and CD22-targeted CARs was investigated in this model by real-time PCR analysis for the presence of CAR DNA in the peripheral blood, bone marrow, and spleen of mice at the conclusion of the study on day 29 (Figure 11C ~11E). Although complete tumor rejection was achieved in all tandem 22-19CAR groups by day 14, measurable CAR copy numbers were detected in blood, bone marrow and spleen at day 29, and the 22-19CAR construct The persistence of was clearly shown (Figures 11C to 11E). The highest CAR copy numbers were found for CAR D0140 and D0137, followed by dual-targeted CAR D0148, followed by D0136, D0186 and LTG2737 CARs, while D0135 and D0146 were barely detectable. (Figures 11C-11E). Therefore, results from both wild-type Raji and heterogeneous Raji in vivo models support the efficacy and long-term persistence of D0140, D0145. Furthermore, the combination of CD28 and BB costimulatory domains in the third generation tandem 22-19CAR construct had a dramatic synergistic effect on its persistence in peripheral blood, bone marrow and spleen.
[0336] These results demonstrate that the antitumor function of tandem CAR22-19BBζ (LTG2737) in vivo can be modulated and dramatically improved by utilizing alternative costimulatory domains. Specifically, optimization of the CAR22-19 costimulatory sequence, hinge and transmembrane domains, and implementation of a third generation CAR architecture resulted in a tandem 22-19 CAR candidate with superior anti-tumor functionality. Therefore, it is important to determine whether these improved CAR constructs are better suited for the detection of low-antigen-density tumor cell variants, which remain a thorny obstacle to the clinical efficacy of CARs.
[0337] Alternative costimulatory domains improved 22-19BBz CAR T cell responses to tumor targets with low antigen density The reduction in CD22 surface expression was sufficient to result in tumor recurrence due to tumor antigen escape in a recent CD22 CAR clinical trial using a single-targeting CAR construct with a BB costimulatory domain and a CD3ζ activation domain. There was (6). To determine whether tandem CAR22-19 constructs with alternative costimulatory domains that were highly effective in tumor killing in vitro and in vivo may have greater sensitivity to reduced levels of CD22. Single-antigen Raji clones with high or low surface density of CD22, CRISPR-Cas9 double-knockout of CD19 and CD22, and CD19 neg CD22 neg generated by lentiviral transduction of CD22 into the Raji background (Figure 12A). Tandem CAR constructs and single targeting CAR22 controls were incubated overnight at 5:1, 10:1 or 20:1 E:T ratios in Raji. hi or Raji low Co-incubated with target. The reduction in lytic efficacy due to reduced CD22 surface density was most pronounced for the LTG2737 tandem 22-19CAR construct with the BB co-stimulatory domain, with a particularly dramatic loss of cytotoxic ability against CD22 low target density strains. (Figure 12B). Tandem 22-19 third generation CARs D0140, tandem CARs with 28 co-stimulatory domains D0135 and D0139, and dual targeting CARs D0146, D0147, D0148, D0149 and D0186 have a high It showed killing efficacy (FIGS. 12C to 12E, 12J to 12N). Next in lysis efficiency was the tandem CAR D0136 and D0145 with ICOS co-stimulation (FIGS. 12F, 12G), followed by CAR D0137 and CAR D0138 (FIGS. 12H, 12I). The lytic capacity of the single CAR22 control was lower than for most 22-19 CAR variants, except for the LTG2737 CAR (Figure 12O). Therefore, the reduced lytic ability and sensitivity of CAR to low target density clones observed in tandem CAR22-19BBζ LTG2737 compared to single CAR22 is corrected over the original CAR22 by incorporation of the CAR costimulatory domain. , enhanced. Notably, the order of tandem CAR22-19 variants on CD22 antigen density closely followed their potency in the in vivo xenograft model: Ig-superfamily CD28 and 28-BB CARs were the strongest, followed by ICOS. TNFR superfamily CAR variants ranked lower than Ig superfamily groups, and OX co-stimulation was comparable to or somewhat less efficient than ICOS, followed by CD27 and BB (Figure 12) . Interestingly, all dual CAR constructs showed that Raji CD22 compared to single CAR22 low showed excellent cytotoxicity and sensitivity to Consistently, in xenograft models, the dual-targeted CAR constructs tested had comparable or better functionality than the best tandem constructs D0135 and D0140, demonstrating rapid tumor eradication (Figure 11) .
[0338] Notably, an identical potency order of tandem 22-19CARs emerged when tested against Raji clones with high and reduced CD19 densities (FIGS. 13A-P). This observation indicates that although the binding properties of individual binders in a tandem CAR format contribute to their lytic capacity, the sensitivity to low antigen density targets for each binder can be greatly improved by replacement of the co-stimulatory domain. There is.
[0339] equivalent Each application and patent cited in the text, and each issued patent in litigation, each document or reference cited therein (including each issued patent in litigation, an “Application Cited Document”); Each PCT and foreign application or patent that corresponds to and / or claims priority to any of the applications and patents of, and each document cited or referenced in the respective application cited document is hereby expressly It is incorporated herein by reference and can be used in practicing the present invention. More generally, documents or references are cited either in the text, in the reference list before the claims, or in the text itself, and each of these documents or references (“this specification References cited herein), and each document or reference cited in each Reference cited herein (including any manufacturer's specifications, instructions, etc.) is hereby expressly cited. Incorporated herein by reference.
[0340] The foregoing description of some specific embodiments allows others to easily modify the specific embodiments, etc. with respect to various applications without departing from the general concept by applying knowledge of the present invention. or provide sufficient information to enable adaptations to be made, and therefore such adaptations and modifications should and are intended to be understood to be within the meaning and range of equivalents of the disclosed embodiments. There is. It is understood that the words or predicates employed herein are for purposes of description and not of limitation. In the drawings and description, illustrative embodiments are disclosed and specific terminology may be utilized, but unless stated otherwise, they are intended only in a general and descriptive sense and not for purposes of limitation. as used herein, and therefore the claims are not so limited. Additionally, those skilled in the art will appreciate that certain steps of the methods discussed herein can be sequenced in another order, or the steps can be combined. Therefore, it is intended that the appended claims not be limited to the detailed embodiments disclosed herein. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the embodiments of the invention described herein. Such equivalents are covered by the following claims.
[0341] Sequence list The nucleic acid and amino acid sequences listed below are shown using standard abbreviations for nucleotide bases and three letter codes for amino acids, as defined in 37 C.F.R. 1.822. Although only one strand of each nucleic acid sequence is shown, complementary strands are understood to be included by reference to the shown strand. In the attached sequence listing: SEQ ID NO: 1 is the nucleotide sequence of LTG2681 D0023 Leader-CD22VH-(GGGGS)-3 CD22VL(GGGGS)-5 CD19VH(GGGGS)-3 CD19VL CD8 Hinge+TM-4-1BB-CD3z (Construct CAR2219). ATGCTCTTGCTCGTGACTTCTTTGCTTTGTGCGAACTTCCGCACCCAGCCTTCCTTTTGATACCTCAGGTACAGCTTCAACAAAGCGGACCGGGACTTGTTAAGCATTCCCAAACCCTTTCTCTCACGTGTGCAATTAGCGGCGATAGTGTATCCTCTAATTCTGCGGCCTGGAACTGGATACGACAATCACCAAGCCGGGGACTCGAGTGGTTGGGCCGAACCTACTATCGGTCCAAATGGTATAATGACTACGCAGTATC CGTGAAATCTCGCATTACGATCAATCCAGACACCTCCAAAAATCAATTTTCTCTGCAGTTGAATAGCGTGACTCCCGAGGACACGGCCGTTTACTATTGCGCCCAGGAAGTTGAACCCCACGATGCATTTGATATTTGGGGCCAGGGAACCATGGTGACAGTGAGTAGTGGGGGTGGAGGATCTGGAGGAGGCGGTAGCGGCGGGGGCGGCAGTGATATCCAGATGACGCAGTCACCTTCCAGCGGGTATGCGAGTGT GGGACAAGGTCACCATAACCTGTCGCGCTAGCCAAGATGTCAGCGGTGGCTGGCTTGGTACCAGCAGAAACCAGGTTTGGCTCCTCAGCTTTTGATCTCAGGAGCGAGCACGCTTCAGGGTGAGGTCCCAAGTCGCTTTAGTGGCTCTGGCTCCGGGACAGACTTCACGTTGACGATCAGCAGTTTGCAGCCTGAGGATTTCGCGACCTACTACTGCCCAGCAAGCGAAATATTTTCCGTACACTTTCGGTCAGGGGACC AAATTGGAGATCAAAGGTGGGGGTGGTTCAGGCGGCGGAGGCTCAGGCGGCGGCGGTAGCGGAGGAGGCGGAAGCGGGGGTGGCGGATCAGAAGTGCAACTCGTTCAGAGTGGCGCGGAGGTTAAGAAACCCGGTGCATCTGTAAAGGTTAGCTGTAAGGCATCAGGATACACTTTTACCAGCTATTACATGCATTGGGTGAGACAGGCTCCCGGTCAGGGGCTCGAATGGATGGGGTTGATCAACCCGAGTGGTGGTTCAA CATCTTACGCCCAGAAGTTTCAGGGCCGAGTAACAATGACTCGGGACACGTCTACCTCAACTGTGTATATGGAGCTTTCCAGCCTGCGCTCAGAGGATACAGCAGTCTATTACTGCGCACGGTCAGACAGAGGTATAACGGCCACTGATGCGTTCGATATCTGGGGACAAGGGACTATGGTAACTGTGTCTTCCGGAGGAGGAGGTAGTGGAGGGGGAGGAAGCGGTGGGGGGGGCTCACAGTCCGTTTTGACTCAGCCACC AAGCGTCTCAGTCGCACCGGGGCGAATGGCGAAAATTACTTGCGGCGGGAGCGACATAGGCAACAAGAATGTGCATTGGTACCAACAGAAACCAGGTCAAGCACCTGTTCTCGTGGTGTATGATGACTACGATCGCCCAAGCGGGATCCCGGAGCGGTTCTCTGGATCAAATTCTGGTGATGCAGCCACTCTGACAATATCAACGGTGGAAGTCGGTGACGAGGCTGATTACTTCTGCCAAGTATGGGATGGCAGCGGAGATC CCTACTGGATGTTTGGAGGAGGTACTCAACTGACAGTTCTGGGCGCGGCCGCAACGACCACTCCTGCACCCCGCCCTCCGACTCCGGCCCAACCATTGCCAGCCAGCCCCTGTCCCTGCGGCCGGAAGCCTGCAGACCGGCTGCCGGCGGAGCCGTCCATACCCGGGACTGGATTTCGCCTGCGATATCTATATCTGGGCACCACTCGCCGGAACCTGTGGAGTGCTGCTGCTGTCCCTTGTGATCACCCTGTACTGCAA GCGCGGACGGAAGAAAACTCTTGTACATCTTCAAGCAGCCGTTCATGCGCCCTGTGCAAACCACCCAAGAAGAGGACGGGTGCTCCTGCCGGTTCCCGGAAGAGGAAGAGGGCGGCTGCGAACTGCGCGTGAAGTTTTCCCGGTCCGCCGACGCTCCGGCGTACCAGCAGGGGCAAAACCAGCTGTACAACGAACTTAACCTCGGTCGCCGGGAAGAATATGACGTGCTGGACAAGCGGCGGGGAAGAGATCCCGAGATGGGT GGAAAGCCGCGGCGGAAGAACCTCAGGAGGGCTTGTACAACGAGCTGCAAAAGGACAAAATGGCCGAAGCCTACTCCGAGATTGGCATGAAGGGAGAGCGCAGACGCGGGAAGGGACACGATGGACTGTACCAGGGACTGTCAACCGCGACTAAGGACACTTACGACGCCCTGCACATGCAGGCCCTGCCCCCGCGC SEQ ID NO: 2 is the amino acid sequence of LTG2681 D0023 Leader-CD22VH-(GGGGS)-3 CD22VL(GGGGS)-5 CD19VH(GGGGS)-3 CD19VL CD8 Hinge+TM-4-1BB-CD3z (Construct CAR2219). MLLLVTSLLLCELPHPAFLLIPQVQLQQSGPGLVKHSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAQEVEPHDAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSVYASVGDKVTITCRASQDVSGWLAWYQQKPGLAPQ LLISGASTLQGEVPSRFSGSGSGTFTLTISSLQPEDFATYYCQQAKYFPYTFGQGTKLEIKGGGGSGGGGSGGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGLINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARSDRGITATDAFDIWGQGTMVTVSSGGGGS GGGGSGGGGSQSVLTQPPSVSVAPGRMAKITCGGSDIGNKNVHWYQQKPGQAPVLVVYDDYDRPSGIPERFSGSNSGDAATLTISTVEVGDEADYFCQVWDGSGDPYWMFGGGTQLTVLGAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGC SCRFPEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR SEQ ID NO: 3 is the nucleotide sequence of LTG2791 D0024 leader-CD19VH(GGGGS)3-CD19VL-(GGGGS)5-CD22VH(GGGGS)3-CD22VH CD8 hinge+TM-4-1BB-CD3z (construct CAR1922). ATGTTGCTTCTGGTTACTTCCCTTCTTCTTTGCGAGCTTCCACACCCAGCATTCCTGCTCATTCCGGAGGTGCAACTCGTCCAATCCGGGGCCGAAGTTAAGAAGCCGGGAGCATCTGTTAAAGTATCCTGTAAGGCCAGTGGGTATACTTTCACCTCATATTATATGCACTGGGTGAGGCAGGCTCCAGGCCAAGGGTTGGAGTGGATGGGACTGATAAACCCATCTGGGGATCAACTTCTTATGCGCAAAAGTTC CAAGGTCGGGTCACTATGACAAGGGACACATCCACCAGCACTGTTTATATGGAACTGAGCAGCCTGAGATCTGAGGATCCGCAGTATATTACTGTGCACGCAGTGATAGAGGCATAACGGCGACTGACGCCTTCGACATTTGGGGCCAAGGGACAATGGTCACGGTTTCAAGTGGAGGTGGAGGGTCTGGTGGCGGGGGGTCTGGTGGTGGAGGCAGTCAGAGCGTCCTGACCCAGCCGCCTAGCGTCAGTGTGGCCCCCGGC CGCATGGCCAAGATAACGTGTGGCGGAAGCGATATTGGGAATAAGAACGTCCACTGGTATCAGCAGAAGCCAGGGCAGGCTCCCGTCCTCGTAGTATACGACGATTATGATCGGCCCAGTGGAATCCCGAGAGATTTAGCGGGAGTAACTCTGGGGATGCAGCGACACTTACTATCTCCACTGTTGAAGTAGGAGACGAGGCTGACTATTTTTGTCAGGTTTGGGACGGATCCGGAGATCCTTTATTGGATGTTTGCGCG GAGGTACTCAATTGACCGTGCTTGGAGGTGGCGGAGGGAGCGGGGGTGGGGGCTCAGGGGGAGGTGGGTCAGGCGGGGGCGGAAGTGGTGGCGGGGTCCCAAGTCCAACTCCAGCAGTCAGGACCTGGACTGGTAAAACACTCTCAAACCCTGTCTCTCACGTGTGCCATATCTGGCGATAGTGTATCTTCAAACTCTGCTGCATGGAACTGGATCAGGCAAAGTCCATCCCGCGGCCTTGAGTGGCTCGGTCGAACCT ATTACCGAAGCAAATGGTACAACGATTATGCGGTTTCAGTCAAGTCAAGAATTACGATCAACCCTGATACGAGTAAGAACCAGTTTAGTTTGCAATTGAACAGTGTAACTCCCGAGGACACGGCGGTGTACTATTGTGCGCAAGAAGTCGAACCGCATGATGCGTTCGATATCTGGGGGCAGGGCACAATGGTGACCGTATCTTCTGGCGGCGGCGGCTCTGGAGGAGGAGGAAGCGGCGGAGGGGGATCTGACATACAAATGACA CAATCCCCAAGTTCAGTATATGCTAGCGTCGGGGATAAAGTGACAATTACTTGTAGGGCTTCTCAAGACGTAAGTGGCTGGTTGGCGTGGTACCAGCAAAAGCCGGGTCGCCCCTCAACTCCTTATCAGCGGAGCTTCAACTCTTCAGGGAGAGGTCCCAAGTCGATTCTCAGGCTCTGGCTCCGGGACAGATTTCACCTTGACAATTAGTTCACTGCAACCCGAGGATTTCGCAACTTACTACTGTCAACAGGCCAAGTACT TCCCGTATACGTTTGGTCAAGGCACAAAACTGGAGATTAAGGCGGCCGCAACGACCACTCCTGCACCCCGCCCTCCGACTCCGGCCCAACCATTGCCAGCCAGCCCCTGTCCCTGCGGCCGGAAGCCTGCAGACCGGCTGCCGGCGGAGCCGTCCATACCCGGGACTGGATTTCGCCTGCGATATCTATATCTGGGCACCACTCGCCGGAACCTGTGGAGTGCTGCTGCTGTCCCTTGTGATCACCCTGTACTGCAAGCGCG GACGGAAGAAACTCTTGTACATCTTCAAGCAGCCGTTCATGCGCCCTGTGCAAACCACCCAAGAAGAGGACGGGTGCTCCTGCCGGTTCCCGGAAGAGGAAGAGGGCGGCTGCGAACTGCGCGTGAAGTTTTCCCGGTCCGCCGACGCTCCGGCGTACCAGCAGGGGCAAAACCAGCTGTACAACGAACTTAACCTCGGTCGCCGGGAAGAATATGACGTGCTGGACAAGCGGCGGGGAAGAGATCCCGAGATGGGTGGAAAGC CGCGGCGGAAGAACCCTCAGGAGGGCTTGTACAACGAGCTGCAAAAGGACAAAATGGCCGAAGCCTACTCCGAGATTGGCATGAAGGGAGAGCGCAGACGCGGGAAGGGACACGATGGACTGTACCAGGGACTGTCAACCGCGACTAAGGACACTTACGACGCCCTGCACATGCAGGCCCTGCCCCCGCGC SEQ ID NO: 4 is the amino acid sequence of LTG2719 D0024 leader-CD19VH(GGGGS)3-CD19VL-(GGGGS)5-CD22VH(GGGGS)3-CD22VH CD8 hinge+TM-4-1BB-CD3z (construct CAR1922). MLLLVTSLLLCELPHPAFLLIPEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGLINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARSDRGITATDAFDIWGQGTMVTVSSGGGGSGGGGSGGGSQSVLTQPPSVSVAPGRMAKITCGGSDIGNKNVHWYQQKPGQAPVLVVYDDYDRPS GIPERFSGSNSGDAATLTISTVEVGDEADYFCQVWDGSGDPYWMFGGGTQLTVLGGGGGSGGGGSGGGGSGGGGSGGGGSQVQLQQSGPGLVKHSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAQEVEPHDAFDIWGQGTMVTVSSGGGGGSGGGGSGGG GSDIQMTQSPSSVYASVGDKVTITCRASQDVSGWLAWYQQKPGLAPQLLISGASTLQGEVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAKYFPYTFGQGTKLEIKAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGC SCRFPEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR SEQ ID NO: 5 is the nucleotide sequence of fully human CAR19 LTG2065 (M19217-1-CD8TM-4-1BB zeta). ATGCTGCTGCTGGTGACCAGCCTGCTGCTGTGCGAACTGCCGCATCCGGCGTTTCTGCTGATTCCGGAGGTCCAGCTGGTACAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATTAATCAACCCTAGTGGTGGTAGCACAAGCTACGCACAGAAG TTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGATCGGATCGGGGAATTACCGCCACGGACGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGGCGGAGGAGGCTCCGGGGGAGGAGGTTCCGGGGGCGGGGGTTCCCAGTCTGTGCTGACTCAGCCACCGGCTCGGTGTCAGT CCCCAGGGCGGATGGCCAAGATTACCTGTGGGGAAGTGACATTGGAAATAAAAATGTCCACTGGTATCAGCAGAAGCCAGGCCAGGCCCCTGTCCTGGTTGTCTATGATGATTACGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGGACGCGGCCACCCTGACGATCAGCACGGTCGAAGTCGGGGATGAGGCCGACTATTTCTGTCAGGTGTGGGACGGTAGTGGTGATCCTTATTGGAT GTTCGGCGGAGGGACCCAGCTCACCGTTTTAGGTGCGGCCGCAACTACCCCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGG AAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGAAACC ACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGG SEQ ID NO: 6 is the amino acid sequence of fully human CAR19 LTG2065 (M19217-1-CD8TM-4-1BB zeta). MLLLVTSLLLCELPHPAFLLIPEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGLINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARSDRGITATDAFDIWGQGTMVTVSSGGGGSGGGGSGGGSQSVLTQPPSVSVAPGRMAKITCGGSDIGNKNVHWYQQKPGQAPVLVVYDDYDRPS GIPERFSGSNSGDAATLTISTVEVGDEADYFCQVWDGSGDPYWMFGGGTQLTVLGAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRK NPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR SEQ ID NO: 7 is the nucleotide sequence of mouse scFv CAR19 LTG1538. ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACATTCAGATGACTCAGACCACCTCTTCCTTGTCCCGTCACTGGGAGACAGAGTGACCATCTCGTGTCGCGCAAGCCAGGATATCTCCAAGTACCTGAACTGGTACCAACAGAAGCCCGACGGGACTGTGAAGCTGCTGATCTACCACACCTCACGCCTGCACAGCGGAGTGCCAAGCAGATTCTCCGGC TCCGGCTCGGGAACCGATTACTCGCTTACCATTAGCAACCTCGAGCAGGAGGACATCGCTACCTACTTCTGCCAGCAAGGAAATACCCTGCCCTACACCTTCGGCGGAGGAACCAAATTGGAAATCACCGGCGGAGGAGGCTCCGGGGGAGGAGGTTCCGGGGGCGGGGGTTCCGAAGTGAAGCTCCAGGAGTCCGGCCCCGGCCTGGTGGCGCCGTCGCAATCACTCTCTGTGACCTGTACCGTGTCGGGAGTGTCCCTGCC TGATTACGGCGTGAGCTGGATTCGGCAGCCGCCGCGGAAGGGCCTGGAATGGCTGGGTGTCATCTGGGGATCCGAGACTACCTACTACAACTCGGCCCTGAAGTCCCGCCTGACTATCATCAAAGACAACTCGAAGTCCCAGGTCTTTCTGAAGATGAACTCCCTGCAAACTGACGACACCGCCATCTATTACTGTGCTAAGCACTACTACTACGGTGGAAGCTATGCTATGGACTACTGGGGGCAAGGCACTTCGGTGACTGTGTCAAGC GCGGCCGCAACTACCCCCCTGCCCCTCGGCCGCCGACTCCGGCCCACACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTT CATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGA ACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGG SEQ ID NO: 8 is the amino acid sequence of mouse scFv CAR19 LTG1538. MLLLVTSLLLCELPHPAFLLIPDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGGGGSGGGGSGGGGSEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTII KDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYI...
Claims
1. 1. An isolated nucleic acid molecule encoding a CD19 / CD22 tandem chimeric antigen receptor (CAR), comprising at least one extracellular antigen binding domain comprising a CD19 / CD22 antigen binding domain, at least one transmembrane domain, and at least one intracellular signaling domain, wherein said CD19 / CD22 tandem chimeric antigen receptor (CAR) is encoded by a nucleotide sequence comprising SEQ ID NO: 84 or 86.
2. A vector comprising the nucleic acid molecule described in claim 1.
3. The vector described in claim 2, selected from the group consisting of a DNA vector, an RNA vector, a plasmid vector, a cosmid vector, a herpes virus vector, a measles virus vector, a lentivirus vector, an adenovirus vector, or a retrovirus vector, or a combination thereof.
4. A cell containing the vector described in claim 2.
5. A method for producing cells, comprising the step of transducing the vector described in claim 2 into a T cell.
6. A pharmaceutical composition comprising an anti-tumor effective amount of a population of human T cells, wherein the T cells comprise a nucleic acid sequence encoding a chimeric antigen receptor (CAR), the CAR comprising at least one extracellular antigen-binding domain comprising a CD19 / CD22 antigen-binding domain, at least one transmembrane domain, and at least one intracellular signaling domain, the CD19 / CD22 tandem CAR comprising an amino acid sequence comprising SEQ ID NO: 85 or 87, and the T cells are from a human having cancer.
7. Use of a population of T cells for the manufacture of a medicament for treating cancer, wherein the T cells comprise a nucleic acid sequence encoding a chimeric antigen receptor (CAR) comprising at least one extracellular antigen binding domain comprising a CD19 / CD22 antigen binding domain, at least one transmembrane domain, and at least one intracellular signaling domain, and the CD19 / CD22 tandem CAR comprises an amino acid sequence comprising SEQ ID NO: 85 or 87, thereby treating cancer in a subject.
8. The use of claim 7, wherein the at least one transmembrane domain comprises a transmembrane domain of a protein including the alpha, beta or zeta chain of the T-cell receptor, CD8, CD28, CD3 epsilon, CD45, CD4, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD83, CD86, CD134, CD137, CD154, and TNFRSF19, or any combination thereof.
9. The use described in claim 7, wherein the at least one CD19 / CD22 antigen-binding domain, the at least one intracellular signaling domain, or both are connected to the transmembrane domain by a linker or spacer domain.
10. The use of claim 9, wherein the linker or spacer domain is derived from the extracellular domain of CD8 or CD28 and is linked to a transmembrane domain.
11. The use of claim 7, wherein the at least one extracellular CD19 / CD22 antigen-binding domain is preceded by a leader nucleotide sequence encoding a leader peptide.
12. The isolated use of claim 7, wherein the at least one intracellular signaling domain comprises a costimulatory domain comprising a functional signaling domain selected from the group consisting of OX40, CD70, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), DAP10, DAP12 and 4-1BB (CD137), or any combination thereof.
13. The use of claim 7, wherein the nucleic acid sequence encoding the CD19 / CD22 tandem chimeric antigen receptor (CAR) is encoded by a nucleotide sequence comprising SEQ ID NO: 84 or 86, or a sequence thereof having 85%, 90%, 95%, 96%, 97%, 98% or 99% identity.
14. The use described in claim 7, wherein the at least one intracellular signaling domain comprises a costimulatory domain, a primary signaling domain, or any combination thereof.
15. The use described in claim 7, wherein the at least one intracellular signaling domain further comprises a CD3 zeta intracellular domain.
16. The use described in claim 7, wherein the cancer is a hematological cancer.
17. The use described in claim 16, wherein the hematological cancer is leukemia or lymphoma.
18. The use of claim 17, wherein the leukemia is chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL) or chronic myeloid leukemia (CML).
19. The use described in claim 17, wherein the lymphoma is mantle cell lymphoma, non-Hodgkin's lymphoma or Hodgkin's lymphoma.
20. The use of claim 7, wherein the cancer is selected from the group consisting of oral cavity and pharyngeal cancer, digestive system cancer, respiratory system cancer, bone and joint cancer, soft tissue cancer, skin cancer, childhood tumors, tumors of the central nervous system, and cancers of the breast, reproductive system, urinary system, eye and orbit, endocrine system and brain.
